<allTrials totalCount="190" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">63412511</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus</title>
      <scientificTitle/>
      <acronym>Rosuvastatin in SLE</acronym>
      <studyHypothesis>Systemic lupus erythematosus (SLE) is a rheumatologic multi-systemic auto-immune disease particularly affecting joints, skin and kidneys. The aim of this trial was to investigate the effects of rosuvastatin on markers of lipid metabolism and inflammatory parameters in patients with SLE.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at baseline and after three months of treatment:
1. Total cholesterol 
2. Low density lipoprotein (LDL) cholesterol
3. C-reactive protein (CRP)
4. Tumour necrotising factor (TNF)</primaryOutcome>
      <secondaryOutcome>Measured at baseline and after three months of treatment:
1. Interleukin-6 (IL6), interleukin-10 (IL10), interleukin-8 (IL8)
2. Complement C3 and C4q
3. Anti-double stranded deoxyribonucleic acid (anti-dsDNA)
4. Urine protein</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of the Slotervaart Hospital (The Netherlands) on the 29th November 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63412511</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-labelled, cross-over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d60ff033-707e-4bb9-a5f6-3d5f440df5ec">
	  <name>Department of Internal Medicine</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6229 HX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic, non-acute SLE
2. Greater than 18 years old, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>19</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>19</totalTarget>
      <exclusion>1. Use of statins
2. Pregnancy
3. Raised liver enzymes
4. Recent (less than three months) major surgery or myocardial infarction</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic lupus erythematosus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic lupus erythematosus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rosuvastatin 10 mg once daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17593-0</funderId>
      <contactId>Contact55560_17593</contactId>
      <sponsorId>Sponsor54139</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55560_17593">
    <title>Prof</title>
    <forename>Hugo</forename>
    <surname>ten Cate</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Internal Medicine
Academisch Ziekenhuis Maastricht</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6229 HX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.Tencate@BIOCH.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54139">
    <organisation>AstraZeneca (The Netherlands)</organisation>
    <website>http://www.astrazeneca.nl</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Postbus 599</address>
      <city>Zoetermeer</city>
      <country>Netherlands</country>
      <zip>2700 AN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)79 363 2222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info.nl@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476086.b</gridId>
    <rorId>https://ror.org/021tmn508</rorId>
  </sponsor>
  <funder id="Funder17593-0">
    <name>AstraZeneca (The Netherlands) - unrestricted research grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">52111135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of three diagnostic tools for latent tuberculosis in haemodialysis patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Latent tuberculosis is hard to diagnose in immunocompromised hosts like haemodialysis patients, and widespread bacille calmette-guerin (BCG) vaccination make it complicated to interpretate Mantoux test results in Korea. Therefore, we need more sensitive and specific diagnostic tools for latent tuberculosis in haemodialysis patients. 

Hypothesis:
T-spot assay or Quantiferon assay is more sensitive and specific than Mantoux test for latent tuberculosis in haemodialysis patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Skin test: positive or negative
2. Quantiferon-gold: positive or negative
3. T-spot test: positive or negative

These outcomes will be measured on the day of testing.</primaryOutcome>
      <secondaryOutcome>1. Skin test: size of induration
2. Quantiferon-gold: concentration
3. T-spot test: number, mean area

These outcomes will be measured on the day of testing.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board (IRB) of Gachon University of Medicine and Science on the 28th February 2008 (ref: 20080228 tuberculosis in haemodialysis).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52111135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, observational, cross-sectional, open trial</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cross-section survey</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7590e94-2e99-4147-96a9-86319001fdd7">
	  <name>Division of Nephrology</name>
	  <address/>
	  <city>Incheon</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>405-760</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic maintenance haemodialysis patients who continue to receive haemodialysis for more than three months in the Gil Medical Centre
2. Older than 18 years, and less than 80 years, either sex
3. Agrees to participate in this trial
4. Medical staff in the haemodialysis centre of the Gil Medical Centre</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>162</totalTarget>
      <exclusion>1. Patients who suffer from skin diseases which may interfere with Mantoux test
2. Patients with an active infection, except tuberculosis
3. Patients who cannot make independent decision due to mental disorders</exclusion>
      <patientInfoSheet>Not available in web format, please contact Jaeseok Yang at jcyjs@hanafos.com to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Latent tuberculosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Agreement of three diagnostic tests for latent tuberculosis will be tested in haemodialysis patients. Blood samples are taken for:
1. Quantiferon-gold assay, an enzyme linked immunosorbent assay (ELISA) assay for interferon gamma in response to tuberculosis specific antigens
2. T-spot assay, an enzyme-linked immunosorbent spot (ELISPOT) assay for interferon gamma

After sampling, the Mantoux test will be performed, and the results will be read in two days. Agreement of three test results will be analysed using kappa coefficients, and results will be analysed per each categories of risk groups such as low risk group, casual contact group, latent tuberculosis patients, and active tuberculosis patients. Agreement will be also analysed in medical staff group with normal immunity.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17617-0</funderId>
      <contactId>Contact55587_17617</contactId>
      <sponsorId>Sponsor54163</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55587_17617">
    <title>Prof</title>
    <forename>Jaeseok</forename>
    <surname>Yang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Nephrology
Department of Internal Medicine
Gil Medical Center
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54163">
    <organisation>Gachon University of Medicine and Science (South Korea)</organisation>
    <website>http://home.gachon.ac.kr/icc/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institutional Review Board (IRB)
Department of Pharmacy
Gil Medical Centre
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.256155.0</gridId>
    <rorId>https://ror.org/03ryywt80</rorId>
  </sponsor>
  <funder id="Funder17617-0">
    <name>Gachon University of Medicine and Science (South Korea) - Division of Nephrology, Department of Internal Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">11431649</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>25- versus 29-gauge Quincke spinal needles</title>
      <scientificTitle>Comparison of 25- versus 29-gauge Quincke spinal needles for minor anorectal surgery as well as abdominal caesarean section in respect of patient satisfaction and handling</scientificTitle>
      <acronym/>
      <studyHypothesis>It is considered, that the incidence of post-puncture dural headache is correlated with the size of the spinal needle. For reason of patients' satisfaction and to minimize complications, a 29-gauge spinal needle is suitable for this purpose, especially in pregnant patients and patients undergoing ambulatory surgery. Though, the handling of this very thin spinal needle is described as difficult and therefore denied by several anaesthesiologists. 

The aim of this study is to evaluate the patients' satisfaction, the incidence of post-puncture dural headache and the handling conditions for the anaesthesiologist. 

Hypothesis:
The performance of a spinal anaesthesia with 29-gauge compared to a 25-gauge Quincke needles has a lower incidence of complications in patients undergoing minor anorectal surgery and abdominal caesarean section.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of post-dural puncture headache and other complications, measured one week after anaesthesia.</primaryOutcome>
      <secondaryOutcome>Time for the performance of spinal anaesthesia and occurring complications, measured one week after anaesthesia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Kommission II: Medizinische Fakultat Mannheim der Ruprecht-Karls-Universitat Heidelberg) on the 19th September 2007 (ref: 2007-236N-MA).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11431649</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75eefce8-88ad-4c92-8d6b-08065f2f0f55">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with minor anorectal surgery, or 
2. Patients (female) for abdominal caesarean section
3. Age 18 - 80 years
4. American Society of Anaesthesiology (ASA) grade I - III
5. No contraindications for spinal anaesthesia</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Contraindications for spinal anaesthesia
2. Allergy against local anaesthetics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-puncture dural headache</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Post-puncture dural headache</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients are 1:1 randomised to either a 25-gauge or a 29-gauge spinal needle. Patients receive a questionnaire to obtain information about satisfaction and occurring complications. The time for the performance of the spinal anaesthesia and problems with the handling of the spinal needle are recorded by the anaesthesiologist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17347-0</funderId>
      <contactId>Contact55308_17347</contactId>
      <sponsorId>Sponsor53876</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55308_17347">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53876">
    <organisation>B. Braun Melsungen AG (Germany)</organisation>
    <website>http://www.bbraun.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Carl-Braun-Strasse 1</address>
      <city>Melsungen</city>
      <country>Germany</country>
      <zip>34212</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@bbraun.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.462046.2</gridId>
    <rorId>https://ror.org/04nxj7050</rorId>
  </sponsor>
  <funder id="Funder17347-0">
    <name>B. Braun Melsungen AG (Germany) - provided the spinal needles</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">36101176</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Hospital at home care in chronic obstructive pulmonary disease (COPD): a study on the associated health economy and disease-related quality of life</title>
      <scientificTitle>Hospital at home care in exacerbations of chronic obstructive pulmonary disease (COPD)</scientificTitle>
      <acronym>HBKOLS</acronym>
      <studyHypothesis>Previous studies in other countries indicate that home treatment with nursing support is suitable in selected patients with exacerbations of chronic obstructive pulmonary disease (COPD), presenting to hospital as an emergency. 

Hypothesis: 
Three days of hospital at home care in mild to moderate exacerbations of COPD is cost saving in the Norwegian health care system and implies at least the same level of disease-related quality of life as traditional hospital care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Health economy measures.

Time points: 6 weeks, 6 months and 12 months.</primaryOutcome>
      <secondaryOutcome>1. Level of disease-related quality of life, measured with the St. George Respiratory Questionnaire
2. Mental health (level of anxiety and depression), measured with the Hospital Anxiety and Depression Scale

Time points: 6 weeks, 6 months and 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Regional Ethics Committee for Medical Research of East Norway on the 21st December 2007 (ref: 1.2007.2613).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36101176</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b38f729-f8b1-4940-9305-8d9f5c94fc4e">
	  <name>HØKH</name>
	  <address/>
	  <city>Lørenskog</city>
	  <state/>
	  <country>Norway</country>
	  <zip>1478</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients under 80 years of age, either sex, with exacerbation of COPD
2. Presenting to the hospital as an emergency</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Serious exacerbation including impending or actual respiratory failure
2. Serious comorbidity</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Hospital-at-home group (experimental arm): 
Three days organised by the hospitals with specially trained nurses. In the same period of time the patient can contact the lung department at the hospital by phone for advice. Thereafter, if medical follow up is needed, by the primary care system (primary physician, home nurses).

Hospital group (control arm): 
As long as needed in the hospital. Thereafter, if needed, by the primary care personnel as for the other group. In contrast to the other group, the length of the in-hospital treatment is not specified. 

Follow up for both groups: After 6 weeks, 6 months and 12 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17434-0</funderId>
      <funderId>Funder17434-1</funderId>
      <contactId>Contact55395_17434</contactId>
      <sponsorId>Sponsor53965</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55395_17434">
    <title>Dr</title>
    <forename>Torbjørn </forename>
    <surname>Haugen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>HØKH
Akershus Unversitetssykehus HF
Sykehusveien 27</address>
      <city>Lørenskog</city>
      <country>Norway</country>
      <zip>1478</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53965">
    <organisation>Regional Authorities for Hospital Care, South-East Norway (Helse Sør-Øst Norge RHF) (Norway)</organisation>
    <website>http://www.helse-ost.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>PO Box 404</address>
      <city>Hamar</city>
      <country>Norway</country>
      <zip>2301</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+47 625 85 500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmottak@helse-ost.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.454198.5</gridId>
    <rorId>https://ror.org/02qx2s478</rorId>
  </sponsor>
  <funder id="Funder17434-0">
    <name>Regional Authorities for Hospital Care, South-Eastern Norway (Helse Sør-Øst RHF) (Norway)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17434-1">
    <name>The Norwegian Research Council (Norsk Forskningsråd) (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">75453816</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dietary fibre supplementation to prevent ulcerative colitis relapse: randomised double-blind placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By taking 60 g of oat bran daily the relapse rate of patients with ulcerative colitis will be lowered from 40% to 20% at six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Colitis relapse at six months.</primaryOutcome>
      <secondaryOutcome>The following will be assessed at six months:
1. General health
2. Bowel symptoms 
3. Faecal butyrate concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ethics committee of Linköping University, Sweden (ref: M 159-04)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75453816</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>v.13</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fa33c085-ab64-4b75-9d53-b0161ff16756">
	  <name>Norrköping Hospital NSÖ stab</name>
	  <address/>
	  <city>Norrköping</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-60182</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults with ulcerative colitis or proctitis in clinical and endoscopic remisson following a colitis relapse within prior 12 months
2. Written consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>130</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>130</totalTarget>
      <exclusion>1. Antibiotics at inclusion
2. Steroids in last two weeks
3. Ongoing treatment with immunosuppressive drugs
4. Pregnancy or planned pregnancy
5. Concomitant serious disorder
6. Inability to comply with study protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Swedish)</patientInfoSheet>
      <recruitmentStart>2006-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ulcerative colitis and proctitis in remission</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Ulcerative colitis and proctitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>60 g of oat bran to the daily diet for six months versus no intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Oat bran</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17486-0</funderId>
      <funderId>Funder17486-1</funderId>
      <contactId>Contact55448_17486</contactId>
      <sponsorId>Sponsor54028</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55448_17486">
    <title>Prof</title>
    <forename>Claes</forename>
    <surname>Hallert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norrköping Hospital NSÖ stab</address>
      <city>Norrköping</city>
      <country>Sweden</country>
      <zip>S-60182 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)70 543 8282 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claes.Hallert@telia.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54028">
    <organisation>Lantmännen Food (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ingmar Börjesson
R&amp;D Department</address>
      <city>Järna</city>
      <country>Sweden</country>
      <zip>153 81</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 519 787 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ingmar.borjesson@lantmannen.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.502516.5</gridId>
  </sponsor>
  <funder id="Funder17486-0">
    <name>Lantmannen Food R&amp;D (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17486-1">
    <name>Medical Research Council of South-East Sweden (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">19821978</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Met-Hb and inflammation markers with tumescence local anaesthesia (TLA)</title>
      <scientificTitle>Met-Hb-concentration and inflammation markers in patients undergoing tumescence local anaesthesia (TLA) with supramaximal dosages of prilocaine</scientificTitle>
      <acronym/>
      <studyHypothesis>Tumescence local anaesthesia (TLA) is an established anaesthesia technique, where large amounts of highly diluted local anaesthetics are used. Due to its low toxicity, prilocaine is used frequently. Though, prilocaine can - dosage-dependant - cause a methemoglobinaemia, leading to a reduced oxygen transport capacity. Furthermore, certain processes of the inflammation cascade are initiated. These effects are important for ambulatory patients and the following healing process. 

The aim of the study is to evaluate the Met-Hb concentration and inflammation markers like  interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), tumour necrotising factor (TNF), C-reactive protein (CRP) in a chronological sequence.

Hypothesis:
TLA in supramaximal dosages of prilocaine has an influence on plasmatic inflammation markers, which will elevate in the first 48 hours. Furthermore, the Met-Hb production will not be finished within this time.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Met-Hb-concentration over the time, measured over 48 hours.</primaryOutcome>
      <secondaryOutcome>Elevation of inflammation markers, measured over 48 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Komission II: Medizinische Fakultat Mannheim der Ruprechts-Karls-Universitat Heidelberg) on the 22nd November 2007 (ref: 2007-258N-MA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19821978</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study until 48 hours after surgery</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="adaa9697-0634-437a-ad35-cd5ebac75cc4">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with operations which are performed in TLA with prilocaine
2. Age: 18 - 85 years
3. American Society of Anaesthesiologists (ASA) grade I - III
4. No allergy against prilocaine</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Allergy against prilocaine
2. Pregnancy
3. Patient denies operation in TLA</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tumescence local anaesthesia (TLA)/established anaesthesia techniques</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Anaesthesia techniques</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As a standard procedure in our clinic, patients with dermatological operations will receive a TLA with more than 600 mg prilocaine. Seven blood samples (approximately 8 ml) will be taken 0, 1, 2, 4, 12, 24 and 48 hours after TLA, where the following parameters will be determined from:   
1. Demographic data and vital parameters
2. Met-Hb-concentration
3. Prilocaine-concentration
4. IL-1
5. IL-6
6. IL-8
7. TNF-alpha
8. CRP
9. Procalcitonin (PCT)
10. Creatine kinase (CK)
11. Lactate dehydrogenase (LDH)
12. Reticulocytes
13. Myoglobin
14. Haptoglobin 
15. Complications</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17346-0</funderId>
      <contactId>Contact55307_17346</contactId>
      <sponsorId>Sponsor53875</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55307_17346">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53875">
    <organisation>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine </organisation>
    <website>http://www.klinikum-mannheim.de/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marc.schmittner@anaes.ma.uni.heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411778.c</gridId>
    <rorId>https://ror.org/05sxbyd35</rorId>
  </sponsor>
  <funder id="Funder17346-0">
    <name>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">01121161</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of lifespan in AN69ST with two different heparinization strategies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Reduction of heparin dose in acute renal failure treated with hemodiafiltration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Filter lifespan, defined as the time period between patient's connection and filter disconnection due to filter clotting.</primaryOutcome>
      <secondaryOutcome>Adverse events, monitored for up to 24 days of treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Local research ethics committee, Göteborg, Sweden. Date of approval: 17/12/2007 (Dnr. 576-07)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01121161</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1446</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, open, randomised and controlled study with two parallel groups.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ae69dc32-626c-4977-adfb-92a93462aa2d">
	  <name>Sahlgrenska University Hospital</name>
	  <address/>
	  <city>Gothenburg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE- 413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients requiring continuous renal replacement therapies (CRRT) 
2. Aged 18 and over 
3. Patients weighing 30-120 kg 
4. Patients having signed a written consent to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. History of heparin antibodies or heparin-induces thrombocytopenia
2. Known hypertensive to any dialysis membrane
3. Current enrolment in another trial which could impact the successful completion of this study
4. Patients under guardianship
5. Patient anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week .These patients  can eventually be included in a later more stable phase
6. Unconscious patients for whom no relative or person of trust can give consent to treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study
7. Patient requiring anticoagulation for other indications e.g., valvular surgery or extracorporeal ventricular assist devices
8. Patients with active bleeding who does not require heparinization</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Swedish only)</patientInfoSheet>
      <recruitmentStart>2008-02-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute renal failure/  fluid overload</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Acute renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The same dialysis membrane, AN69ST, will be used for both the intervention and control treatment. Two different heparinization strategies will be compared: 

Control group (usual heparin doses): Bolus at start (between 1,000 IU - 2,500 IU) + usual infusion dose (10 IU/kg/h)  
Intervention group (Reduction of heparin dose): No bolus at start + infusion decreased by 50% (5 IU/kg/h)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17516-0</funderId>
      <contactId>Contact55478_17516</contactId>
      <sponsorId>Sponsor54061</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55478_17516">
    <title>Dr</title>
    <forename>Beng-Åke</forename>
    <surname>Henriksson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sahlgrenska University Hospital 
Department of Intensive Care (CIVA) </address>
      <city>Gothenburg</city>
      <country>Sweden</country>
      <zip>SE- 413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54061">
    <organisation>Gambro Lundia AB (Sweden)</organisation>
    <website>http://www.gambro.com/int</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Trial Function
Clinical Affairs
P.O. Box 10101</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>SE -220 10</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420188.7</gridId>
    <rorId>https://ror.org/05mw5ed57</rorId>
  </sponsor>
  <funder id="Funder17516-0">
    <name>Gambro Lundia AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-13T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">09648950</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to compare spinal cord stimulator implantation with laser treatment of the heart in patients with chronic angina</title>
      <scientificTitle>An open label, single-centre, randomized trial of spinal cord stimulation vs percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial</scientificTitle>
      <acronym>SPIRIT</acronym>
      <studyHypothesis>Refractory angina pectoris leads to significant morbidity. There is an increasing group of patients with 'refractory angina pectoris' who are unsuitable for conventional revascularization by coronary artery bypass surgery or percutaneous intervention. This patient group often have significant disability, with limiting symptoms, multiple medications, and frequent hospital admissions. 

Treatment options include percutaneous myocardial laser revascularization (PMR) and spinal cord stimulation (SCS). The primary objective of this study was to compare the effect of SCS vs PMR on treadmill exercise time on a modified Bruce protocol over a period of 12 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total exercise time on a modified Bruce protocol (ETT) at 12 months after SCS compared with PMR. In this study, all tests were terminated by the subject. Both SCS and PMR aim to reduce the frequency and severity of angina, and exercise tolerance is a comparatively objective method of measuring angina-free functional capacity.</primaryOutcome>
      <secondaryOutcome>1. Time to patient-reported angina during exercise test
2. Angina class as measured by the Canadian Cardiovascular Score angina scale
3. Morbidity and mortality
4. Safety profiles of each therapy
5. Health-related quality of life was assessed using questionnaires administered at 3, 12, 24 and 36 month follow-up (disease-specific Seattle Angina Questionnaire, the generic Short Form 36 health survey , and EuroQoL questionnaires)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval was obtained from the Huntingdon Local Research Ethics Committee, UK, prior to study commencement, on 15 August 2000 (ref: H00/557)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09648950</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Version 2.2 dated 5 January 2004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, open, parallel, single-centre, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a4ccb758-67b1-45f8-baeb-33fee1f20445">
	  <name>Papworth Hospital NHS Foundation Trust</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB23 3RE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with limiting angina (Canadian Cardiovascular Society [CCS] III or IV) despite maximally tolerated medical therapy 
2. Documented coronary artery disease (within the last 9 months prior to baseline), which is 
unsuitable for conventional revascularisation techniques
3. Patient has documented reversible ischaemia on nuclear scan (Tc-99 sestamibi) 
4. Patient is limited in daily activities, primarily exercise capability, by their anginal pain 
5. Age 18 or older
6. Patient must understand the therapy and give informed consent
7. Patient must be available for appropriate follow-up times for length of study
8. Non-pregnant women (only women who are post menopausal, surgically sterile or those of 
child bearing potential who are using an acceptable method of contraception) as safety for 
use of SCS during pregnancy or delivery has not been established. Acceptable methods of 
contraception include the following: 
a. Barrier type devices (e.g. female condom, diaphragm and contraceptive sponge) used only in combination with a spermicide 
b. Intrauterine devices (IDUs) 
c. Oral contraceptive agent 
d. Depro-ProveraTM (medroxyprogesterone acetate) 
e. Levonorgestrel implants 
f. Naturally sterile (amenorrheic for at least 1 year) in patients over 50 
Note: Abstinence, the rhythm method or contraception by the partner alone are NOT acceptable methods of contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Patient who is not a candidate for surgical implantation of the spinal cord stimulation system,
and/or not a candidate for a PMR procedure and/or unable to use the SCS device appropriately for treatment
2. Patient who has had one or more major cardiac events within the last 2 months
3. Patient with a myocardial wall thickness &lt;8 mm in the ischaemic area to be treated as verified
by echocardiography
4. Patient with extensive peripheral vascular disease that precludes vascular access required for
PMR
5. Patient on intravenous therapy to control their symptoms
6. Patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.
malignancy
7. Patient who has other diseases that are considered of greater clinical significance than the
angina pectoris (e.g. inadequately controlled diabetes mellitus, heart failure) that would impact
the ability of the clinician to adequately assess the incremental effects of the trial treatment
8. Patient with ejection fraction of less than 30% as verified by echocardiography
9. Patient with cause of angina other than coronary artery disease (e.g. syndrome "X" patient)
10. Patient who is unable to perform treadmill exercise test per protocol
11. Patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol
12. Patient who has had spinal cord stimulation (SCS) therapy, a transmyocardial laser revascularization (TMLR) or PMR procedure in the past
13. Patient with an implanted pacemaker or defibrillator
14. Patient who has medical conditions which may require Magnetic Resonance Imaging (MRI)
15. Patient with a history of dementia or other persisting mental disorders significantly interfering
with ability to cooperate or comply with the requirements of the study or comprehend informed
consent
16. Patient with history of alcohol or drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic angina pectoris</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Angina pectoris</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Trial patients were randomised to either Spinal Cord Stimulation System implant (SCS) or Percutaneous Myocardial Laser Revascularisation (PMR). 

The Spinal Cord Stimulation System used for this trial was a Medtronic fully implantable SCS systems. Either Itrel 3 or Synergy implantable generators were used. The spinal cord stimulation lead was chosen by the investigator from any Medtronic commercially available lead approved for use in refractory angina pectoris. The implant was performed according to the instructions in the technical manuals accompanying the devices. The lead was placed such that adequate/optimal paraesthesia was obtained in the area of angina pain. When adequate paraesthesia coverage was obtained the physician went on to permanent implant of the pulse generator. Proper patient education both pre and post implant of the device is essential. The investigator was responsible for adequately and regularly checking the integrity of the system at 3 months, 12 months and then annually. The stimulator should be used prophylactically by the patient for a minimum of 3 hours per day (for example: 3 times per day for a duration of 1 hour each). However, there is no upper limit and the patient may use the device as much as needed. Parameters for this stimulation vary from patient to patient. Therefore, the physician and patient need to work together to establish an effective and tolerable level. The stimulator should also be used at time of anginal attack to treat the pain. A higher level of stimulation may be used for this acute treatment. The maximum tolerable amplitude should be set for such use. However, it is necessary to assure that this level is not uncomfortable or painful. 

For this trial any commercially available Percutaneous Myocardial Revascularisation could be used. An optical fibre is inserted via the femoral artery under local anaesthesia and passed up into the left ventricle. Energy from a Ho:YAG laser is applied to the endocardial surface of the myocardium to vaporise the myocardial tissue and create channels from the endocardial surface into the myocardium. The co-axial system allows the laser to be manipulated in 3 planes giving access to the whole of the left ventricle. The laser position is monitored by fluoroscopy in orthogonal views. Once the position of the laser has been checked in both views, the laser is fired. Two bursts of the laser are used to create a channel 4-6 mm deep, in the myocardium, except in the apex where only one burst is used. The position is marked in both views on acetate sheets attached to the fluoroscopy monitors. Laser channels are created at a minimum of 1 cm apart, and are placed to cover the target region. Typically 10-15 channels are being made.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16554313 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ecfb6b5-2300-4e80-b1a6-ab84cb9c90b8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16554313"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17581-0</funderId>
      <contactId>Contact55543_17581</contactId>
      <sponsorId>Sponsor54127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55543_17581">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Schofield</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Papworth Hospital NHS Foundation Trust
Papworth Everared</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB23 3RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1480 830541</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.schofield@papworth.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54127">
    <organisation>Medtronic Sàrl (Switzerland)</organisation>
    <website>http://www.medtronic.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Route du molliau</address>
      <city>Tolochenaz</city>
      <country>Switzerland</country>
      <zip>CH-1131 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.471158.e</gridId>
    <rorId>https://ror.org/04pf17v09</rorId>
  </sponsor>
  <funder id="Funder17581-0">
    <name>This study was sponsored by Medtronic SA, who were responsible for funding of the trial related investigations such as perfusion scans and treadmill tests, research staff for data collection and travelling expenses for the subjects. The sponsor had no role in study design, data collection and interpretation, or in the decision to submit the above report for publication.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">14206374</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Posture control after lumbar microdiscectomy</title>
      <scientificTitle>Posture control after lumbar microdiscectomy: effect of transmuscular surgical approach and of early postoperative physiotherapy - a randomised clinical trial</scientificTitle>
      <acronym/>
      <studyHypothesis>1. Transmuscular surgical approach causes less damage to postoperative posture control because it does not damage the back muscle insertions
2. Early postoperative physiotherapy improves short and long term posture control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle control (assessed by postural balance test and sit-to-stand test), assessed in the lab at two weeks, eight weeks and six months post-operatively.</primaryOutcome>
      <secondaryOutcome>Comfort:
1. Back pain
2. Sciatica
3. Functional status
4. Return to work

Secondary outcome measures are assessed by standardised patient questionnaires preoperatively and at two weeks, eight weeks, six months and one year postoperatively.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Commissie Medische Ethiek of Leuven University Hospitals in November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14206374</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S50782</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, randomised, single centre trial with four arms (two variables: early specific physio versus later non-specific physio; transmuscular versus paramedian surgical approach).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-18T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a8b3dae0-262c-42e2-882b-d1bcbd038e75">
	  <name>Department of Neurosurgery</name>
	  <address/>
	  <city>Leuven</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>3000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. One level disc herniation, either L4-L5 or L5-S1, explaining symptoms and representing operative indication. Purely median disc herniations are excluded.
2. Age: 18 - 60 years, either sex
3. Living within 30 km perimeter of the hospital
4. Informed consent signed</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Emergency operation required
2. Litigation, worker's compensation
3. Clinical suspicion of depression or fibromyalgia (the suffering is not exlusively explained by the disc herniation)
4. Previous lumbar surgery, irrespective of the level
5. Significant neurological deficit (weakness worse than 4/5)
6. Systemic disease significantly affecting patient's functioning (American Society of Anaesthesiologists [ASA] grade greater than 3)
7. Median disc herniation
8. Patient unable to communicate in the Dutch language</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Dutch).</patientInfoSheet>
      <recruitmentStart>2008-02-18T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sciatica caused by a lumbar disc herniation</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other intervertebral disc disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Transmuscular surgical approach versus classic paramedian approach to the disc herniation at surgery
2. Early postoperative physiotherapy, starting two weeks postoperatively, and consisting of an individualised program with standardised goals versus 'conservative' treatment: no physiotherapy in the first six weeks post-operation and after six weeks only when indicated

Follow up is one year for all four arms.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17533-0</funderId>
      <funderId>Funder17533-1</funderId>
      <funderId>Funder17533-2</funderId>
      <contactId>Contact55495_17533</contactId>
      <sponsorId>Sponsor54079</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55495_17533">
    <title>Prof</title>
    <forename>Bart</forename>
    <surname>Depreitere</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Neurosurgery
University Hospitals Leuven
Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54079">
    <organisation>University Hospitals Leuven (The Netherlands)</organisation>
    <website>http://www.uzleuven.be/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410569.f</gridId>
    <rorId>https://ror.org/0424bsv16</rorId>
  </sponsor>
  <funder id="Funder17533-0">
    <name>Contribution for logistic expenses:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-1">
    <name>Medtronic B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-2">
    <name>Stryker Nederland (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">84003996</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of mesalazine to prevent relapse in paediatric crohn&#146;s disease</title>
      <scientificTitle>Prevention of relapse by mesalazine (Pentasa®) in paediatric crohn's disease: a multicentric double-blind randomised placebo-controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>The trial&#146;s primary objective was to compare the efficacy of mesalazine (Pentasa®, Ferring) versus placebo in maintaining remission in paediatric crohn's disease (CD) patients, when used after the successful treatment of an acute episode with either medication alone or parenteral/enteral nutrition techniques combined or not with medication.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical relapse (HB score greater than or equal to 5, if confirmed within two weeks) 
2. Surgery for an acute complication of CD

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</primaryOutcome>
      <secondaryOutcome>Treatment failure, defined as:
1. Relapse
2. Failure of steroid withdrawal (weaning failure)
3. Side-effects intolerance requiring treatment discontinuation
4. Worsening or aggravation of patient status requiring treatment interruption 
5. Initiation of a new treatment as decided by the clinician

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethcis approval received from the Ethics Committee of Paris VII on the 10th January 1991 (ref: Etude Pentacomp/90/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84003996</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Etude Pentacomp/90/91</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentric, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e3e431c1-1ff0-4c65-9ce5-adb87da73520">
	  <name>Hopital Robert Debré 48 Bd Sérurier</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>75019</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children less than 18 years old, either sex
2. Diagnosed with crohn&#146;s disease before the age of 16 by means of clinical, radiological, endoscopic and histological data
3. Had to be in an active phase defined by:
3.1. A Harvey Bradshaw score (HB) greater than or equal to 5, and
3.2. An erythrocyte sedimentation rate (ESR) greater than or equal to 25 mm at hour one
4. All lesion localisations, except exclusive anorectal localisation, were included, providing patients&#146; lesion extension had been assessed within two years prior to inclusion

After flare-up treatment, inclusion criteria were as follows: 
1. Patients in clinical remission within six months following flare-up treatment initiation at pre-inclusion
2. An HB score under 5
3. An ESR under 25 mm
4. Normal hepatic and renal functions</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60, extended to 120</totalTarget>
      <exclusion>1. Flare-up had been treated with mesalazine or had required immuno-suppressors
2. Patients with known hypersensitivity to salicylate
3. Patients whose flare-up had occurred at pre-inclusion when on a 5-aminosalicylic acid (5-ASA) dose greater than 50 mg/kg/day for over two months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Paediatric crohn's disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Crohn's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>At inclusion, patients were randomised per stratum, within each centre, using random permuted two to four sized-blocks (each centre did not know the size of their own block), to the following:
1. 50 mg/kg/day mesalazine dose 
2. Placebo (identical tablets) 

This was taken over a one-year period. Patients were monitored every three months over a one-year period or until endpoint. 

The study treatment was initiated either one week after the interruption of parenteral or enteral nutrition, or at the end of a sulfalazine or metronidazole treatment, or if the prednisone dose during the steroid weaning period was below 0.2 mg/kg. After the study treatment began, only antispasmodic and antidiarrhoeal agents, as well as sedatives were to be given as possible additional medications. 

Following the recruitment of 57 children from 1991 to 1993, trial results showed a trend favouring mesalazine. Recruitment was consequently resumed from 1996 to 1999.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mesalazine (Pentasa®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17517-0</funderId>
      <contactId>Contact55479_17517</contactId>
      <sponsorId>Sponsor54062</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55479_17517">
    <title>Prof</title>
    <forename>Jean Pierre</forename>
    <surname>Cezard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hopital Robert Debré 48 Bd Sérurier</address>
      <city>Paris</city>
      <country>France</country>
      <zip>75019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+33 (0)1 40 03 23 62</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jean-pierre.cezard@rdb.aphp.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54062">
    <organisation>Ferring SA (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>7 rue Jean Baptiste Clément</address>
      <city>Gentilly</city>
      <country>France</country>
      <zip>94250</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487243.e</gridId>
    <rorId>https://ror.org/03vrwsp35</rorId>
  </sponsor>
  <funder id="Funder17517-0">
    <name>Ferring SA (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">45000842</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimisation of incision hernia surgery treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Open mesh repair hernia surgery is better than suture repair hernia surgery of incision hernia treatment
2. The recurrence rate using suture hernia repair technique is much higher than mesh repair technique
3. The recovering time to the normal physical activity after surgery is faster, quality of life is better using mesh repair with sublay technique than mesh repair with onlay technique or suture repair technique of the incision hernia treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Recurrence rate, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Quality of life, measured using the 36-item Short Form health survey version 2 (SF-36 v2)at 2 weeks, 1, 3, 6 and 12 months after surgery</primaryOutcome>
      <secondaryOutcome>1. Postoperative complications, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Change of the blood gas and intra-abdominal pressure, measured before and after surgery
3. Recovering time to the normal physical activity after surgery, measured at 2 weeks, 1, 3, 6 and 12 months after surgery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Kaunas Biomedical Research Ethics Committee on the 5th June 2007 (ref: BE-2-41).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45000842</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>73/2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lithuania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dab1e29b-4963-4afa-8cd1-4bd21622092f">
	  <name>Eiveniu str. 2</name>
	  <address/>
	  <city>Kaunas</city>
	  <state/>
	  <country>Lithuania</country>
	  <zip>LT50009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All 18 - 80 years old patients with incision hernia, who will be operated and agree to participate in this clinical trial.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50 patients in each group, 150 patients in all</totalTarget>
      <exclusion>1. Patients older than 80 years
2. Incarcerated incision hernia
3. Mental patients with incision hernia
4. Pregnant women with incision hernia
5. Patients with incision hernia do not agree to participate in this clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hernia</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Hernia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Three groups:
1. Keel technique
2. Onlay technique
3. Sublay technique

The follow up period is 2 weeks, 1, 3, 6 and 12 months after surgery. Surgery, blood gas analysis and intra-abdominal pressure investigation before and after operation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17283-0</funderId>
      <contactId>Contact55244_17283</contactId>
      <sponsorId>Sponsor53812</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55244_17283">
    <title>Dr</title>
    <forename>Linas</forename>
    <surname>Venclauskas</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53812">
    <organisation>Kaunas Medical University Hospital (Lithuania) - Department of Surgery </organisation>
    <website>http://www.kmu.lt/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.45083.3a</gridId>
    <rorId>https://ror.org/0069bkg23</rorId>
  </sponsor>
  <funder id="Funder17283-0">
    <name>Kaunas Medical University Hospital (Lithuania) - Department of Surgery</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">72781592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Short versus long buprenorphine-naloxone treatment in intravenous buprenorphine withdrawal: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>BUNXLOW</acronym>
      <studyHypothesis>1. To investigate the effectiveness of buprenorphine-naloxone compared with treatment as usual (lofexidine) in withdrawal of intravenous buprenorphine dependence
2. To determine whether a longer regime is more effective than a shorter one</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Completion of withdrawal
2. Retention in rehabilitation for one month
3. Abstinence at one month after withdrawal
4. Abstinence at six months after withdrawal</primaryOutcome>
      <secondaryOutcome>1. The extent of withdrawal symptoms experienced, recorded every day during withdrawal
2. The amount of additional medication needed, recorded every day during withdrawal
3. Whether the patient begins naltrexone medication, patients will be offered an opportunity to begin naltrexone three days before finishing withdrawal 
4. Patient satisfaction, measured at the last day of withdrawal, whether at the intended finishing date, or at premature termination of withdrawal. Satisfaction will be measured by a self-made questionnaire of seven questions concerning the satisfaction with the medication, the length of medication, the additional medication, the length of withdrawal, the staff, the opportunity of beginning naltrexone and the overall satisfaction with the withdrawal treatment. Answers will be recorded with a five-grade scale</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The Ethics Committee for Pediatrics, Adolescent Medicine and Psychiatry/Hospital District of Helsinki and Uusimaa on the 15th May 2007; amendment on the form of informed consent was approved 19th June 2007 (ref: 148/E7/2007)
2. The National Agency for Medicines approval on the 22nd August 2007 (ref: 96/2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72781592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HDL07-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, three-arm, parallel group, single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="587bfde4-7c31-404f-a050-a7361d54ff19">
	  <name>Munkkisaarenkatu 16</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>01500</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Opiate dependence (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition [DSM IV])
2. Current misuse of buprenorphine intravenously (mimimun 3 mg/day) (use confirmed by urinalysis)
3. Willingness to participate in withdrawal in the treatment centre and in rehabilitation afterwards
4. Aged between 18 and 50</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="50.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 patients</totalTarget>
      <exclusion>1. Other than buprenorphine as the primary drug of misuse
2. Misuse of other opiates then buprenorphine during the last week (confirmed by urinalysis)
3. Opiate maintenance therapy
4. Psychotic symptoms at recruitment
5. Psychiatric or somatic disease or symptoms that may require hospitalisation at near future
6. Salient increase in alanine aminotransferase (ALAT)
7. Pregnancy
8. Allergy to lofexidine, buprenorphine or naloxone
9. Former participation to the same study
10. Concurrent participation to other intervention studies
11. Native language other than Finnish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intravenous misuse of buprenorphine</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Opiate dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Short buprenorphine-naloxone (Bu-nx) arm: for 9 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 5: 8 mg
Days 6 - 7: 4 mg 
Days 8 - 9: 2 mg

2. Long buprenorphine-naloxone arm: for 25 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 9: 8 mg
Days 10 - 12: 6 mg 
Days 13 - 16: 4 mg 
Days 17 - 20: 2 mg 
Days 21 - 25: 1 mg

3. Lofexidine arm: lofexidine according to clinical assessment, maximum dose 2.4 mg/d divided into two to three doses, maximum duration 21 days

 In all arms, the intended withdrawal duration (in-patient treatment) is 28 +/- 7 days, and the follow-up period is up to six months after that.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Buprenorphine-naloxone, iofexidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16935-0</funderId>
      <funderId>Funder16935-1</funderId>
      <funderId>Funder16935-2</funderId>
      <contactId>Contact54896_16935</contactId>
      <sponsorId>Sponsor53461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54896_16935">
    <title>Dr</title>
    <forename>Outi</forename>
    <surname>Kuikanmäki</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53461">
    <organisation>Helsinki Deaconess Institute (Finland)</organisation>
    <website>http://www.hdl.fi</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Outi Kuikanmäki
Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487156.9</gridId>
    <rorId>https://ror.org/04zqw9t81</rorId>
  </sponsor>
  <funder id="Funder16935-0">
    <name>Academy of Finland (Finland)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002341</fundRef>
  </funder>
  <funder id="Funder16935-1">
    <name>National Public Health Institute (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16935-2">
    <name>Helsinki Deaconess Institute (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">84133969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fractional photothermolysis versus triple therapy for the treatment of melasma: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Fractional photothermolysis may be an effective and safe alternative for the treatment of melasma and the effect of the treatment with fractional photothermolysis may last longer than the effect of the triple therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Observer blinded clinical score (Melasma Area and Severity Index [MASI] score), measured before treatment and during 3, 12 and 24 weeks of follow-up
2. Objective colour measurement by reflectance spectroscopy, measured before treatment and during 3, 12 and 24 weeks of follow-up</primaryOutcome>
      <secondaryOutcome>1. Visual assessment of side effects and quality of life measurements (skindex):
1.1. Fraxel laser group: after laser treatment and during follow-up (3, 12, 24 weeks)
1.2. Triple group: during follow-up (3, 12, 24 weeks)
2. Registration of side effects noticed by the patient: 
2.1. Fraxel group: after laser treatment and during follow-up
2.2. Triple group: after three weeks of treatment by telephone</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Centrale Commissie Mensgebonden Onderzoek (CCMO) on the 19th September 2007 (ref: NL18605.018.07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84133969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>fraxel-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, observer blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fe24a693-9360-407e-8947-a0ba8e4e612a">
	  <name>Meibergdreef 35</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients with melasma
2. Skin photo type II - V
3. Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders
4. Aged at least 18 years
5. Subject is willing and able to give written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Bleaching cream during the past four weeks
2. Local corticosteroids during the past four weeks
3. Subjects with a history of keloids
4. Subjects with active eczema
5. Subjects with active acne in the face
6. Subjects with a history of facial eczema
7. Suspect allergy to lidocaine or the triple therapy
8. Use of roaccutane in the past six months
9. Subjects not competent to understand what is involved
10. Pregnancy
11. Lesion suspicious for malignancy
12. High exposure to sunlight (vacation in southern countries) or ultraviolet (UV) light (UVA or UVB)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melasma</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Disorders of pigmentation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will be randomly allocated to one of two groups who receive either triple therapy (bleaching cream [hydrochinon 5%, tretinoin 0.05% and triamcinolon acetonide 0.1% in cremor lanette II]) or fractional photothermilysis using the fraxel laser. 

Triple therapy: 
The triple therapy will be applied once a day in the evening on all hyperpigmented macules for eight weeks. Follow-up will take 3, 12 and 24 weeks post therapy. 

Fractional photothermolysis: 
Subject will receive a total of four laser treatments, with two week intervals. A topical anaesthetic ointment will be applied to the skin before treatment. The treated area will be less than 3% of the body surface. Follow-up will take place 3, 12 and 24 weeks post therapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triple therapy bleaching cream (hydrochinon, tretinoin, triamcinolon acetonide)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16718-0</funderId>
      <contactId>Contact54676_16718</contactId>
      <sponsorId>Sponsor53232</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54676_16718">
    <title>Dr</title>
    <forename>Albert</forename>
    <surname>Wolkerstorfer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53232">
    <organisation>Academic Medical Centre (AMC) (The Netherlands) </organisation>
    <website>http://www.amc.uva.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16718-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">14127815</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The SphynX trail: a randomised clinical trial comparing the outcome of endoluminal fundoplication with EsophyX™ to laparoscopic Nissen fundoplication for refractory gastro-esophageal reflux disease (GERD)</title>
      <scientificTitle/>
      <acronym>SphynX</acronym>
      <studyHypothesis>Endoluminal fundoplication with Esophyx™ will not be less effective than laparoscopic Nissen fundoplication, expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effectiveness will be expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery (Visick grading). Visick classification: grade I: No symptoms, resolved; grade II: Mild occasional symptoms easily controlled, improved; grade III: Mild symptoms not controlled, unchanged; grade IV: Not improved, worsened. Success will be defined as grade I or II and failure will be defined as grade III or IV.</primaryOutcome>
      <secondaryOutcome>1. Success expressed as the percentage of patients with normalisation of acid exposure on pH metry, minus the percentage of patients needing reintervention (dilatation or re-operation) for troublesome dysphagia at six months

Definition of objective normalisation of acid exposure: 
The combination of the following:
a. Upright acid exposure &lt;8.4%
b. Supine acid exposure &lt;3.4 % 
c. Total acid exposure &lt;5.8% on post-operative 24-h pH-monitoring
The presence of troublesome dysphagia will render the procedure unsuccessful. 

2. Percentage of patients free from PPIs at three and six months
3. Quality of Life (QoL) assessment: Visual analogue scale [VAS] score, the 36-item Short Form health survey (SF-36) and EuroQol (EQ-5D) at three and six months
4. Impact of reflux symptoms on QoL: The Gastro-Oesophageal Reflux Disease Health-Related Quality-of-Life scale  (GORD-HRQoL) at three and six months
5. Esophageal symptoms: OES18 score at three and six months
6. Prevalence of esophagitis on upper endoscopy at six months
7. Cost-effectiveness expressed as costs per successfully treated patients and incremental costs per Quality Adjusted Life Year gained at six months</secondaryOutcome>
      <trialWebsite>http://www.esophyx.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Independent central medical ethics committee of the University Medical Center Utrecht has approved the study protocol. Date of approval: 08/01/2008 (EC ref: 07-214; CCMO ref: 1795404107)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14127815</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>07-214</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised non-inferiority multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2009-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="944ca3ea-fb2a-4784-b3d4-d6b483d46e6a">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. GERD patients of eight Dutch hospitals with reflux symptoms persisting for over 6 months despite double dose of Proton Pump Inhibitor (PPI) (&gt;40 mg omeprazole/24 hours or comparable therapy) and/or patients who refuse or do not tolerate to take acid suppressing drugs for life.  
2. Documented temporal relation between pathological reflux and symptoms during 24-hr pH monitoring. 
Pathological reflux is defined as upright acid exposure &gt;8.4%, supine acid exposure &gt;3.4 % and/or total acid exposure &gt;5.8% on 24-hr pH monitoring. A documented relation between reflux and symptoms is reflected by a Symptom Association Probability (SAP) &gt;95%. 
3. Patients without a diaphragmatic hernia or a sliding hernia not exceeding 2 cm (endoscopically measured distance from Z-line and impression of the diaphragm). 
4. Age between 18 and 65 years. 
5. Informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Patients with a diaphragmatic hernia other than of the sliding type and/or larger than 2 cm.
2. Grade C and D esophagitis according to the Los Angeles classification.
3. Histologically proven long-segment Barrett's oesophagus.
4. Patients with severe esophageal or gastric motility disorders. 
5. Patients with a history of esophageal- or gastric surgery. 
6. American Society of Anaesthesiologists classification III and IV patients. 
7. Patients with a psychiatric disease or other conditions making them incapable of filling out the questionnaires or completing the objective esophageal function tests. 
8. Pregnancy.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2009-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastro-esophageal reflux disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastro-esophageal reflux disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endoluminal fundoplication with EsophyX™ versus laparoscopic Nissen fundoplication.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17532-0</funderId>
      <funderId>Funder17532-1</funderId>
      <funderId>Funder17532-2</funderId>
      <funderId>Funder17532-3</funderId>
      <funderId>Funder17532-4</funderId>
      <funderId>Funder17532-5</funderId>
      <funderId>Funder17532-6</funderId>
      <funderId>Funder17532-7</funderId>
      <funderId>Funder17532-8</funderId>
      <contactId>Contact55494_17532</contactId>
      <sponsorId>Sponsor54078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55494_17532">
    <title>Prof</title>
    <forename>H G</forename>
    <surname>Gooszen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht 
P.O. Box 85500 
H.P. G04.228 </address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54078">
    <organisation>University Medical Center Utrecht and seven participating hospitals (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500 
H.P. G04.228</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder17532-0">
    <name>The costs of this trial are internally covered by the eight participating hospitals in the Netherlands:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-1">
    <name>University Medical Center Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-2">
    <name>Meander Medical Center Amersfoort</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-3">
    <name>Lange Land Hospital Zoetermeer</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-4">
    <name>Catharina Hospital Eindhoven</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-5">
    <name>Medical Center Leeuwarden</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-6">
    <name>Antonius-Mesos Hospital Nieuwegein-Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-7">
    <name>Rivierenland Hospital Tiel</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-8">
    <name>Amphia Hospital Breda</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">09659857</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Outpatient chemotherapy protocol using 3 cosolidated drugs (cisplatin, 5 fluoururacil and leucovorin) in a different scheme for the treatment of head and neck and oesophageal cancer, designed for patients without surgical and radiation therapy options</title>
      <scientificTitle>Low cost, outpatient, cisplatinum, 5-fluoururacil and leucovorin chemotherapy regimen for advanced head and neck, and upper oesophageal carcinomas</scientificTitle>
      <acronym/>
      <studyHypothesis>Evaluate the combination of bolus CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL) in patients with advanced (residual, metastatic or recurrent) squamous cell carcinoma (SCC) of head (H)/neck (N) and oesophagus (E), aiming at a feasible and low cost chemotherapy (CHT) regimen to circumvent the need of infusion pumps and/or hospital admission.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Quality of life (QoL) evaluated using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire, previously used in Portuguese, at the beginning of study and before each cycle
2. Toxicities analysed according to National Cancer Institute (NCI) criteria before each cycle together with KPS, clinical reassessment and laboratory evaluation
3. Response, evaluated by computed tomography (CT) scans after 3rd and 6th cycles of chemotherapy and analysed by response evaluation criteria in solid tumours (RECIST)
4. Performance status by measured with Karnofsky Performance Status (KPS)</primaryOutcome>
      <secondaryOutcome>1. Overall survival - time between enrolment and death
2. Progression Free Survival - time between enrolment and disease progression</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ABC Medical School Ethics Committee in December 2004 (ref: 185/2004).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09659857</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II, single arm study conducted at a single Brazilian Institution</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5eb15996-b980-4766-868b-86b9b89146f3">
	  <name>Rua Mere Amedea 833</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>02125-001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Advanced or recurrent, histologically confirmed, head and neck and oesophagus squamous cell carcinoma
2. Patients have to be 18 years of age or older, either sex
3. Normal renal function
4. Measurable disease by the response evaluation criteria in solid tumours (RECIST)
5. Karnofsky performance status (KPS) equal or greater to 50%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15 patients</totalTarget>
      <exclusion>1. Not meeting the inclusion criteria
2. Concomitant radiation therapy
3. Not a candidate for chemotherapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and Neck and Upper oesophageal carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Squamous cell carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chemotherapy as follows:
Leucovorin 20 mg/m^2/day bolus infusion for four days (D1 - D4), followed by 5-fluoururacil  370 mg/m^2/day bolus infusion for four days (D1 - D4), and Cisplatinum 25 mg/m^2/day in 90 minutes infusion for three days (D1 - D3), every 21 to 28 days, depending upon hematological recovery.

Follow up is until patient death, expected to be less then 24 months for each patient.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17436-0</funderId>
      <funderId>Funder17436-1</funderId>
      <contactId>Contact55397_17436</contactId>
      <sponsorId>Sponsor53967</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55397_17436">
    <title>Dr</title>
    <forename>Vanessa</forename>
    <surname>Fabricio</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Mere Amedea 833</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>02125-001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vcf35@terra.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53967">
    <organisation>Hospital Mario Covas (Brazil) </organisation>
    <website>http://www.hospitalmariocovas.org.br</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Rua Henrique Calderazzo, 321
Bairro Paraíso </address>
      <city>Santo Andre</city>
      <country>Brazil</country>
      <zip>09190-615 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sau@hesa-fuabc.org.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487168.4</gridId>
    <rorId>https://ror.org/00s7ek396</rorId>
  </sponsor>
  <funder id="Funder17436-0">
    <name>ABC Foundation (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17436-1">
    <name>Hospital Mario Covas (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">76047793</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Adhesion prevention with icodextrin</title>
      <scientificTitle>The effect of 4% icodextrin solution vs lactated Ringer's solution on adhesiolysis during Hartmann's reversal: A multi-centre randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Laparotomy almost always causes peritoneal adhesions, which further causes morbidity and even mortality. A regimen to prevent peritoneal adhesions is urgently needed. Icodextrin has been shown to prevent adhesion formation, and our study investigated further the efficacy of icodextrin in colorectal operation. 

Study hypothesis: 
4% icodextrin solution decreases adhesion formation and time needed to divide them after hartmann's procedure compared to lactated Ringer's solution.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Time needed to separate postoperative adhesions, assessed approximately 3 months after hartmann's reversal procedure
2. Total operative time</primaryOutcome>
      <secondaryOutcome>1. Complications and recovery after Hartmann's reversal procedure. Duration of follow-up: 1 month 
2. Safety of icodextrin. Duration of follow-up: 1 month</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>National approval of the study received on 30 April 2003 from the Ethical Committee of Päijät-Häme Hospital District ETL-code Q36. Further approved by every local ethical committee of participating hospitals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76047793</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, multi-centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="df6e5043-6d70-403e-b683-1823b1916eaf">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Lahti</city>
	  <state/>
	  <country>Finland</country>
	  <zip>15850</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients having rectosigmoid colon obstruction, perforation or diverticulitis (with or without perforation) for which a Hartmann's operation was planned</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Refusal to consent
2. Pregnancy
3. Peritoneal carcinoma
4. Postoperative radiotherapy before restorative surgery
5. Reoperation violating study protocol
6. Severe concomitant disease or other reason that would probably interfere with the restorative surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Laparotomy/ peritoneal adhesions</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Laparotomy/ peritoneal adhesions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study group receives at the end of Hartmann's procedure 1000 ml of 4 % icodextrin instilled into the abdomen. The control group receives same amount of lactated Ringer's solution.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17400-0</funderId>
      <contactId>Contact55361_17400</contactId>
      <sponsorId>Sponsor53931</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55361_17400">
    <title>Dr</title>
    <forename>Jyrki</forename>
    <surname>Kössi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Päijät-Häme Central Hospital
Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53931">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder17400-0">
    <name>Internally funded by the Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">65305620</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is misoprostol a safe alternative to manual vacuum aspiration in women with incomplete abortions in developing countries?</title>
      <scientificTitle>Is misoprostol a safe alternative to manual vacuum aspiration in women with early pregnancy failure in a low resource setting?: a randomized controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Misoprostol is just as effective as Manual Vacuum Aspiration (MVA) in treatment of first trimester pregnancy failure, but is more acceptable to clients in a rural setting in low resource countries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Ultrasonographic endometrium thickness at day 8</primaryOutcome>
      <secondaryOutcome>The following will be assessed at day 8: 
1. Changes in hemoglobin (Hb) level
2. Side effects including pain 
3. Adverse events 
4. Patients satisfaction and acceptability 

If any problem is observed on day 8, the patient will be reviewed again on day 15 (No review at day 15 if no problem is observed).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The National Institute of Medical Research Dar es Salaam, approved on 18 October 2007 (ref: NIMR/HR/R.8a/Vol. IX/628)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65305620</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blinded, single-centre, randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-02-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e226d8a5-b2b9-4ac5-ba03-7f20cc8cad96">
	  <name>PO box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. History of passage of tissue and/or blood and &gt;30 mm endometrial thickness on TransVaginal Sonography (TVS) 
2. On TVS an anembryonic gestation or fetal death with an embryonic crown-rump length between 5 and 62 mm without cardiac activity (in case of a Crown-Rump Length [CRL] of 5-9 mm TVS will be repeated after one week to ensure absence of cardiac activity) or an anembryonic gestational sac of 16-45 mm (TVS will be repeated after one week to ensure growth of the gestational sac is &lt;3 mm and exclude a viable pregnancy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. On TVS present fetal heart activity, a crown-rump length &gt;62 mm, molar pregnancy or a endometrial thickness less than or equal to 30 mm
2. Fundal height of more than halfway the umbilicus and the symphysis indicating a gestational age &gt;12 weeks
3. Known allergy to prostaglandins
4. Heavy blood loss or a pulse rate of &gt;120/min
5. Axillary temperature of &gt; 38°C or signs of septic abortion such as pus draining from uterus
6. Ectopic pregnancy</exclusion>
      <patientInfoSheet>Patient information form in Kiswahili is available on request. Please use the contact details below to request.</patientInfoSheet>
      <recruitmentStart>2008-02-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-02-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>First trimester pregnancy failure</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>First trimester pregnancy failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Misoprostol 600 microgram 3 doses (one dose every 4 hours) sublingually versus MVA</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17482-0</funderId>
      <contactId>Contact55444_17482</contactId>
      <sponsorId>Sponsor54024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55444_17482">
    <title>Dr</title>
    <forename>Regine</forename>
    <surname>Unkels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54024">
    <organisation>Tanzanian German Program to Support Health  (TGPSH)  (Tanzania)</organisation>
    <website>http://www.tgpsh.or.tz</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Lindi Office
PO box 97</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17482-0">
    <name>Tanzanian German Program to Support Health (TGPSH) (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-15T00:00:00.000Z">82469428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</title>
      <scientificTitle>A randomised, double-blind, comparative, multi-centre study of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</scientificTitle>
      <acronym/>
      <studyHypothesis>Is 5 x 200 mg iron sucrose over 3 weeks more effective in the treatment of restless legs than placebo?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>International RLS Study Group Rating Scale at 11 weeks</primaryOutcome>
      <secondaryOutcome>1. Epworth Sleepiness Scale at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months
2. Incidences and severities of adverse events, assessed after 3 , 7 and 11 weeks, 5, 8 and 12 months
3. To assess the ability of the treatments to correct aberrant haematology and iron status at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University Hospital, Uppsala. Date of approval: 13 June 2003 (ref: 03-141)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82469428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPV-0105</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-22T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbc1ec18-e878-47d5-87a1-f050de824c58">
	  <name>Medical Department</name>
	  <address/>
	  <city>Avesta</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-774 82</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18-70 years
2. RLS defined by four cardinal criteria
3. Ten points or more on the International RLS (IRLS) Study Group Rating Scale 
4. S-ferritin below 45 µg/L, and with folic acid and vitamin B12 within reference values
5. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Treatment with any of the following: 
1.1. Psychopharmacological treatment with antidepressive and dopaminergic agents, sedatives, anticonvulsants and/or pain relievers, i.e. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or stronger, during the preceding 2 weeks. This was changed in study protocol clarification number 2 to "...i.e. with the exception of NSAIDs - during the last 2 weeks". 
1.2. Calcium antagonists, antihistaminic or antiemetic drugs during the preceding 2 weeks. 
1.3. Iron administration during the preceding 2 months 
1.4. Nutritional supplements or natural pharmaceuticals containing iron 
1.5. Antiepileptics 
1.6. Vitamin B12 or folic acid 
2. Presence of clinically significant disease/dysfunction, which in the opinion of the investigator should disqualify the patient from this study, such as asymptomatic intestinal bleeding 
3. Patients suffering from obstructive sleep apnoea syndrome 
4. S-creatinine &gt;130 µmol/L 
5. Positive result of pregnancy test 
6. Breast-feeding women 
7. Contraindications for iron sucrose</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2003-06-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-22T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Restless legs syndrome</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Restless legs syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg iron sucrose intravenously 5 times over 3 weeks versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>iron sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17503-0</funderId>
      <contactId>Contact55465_17503</contactId>
      <sponsorId>Sponsor54046</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55465_17503">
    <title>Prof</title>
    <forename>Jan</forename>
    <surname>Ulfberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Department
Avesta Hospital</address>
      <city>Avesta</city>
      <country>Sweden</country>
      <zip>SE-774 82 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54046">
    <organisation>Renapharma AB (Sweden)</organisation>
    <website>http://www.renapharma.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Box 938</address>
      <city>Uppsala</city>
      <country>Sweden</country>
      <zip>SE-751 09  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476652.4</gridId>
    <rorId>https://ror.org/03x49ea82</rorId>
  </sponsor>
  <funder id="Funder17503-0">
    <name>Renapharma AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">41063599</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Family orientated early intervention enhances social-interactive behaviour of premature infants and mother-infant-interaction</title>
      <scientificTitle/>
      <acronym>PRIMA Study (Prospective Randomized Implementation of the Model-project Augsburg)</acronym>
      <studyHypothesis>Condition: Very preterm children who are at an increased risk of cognitive impairments, poor educational achievement and behavior problems and psychopathology. Most consistently, an increased risk for attention problems, hyperactivity and social or peer relationship problems have been reported across a range of hospital and geographically defined cohorts. Improvements in infant self-regulation and mother-infant-relationship may avert longterm behavioural and social relationship sequelae of very preterm birth. A first step in demonstrating such a link is to test in a randomised controlled trial whether an individualised family based approach can alter infant social-emotional regulation. 

Hypothesis: Does an individualised family-based early support intervention (case management approach) for mothers of prematurely born infants alter 1) the maternal sensitivity and 2) infant social-emotional regulation and reciprocal quality of mother-infant interaction in the first 6 months of life?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was the improvement in social-interactive behaviour of the infants, mother's sensitivity and the dyadic quality of interaction. Before discharge the nurses assessed the early mother sensitivity with the Boston City Hospital Assessment of Parental Sensitivity (BCHAPS)(Timepoint 1). This questionnaire consists of 13 closed-ended items, evaluating the mother's sensitive responsivness and care giving competence. The items are ranked on 5-point scales from "poor" to "competent" and the scores totalled. 

At 6 months corrected age the infant social-interactive behaviour and mother-infant interaction were assessed with the Mother-Infant Structured Play Assessment (MISPA)(Timepoint 2). This is an 8-minute, semi-structured face-to-face play interaction which includes the Still-Face Paradigm, which provides a method to access infant regulatory capacities and illustrates central qualities of the young infant's capacities for interpersonal engagement. For the interaction records the infants were placed on a blanket or mat on the floor and mothers were asked to sit on the floor opposite their infant. A mirror was mounted at an angle, which enabled the examiner to videotape both the face and body of the infant and the face and upper torso of the mother. Standardised instructions were used to explain the procedure to the mothers. 

Episode 1 involved the mother playing with her baby with a rattle (warm-up). After 2 minutes (Episode 2) she was cued to lay aside the rattle and play (without a toy) with her baby for another 2 minutes. Then she was asked to get her baby to watch her face, which lasted for 1 minute (Episode 3). Next she was asked to make a still-face for 1.5 minutes (Episode 4) and then finally asked to resume playing with her baby for another 1.5 minutes (Episode 5). 

Three existing schemes were modified and adapted to create a suitable coding scheme: 
1. The Play Observation Scheme and Emotion Ratings (POSER)
2. The Emotional Availability Scales (EAS)
3. Tronick and Weinberg's Infant and Caregiver Engagement Phases (ICEP)

Each interaction episode was coded with 5-point scales reflecting maternal sensitivity (apart from episode 4) and infant social regulatory behaviour. Maternal Sensitivity consisted of 5 rating scales (sensitivity, positive response, negative facial emotional expression, verbal involvement, undercontrol) that were totalled to gain a measure of maternal sensitivity. Social Regulatory Behaviour was also assessed using 5 rating scales (emotional state, attentiveness, responsivness, vocalisation, clarity of signals). 

Quality of dyadic interaction consisted of 2 five-point rating scales (Harmony, Control over interaction) and the scores were totalled. Each of the five episodes in the MISPA was scored separately, and infant, maternal and dyadic behaviours were coded individually. The last episode demonstrating mother-infant reunion after perturbation of interaction was decided to be confirmative for the effect of the intervention. This episode presents the infant with a complex and demanding regulatory task: the infant needs to simultaneously cope with the resumption of the maternal behaviour, as well as the carry-over of negative affect from the still-face episode.</primaryOutcome>
      <secondaryOutcome>The demographic characters and the medical and psychosocial burden of the families were recorded with a structured mother-interview at both time points. Several items of the interview ware totalled showing a dyadic adjustment scale and a psyochosocial stress-index.</secondaryOutcome>
      <trialWebsite>http://www.betainstitut.de/fue_erg_prima_studie.php</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics board of Rheinische Friedrich Wilhelms University, Bonn, Germany. Approved on 27/11/2001 (ref: 181/01)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41063599</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, single-blind, single-center trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fb852260-e6c8-4ffe-a509-54be4fc13d92">
	  <name>Stenglinstr. 2</name>
	  <address/>
	  <city>Augsburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D 86156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families with premature births &lt;32 weeks Gestational Age (GA) or birth weight below 1500 g and cared for in the Neonatal Intensive Care Unit (NICU) of the University Children Hospital, Bonn, Germany, between 1 January 2002 and 31 December 2003.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>108</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>87 families with 108 children</totalTarget>
      <exclusion>1. Families living more than 100 km from the hospital
2. Mother did not speak German
3. Infant was transferred to another hospital
4. Infant died or suffered major malformations</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Premature infants</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Premature infants</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>43 families with 55 children were randomized in the intervention group and 44 families with 53 children in the control group.  

The aim of our individualised, family-based intervention was to integrate parents in the care of their babies from the very beginning in the NICU and to support families with social needs by providing parent education, improving care-giving competence, enhancing parent-infant interaction, evaluation of the needs and resources of the family, psychosocial care and emotional support, and establishing a network for the family. Beginning in the first week of life trained nurses, social workers and psychologists as required visited as case managers the mothers in the NICU and at home after discharge of the baby up to six months. The intervention addressed problems in four domains including 1) caregiving environment, 2) infant behaviour and characteristics, 3) home discharge and community resources, and 4) family organisation and functioning. Visiting was every two to three days during hospital stay and 1-2 weekly after discharge as needed by the family. The mean duration of the intervention was 161.9 days (45-277): 35.2 days (1-108) during hospital stay and 126.7 days (14-210) after discharge. The professions involved were: nurses in all families, social workers in 42.6% and psychologists in 4.8%.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17218-0</funderId>
      <funderId>Funder17218-1</funderId>
      <funderId>Funder17218-2</funderId>
      <funderId>Funder17218-3</funderId>
      <contactId>Contact55179_17218</contactId>
      <sponsorId>Sponsor53745</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55179_17218">
    <title>Dr</title>
    <forename>Friedrich</forename>
    <surname>Porz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Stenglinstr. 2</address>
      <city>Augsburg</city>
      <country>Germany</country>
      <zip>D 86156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53745">
    <organisation>Beta Institute for Research and Development in Social Medicine (Germany) </organisation>
    <website>http://www.betainstitut.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Kobelweg 95</address>
      <city>Augbsurg</city>
      <country>Germany</country>
      <zip>D 86156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17218-0">
    <name>The study was internally founded by the beta Institute for Research and Development in Social Medicine (beta Institut für Sozialmedizinische Forschung und Entwicklung), Augsburg, Germany.</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-1">
    <name>The study was also supported by the following institutions:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-2">
    <name>Köhler foundation (Köhler Stiftung), Essen, Germany (S112/10020/02)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-3">
    <name>Northrine-Westphalia Welfarework Foundation (Stiftung Wohlfahrtspflege Nordrhein-Westfalen), Düsseldorf, Germany (SW-620-4206-Z)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">46090514</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to compare the efficacy, safety and tolerability of PSD502, delivered topically onto the upper vagina and cervix, to placebo in controlling discomfort/pain intensity in subjects undergoing outpatient hysteroscopy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Hysteroscopy is used extensively in the evaluation of common gynaecological problems such as premenopausal menstrual disorders, infertility and postmenopausal bleeding. It allows direct visualisation of the uterine cavity and the opportunity for targeted biopsy, safe removal of endometrial polyps, and treatment of submucous fibroids, septa and adhesions. There is a general consensus that hysteroscopy is the current gold standard for evaluating intrauterine pathology, including submucous myomas, polyps, hyperplasia and cancer.

This study aims to evaluate the efficacy of PSD502 in relieving discomfort/pain at placement of the tenaculum on the anterior lip of the cervix during outpatient hysteroscopy.  Topically delivered agents have a theoretical advantage over cervical injection in terms of ease of administration and the potential for side effects with oral or systemically administered agents.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the efficacy of PSD502 in relieving discomfort/pain at placement of the tenaculum on the anterior lip of the cervix assessed using a 100 mm VAPS in subjects undergoing hysteroscopy.</primaryOutcome>
      <secondaryOutcome>1. To evaluate the efficacy of PSD502 in relieving discomfort/pain during insertion of the hysteroscope as assessed using a VAPS in subjects undergoing hysteroscopy
2. To evaluate the efficacy of PSD502 in relieving discomfort/pain during examination of the uterine cavity as assessed using a VAPS in subjects undergoing hysteroscopy
3. To evaluate the efficacy of PSD502 in relieving the worst discomfort/pain experienced during the entire hysteroscopy procedure using a 4-point discomfort/pain scale
4. To evaluate the need for additional analgesia in the 24 hours after the procedure
5. To evaluate the safety and tolerability of PSD502 administered to the cervix and vagina</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Wojskowy Instytut Medyczny) on the 22nd August 2007 (ref: 121/WIM/2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46090514</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PSD502-UP-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c3d81f41-c69f-495a-8da2-47e687406111">
	  <name>Department of Gynaecology</name>
	  <address/>
	  <city>Warsaw</city>
	  <state/>
	  <country>Poland</country>
	  <zip>00-909</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>A subject will be invited to participate if she meets the following inclusion criteria:
1. Healthy, pre-menopausal female who requires hysteroscopy
2. Aged 18 - 50 years inclusive
3. Clinically insignificant medical history and clinical examination other than the underlying condition requiring treatment, in the opinion of the Investigator
4. Post menstruation, but prior to ovulation at the time of the procedure and has a negative pregnancy test
5. Able to understand and complete the visual analogue pain scale (VAPS) and 4-point discomfort/pain scale, in the opinion of the Investigator
6. Willing and able to provide written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>A subject will be excluded from study participation if she meets any of the following criteria:
1. Contraindication to hysteroscopy
2. Known hypersensitivity to amide-type local anaesthetics
3. Received another investigational product within the previous 3 months
4. Current history of alcohol or drug abuse such that the subject is unable to comply with the study procedures or has resulting clinically significant organ damage, in the opinion of the Investigator
5. Clinically-significant medical history or clinical finding (e.g. bleeding diathesis or coagulopathy) that would affect the subject's ability to take part in the study, in the opinion of the Investigator
6. Previous hysteroscopy with technical difficulties or side effects
7. Used lidocaine or prilocaine preparation within 6 hours before the hysteroscopy procedure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Discomfort or pain during hysteroscopy</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Discomfort or pain during hysteroscopy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Study medication (active or placebo) will be sprayed onto the cervix in 10 metered dose sprays (to give a total of 75 mg lidocaine and 25 mg prilocaine, or placebo). The first spray will be to the cervix, followed by each of the 4 vaginal fornices in clockwise fashion from the anterior fornix (anterior, left lateral, posterior, right lateral); the spraying pattern will be repeated immediately to complete 10 sprays in total. The time of final spray application will be recorded. After a minimum of 5 minutes and no more than 10 minutes, the excess fluid will be swabbed away. A tenaculum will then be used to secure the cervix and the hysteroscope will be inserted. The subject will then undergo the hysteroscopy procedure.

Product: PSD502 is a metered dose spray that delivers a eutectic mixture of lidocaine and prilocaine for topical anaesthesia. Each actuation dispenses 7.5 mg lidocaine and 2.5 mg prilocaine in their base forms. The propellant used in this spray is norflurane (HFA-134a), which also serves as a solvent. The spray provides a concentrated film of local anaesthetic base, which facilitates drug penetration and is capable of providing rapid, superficial anaesthesia of non-keratinised skin. 

Dose: Ten metered dose sprays will be used to deliver a total dose of 75 mg lidocaine and 25 mg prilocaine. 

Administration: Topical administration to the vagina and cervix approximately 10 minutes, but no sooner than 5 minutes, prior to hysteroscopy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lidocaine, prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17292-0</funderId>
      <contactId>Contact55253_17292</contactId>
      <sponsorId>Sponsor53821</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55253_17292">
    <title>Prof</title>
    <forename>Wlodzimierz</forename>
    <surname>Baranowski</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Gynaecology
Military Institute of the Health Services
Szaserow Str 128</address>
      <city>Warsaw</city>
      <country>Poland</country>
      <zip>00-909</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)22 510 1175</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wbaranowski@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53821">
    <organisation>Plethora Solutions Limited (UK)</organisation>
    <website>http://www.plethorasolutions.co.uk/index.php </website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4th Floor
233 High Holborn</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1V 7DN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7269 8630</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sheryl.caswell@plethorasolutions.co.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487437.b</gridId>
    <rorId>https://ror.org/02y9vw172</rorId>
  </sponsor>
  <funder id="Funder17292-0">
    <name>Plethora Solutions Limited (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">35198481</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Therapy of locally advanced rectal cancer of the upper third by quality controlled total versus partial mesorectal excision</title>
      <scientificTitle>Therapy of cUICC stage II/III rectal cancer of the upper third by quality controlled total versus partial mesorectal excision, followed by adjuvant chemotherapy</scientificTitle>
      <acronym>GAST-05</acronym>
      <studyHypothesis>The multicentric GAST-05 study aims at identifying the optimal surgical treatment of locally advanced (cUICC stage II/III) rectal cancer located 12 - 16 cm above the anocutaneous verge. Two established surgical techniques are compared: 
1. Total mesorectal excision (TME), to completely eliminate affected and surrounding tissue, bears the risk of post-surgical complications
2. Partial mesorectal excision (PME) restricts surgery to the afflicted tissue and defined surroundings

PME may be equally effective in eliminating cancer while limiting post-operative complications. No clinical data have been raised to date that show if TME or PME is oncologically superior. To answer this requires a refocus on the principles of both resection techniques, including peri- and post-operative quality control. Post-surgical chemotherapy is identical in both trial arms. Primary endpoint is the disease-free survival after 3 years. 

The GAST-05 study is an add-on study to the ongoing CAO/AIO/ARO-04 trial, which intends to optimise the pre-surgical chemoradiotherapy of cUICC stage II/III cancers in the lower two thirds of the rectum (0 - 12 cm). The comparison of the long-term outcomes of both studies (GAST-05: surgical procecures; CAO/AIO/ARO-04: intensified preoperative treatment) will influence future studies; they will apply the surgical procedure that is identified as being superior during the GAST-05 study. Additional gene expression analyses on pre-therapeutically taken tumour probes will show if gene profiling can help to predict individual prognosis. 

The identification of the oncologically superior of two standardised surgical treatments (TME and PME) of cUICC stage II/III cancers of the upper third of the rectum has not been determined. The identification is a prerequisite for further studies, needed to reduce the side effects of optimised surgical treatments. If both techniques, TME and PME, turn out to be equivalent, that technique will be regarded as superior, which promises less comorbidities, a higher qualitiy of life, and lower health care costs (i.e. PME). 

A cross-comparison of disease-free and overall survival data from the GAST-05 trial and the CAO/ARO/AIO-04 trial will further allow judgement on the need for further studies on multimodal therapies for rectal cancers of the upper third. If the rate of local and distant metastases turns out to be equal or lower in the GAST-05 trial (upper third, no neoadjuvant RT/CT, PME/TME) than in the CAO/ARO/AIO-04-trial (lower two thirds, intensified preoperative treatment), further trials may be unnecessary which test multimodal therapies in cancers of the upper third. Patients with cUICC stage II/III cancers of the upper third of the rectum will then be spared potentially ineffective preoperative radiochemotherapy with its toxicities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Disease-free survival after 3 years (local and/ or distant recurrences).</primaryOutcome>
      <secondaryOutcome>1. R0-rate of resection
2. Post-operative 30-day lethality
3. Post-operative morbidity (especially rate of anastomotic insufficiencies)
4. Cumulative incidence of local relapses and distant metastases
5. Survival after 3 and 5 years
6. Acute and late toxicity of the chemotherapy according to the Common Toxicity Criteria of the National Cancer Institute (NCI CTC version 2.0) 
7. Post-operative late complications (defaecation problems, anastomotic  stenoses, loss of sphincter function)
8. Quality of TME and PME as assessed
9. Quality of life according to the European Organisation for Research and Treatment of Cancer (EORTC)-Questionnaire QLQ-30 (3.0)

Assessment of safety: TME, PME, and adjuvant chemotherapy are established procedures.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Georg-August-University Gottingen Ethik-Kommission der Medizinischen Fakultat on the 17th January 2007 (ref: 21/11/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35198481</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, multi-centric, prospectively randomised phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fc2f1f4a-0a47-40dd-b3c1-3f911bac797e">
	  <name>Georg-August University of Gottingen</name>
	  <address/>
	  <city>Göttingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>37075</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Histologically confirmed advanced primary rectum carcinoma at a level 12 - 16 cm above the anocutaneous verge (as measured by rigid endoscopy), endosonographically classified as uT3-4 or uN+ carcinomas, no evidence for synchronous distant metastases
2. Patients aged 18 - 85 years, either sex 
3. No preliminary treatment of rectum carcinoma</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>1. Successfully treated secondary malignoma with the exception of basal cell carcinoma of the skin and in situ cervix carcinoma, respectively, The inclusion of patients with other tumours, that have been treated successfully and have not reappeared during the last 5 years, has to be discussed with the principal investigator 
2. Simultaneous therapy with other anti-cancer drugs 
3. Chronic colonic diseases</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Rectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For all procedures, standard operating procedures (SOPs) are available.  

Experimental intervention:
1. Arm A: total mesorectal excision (TME) including surgical and pathological quality control, followed by standard adjuvant chemotherapy. The mesorectum is completely excised downwards to the pelvic floor:
1.1. Dorsally: entire retro-rectal fat body with the lymph tissue under consideration of the fascial system
1.2. Ventrally: including the spatium prerectale along the Denonvilliers-fascia
1.3. Laterally: entire area up to pelvis

2. Arm B: Partial mesorectal excision (PME) including surgical and pathological quality control, followed by adjuvant chemotherapy. PME follows the same surgical principles as in TME with the following exception: the mesorectum is transected at a right angle to the rectal wall 5 cm beyond the gross distal margin of the tumour, as measured in situ

In both trial arms, surgery is followed by adjuvant chemotherapy: 
1. Folinic acid: 400 mg/m^2, 2-hour infusion, day 1
2. Oxaliplatin: 100 mg/m^2 2-hour infusion in 500 ml glucose 5%, day 1
3. 5-Fluorouracil: 2400 mg/m^2 as 46-hour infusion

Perioperative assessment of mesorectal excision (TME/PME):
Staining of the specimen via inferior mesenteric artery, photo-documentation:
Class 1: no leakage, optimal TME/PME
Class 2: punctual leakage(s), good TME/PME
Class 3: extensive leakage(s), incomplete TME/PME

Standardised pathological assessment of TME/PME (in addition to established TNM/UICC criteria): 
Extent: TME/PME?
In case of PME: 
1. Distance between macroscopically visible distal margin of tumour and distal transection margin measured in centimetres. Measuring method: 
1.1. Fresh, non-stretched specimen
1.2. After fixation (non-pinned)
1.3. After fixation (pinned, non-stretched) 
2. Coning (distal transaction in a plane at 90° to the rectal wall): no, yes
3. Macroscopic assessment of the specimen surface in all cases:
3.1. Intact, smooth (lipoma-like)
3.2. Circumscribed defect(s) no greater than 5 mm
3.3. Extensive defect(s), muscular layer of the rectum invisible
3.4. Extensive defect(s), muscular layer of the rectum visible
3.5. Incision into the tumour or tumour torn open

Pathological quality assessment of the specimens after TME/PME:
1. Complete: intact mesorectum, no defects larger than 5 mm, no PME-coning, smooth circumferential resection margin on slicing
2. Moderate: irregular mesorectal surface, moderate PME-coning, muscularis propria invisible with the exception of area of insertion of levator muscles, moderate irregularity of the circumferential resection margin
3. Incomplete: little bulk of mesorectum with defects down into mucularis and/or very irregular circumferential resection margin, PME-coning

Control intervention: 
None

Duration of intervention per patient: 32 weeks  
Follow-up per patient: 3 years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Folinic acid, oxaliplatin, 5-Fluorouracil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17442-0</funderId>
      <contactId>Contact55403_17442</contactId>
      <sponsorId>Sponsor53973</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55403_17442">
    <title>Dr</title>
    <forename>Torsten</forename>
    <surname>Liersch</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Georg-August University of Gottingen
Department of General and Visceral Surgery
Robert-Koch-Strasse 40</address>
      <city>Göttingen</city>
      <country>Germany</country>
      <zip>37075</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)5513 983 23</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tliersc@gwdg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53973">
    <organisation>Georg-August University of Gottingen (Georg-August-Universitat Gottingen, Universitatsmedizin) (Germany) </organisation>
    <website>http://www.uni-goettingen.de/en/sh/1.html </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. med. H. Becker and Dr. med. Torsten Liersch
Department of General and Visceral Surgery 
Robert-Koch-Strasse 40</address>
      <city>Göttingen</city>
      <country>Germany</country>
      <zip>37075</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)5513 983 23</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tliersc@gwdg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7450.6</gridId>
    <rorId>https://ror.org/01y9bpm73</rorId>
  </sponsor>
  <funder id="Funder17442-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) (ref: 518)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">02971192</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of acupuncture in pain relief and functional improvement in ankylosing spondylitis: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of acupuncture for spinal pain relief in patients diagnosed with Ankylosing Spondylitis (AS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed before and immediately after the interventions: 
1. Patient's assessment of spinal pain (0-10 cm VAS). 
2. Patient's global assessment of disease-activity and function (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Bath Ankylosing Spondylitis Functional Index [BASFI]). The BASDAI measures the severity of fatigue, spinal and peripheral joint pain, localized tenderness, and morning stiffness, assessed on a 10 cm VAS. The BASFI measures the functional status of AS patients, and is also assessed on a 10 cm VAS.
3. Acute-phase reactants (C-Reactive Protein, Erythrocyte Sedimentation Rate [ESR], Immunoglobulin A [IgA]) 
4. Number of analgesic pills per week</primaryOutcome>
      <secondaryOutcome>Subjective assessment of pain, performed before and immediately after the interventions,  using a 7-point Likert scale, where 1 = much worse, 2 = moderately worse, 3 = slightly worse, 4 = no effect, 5 = small improvement, 6 = moderate improvement, 7 = great improvement.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University Hospital, University of Sao Paulo, School of Medicine, approved on 8 October 2003 (CAPPESQ number: 769-03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN02971192</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Project number at Institute of Orthopaedics and Traumatology: 371</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, randomised placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f0cfbb5-a458-484b-9006-d99f84058203">
	  <name>Rua Guaramembé, 589</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>01308-050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age range between 20 and 60 years 
2. Painful complaints in the axial line 
3. Patients who have not received any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesics for three months prior to the inclusion into this trial
4. Those who are referred to the Rheumatology Service, University of São Paulo, University Hospital, School of Medicine with diagnosis of ankylosing spondylitis according to the New York 15 and European 16 criteria for spondyloarthropathies
5. A mean baseline Visual Analogue Scale (VAS) score &gt;= 4 for pain</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Severe psychiatric disease
2. Sensory or motor neurological deficits
3. Fibromyalgia
4. Previous treatment with acupuncture 
5. Unable to visit the hospital for treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain relief in patients diagnosed with ankylosing spondylitis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Pain relief in patients diagnosed with ankylosing spondylitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomization was performed using colored balls. Patients rated their pain intensity using VAS, disease activity, and function level at baseline. 

Patients were randomly allocated to one of two treatment groups: 

Group A: Classical acupuncture. Participants received classical acupuncture treatment associated with the use of NSAIDs and analgesics. Disposable, sterilized, stainless steel 0.25 mm x 40 mm length needles were employed. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Group B: Sham acupuncture. Participants received NSAIDs and analgesics together with non-invasive sham electro acupuncture, which was performed using inactive surface electrodes with audiovisual biofeedback reinforcement, touching patient's skin for seven seconds. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Acupuncture points employed in both groups: GV20b, SI3b, BL62b, GB34b and Ex-B2b</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17479-0</funderId>
      <contactId>Contact55441_17479</contactId>
      <sponsorId>Sponsor54021</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55441_17479">
    <title>Dr</title>
    <forename>Liliana</forename>
    <surname>Lourenço Jorge</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Guaramembé, 589 </address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>01308-050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54021">
    <organisation>University of São Paulo (Brazil)</organisation>
    <website>http://www2.usp.br</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>São Carlos
Ribeirão Preto</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11899.38</gridId>
    <rorId>https://ror.org/036rp1748</rorId>
  </sponsor>
  <funder id="Funder17479-0">
    <name>University of São Paulo, University Hospital (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">06098697</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A one month study of the efficacy and safety of SVS20 versus carbomer and saline in patients with bilateral moderate dry eye syndrome: a randomised, double blind, controlled, parallel group, pilot, phase II study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the efficacy and safety of SVS20 versus saline (as a basic standard reference product) and carbomer (as a standard treatment with a marketing authorisation in most EU countries) in patients with bilateral moderate dry eye syndrome due to Sjogren's syndrome (immune exocrinopathy) or diagnosed as a primary syndrome.

Please note that the results of this study were used to calculate the sample size of a more recent phase III multicentre study conducted in France and UK. For more details on this phase III study, please visit the ISRCTN record at http://www.controlled-trials.com/ISRCTN91412460.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Since this study was a phase II there were no primary or secondary outcomes. Our aim was to analyse the efficacy and safety of SVS20 versus saline and carbomer and to find a parameter that could be used as the primary criterion for the following pivotal phase III study (ISRCTN91412460). Therefore, the following parameters were assessed:
1. Efficacy and tolerability:
1.1. Number of instillations
1.2. Staining with lissamine green
1.3. Symptom intensity and frequency
1.4. Repercussion of symptoms on activities of daily life
1.5. Comfort of the eye drops (presence and duration of blurred vision after instillation)
1.6. Slit lamp examination
1.7. Tear volume (Schirmer I test)
1.8. Tear film BUT
1.9. Corneal staining with fluorescein
1.10. Global evaluation of efficacy

2. Safety: 
2.1. Comfort of the eye drops (presence and duration of blurred vision)
2.2. BCVA
2.3. Impairment of dry eye symptoms
2.4. Ocular adnexa examination 
2.5. Adverse events reporting

Parameters were measured at V1 (Day-16 to Day-12), V2 (Day 0) and V3 (Day 28).</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The National Ethics Committee for Clinical Pharmacology (KFEB) on the 29th June 2005
2. The Ministry of Health on the 14th July 2005

Thereafter, local Institutional Review Board (IRB) at each centre gave favourable opinions on 13 September 2005 (Dr. Deák), 5 October 2005 (Dr. Sohajda), 18 October 2005 (Dr. Márta), 21 November 2005 (Dr. Zeher) and 2 December 2005 (Dr. Bereczki).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06098697</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SVS20-HUN-05-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, controlled, parallel group, pilot, phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hungary</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73a693e1-5579-4240-9240-b80fc77959d8">
	  <name>Szent János Kórház</name>
	  <address/>
	  <city>Budapest</city>
	  <state/>
	  <country>Hungary</country>
	  <zip>1125</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Signed informed consent
2. Male and female patients aged 18 years and over
3. Patients with at least a three-month documented history of bilateral moderate dry eye due to Sjogren's syndrome (immune exocrinopathy) or diagnosed as a primary syndrome
4. Patients with total score of staining with lissamine green of at least 5/12 and not more than 10/12 for each eye
5. Patients with at least two symptoms of dry eye among soreness, scratchiness, dryness, grittiness and burning each:
5.1. Occurring at least often and
5.2. Rated at least 30 mm and not more than 70 mm on the 0 to 100 mm visual analogue scale (VAS)
6. Patients with at least two out of three following objective parameters:
6.1. Schirmer test less than or equal to 10 mm wetting/5 minutes for each eye
6.2. Tear film break-up time (BUT) less than or equal to 10 seconds for each eye
6.3. Staining with fluorescein with a total score greater than or equal to 3/7 for each eye
7. Eligible patients using the following medications should have been taking them continuously for the two months before the screening visit and the dose should not have changed during the whole trial:
7.1. Tricyclic antidepressive agents
7.2. Anti-histaminic agents
7.3. Phenothiazines
7.4. Cholinergic agents
7.5. Antimuscarinic agents
7.6. Non-steroidal anti-inflammatory drugs (NSAIDs)
7.7. Beta-blockers
7.8. Immunomodulators
7.9. Anti-acneic agents
7.10. Diuretic agents
8. Female patients should be post-menopausal or be using a recognised, reliable method of contraception for at least three months before selection
9. Patients complying with the local regulations (e.g. social security system)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>72</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>72 patients were planned for 1:1:1 randomisation to SVS20 (n = 24), saline (n = 24) and carbomer (n = 24)</totalTarget>
      <exclusion>1. Patients who respond to Unilarm® during or at the end of the run-in period so that their inclusion criteria are not met at D0 examinations
2. Patients with unilateral dry eye
3. Severe dry eye syndrome, defined as:
3.1. Staining with fluorescein with a depth score less than 3 in any eye and/or
3.2. Severe bulbar conjunctival hyperaemia (score of 4) in any eye and/or
3.3. Severe limbal hyperaemia (score of 4) in any eye and/or
3.4. Severe palpebral observation (score of 4) in any eye and/or
3.5. Severe blepharitis in any eye
4. Patients who underwent:
4.1. Refractive surgery within the last 12 months before selection and/or
4.2. Any other ocular surgery or ocular trauma within the last four months before selection
5. Patients taking the following systemic concomitant medications within the last two months before selection:
5.1. Corticosteroids and/or
5.2. Tetracyclines
6. Patients requiring concomitant in-eye medication for the whole trial, except Unilarm® during the selection period only
7. Patients with abnormality of the nasolacrimal drainage apparatus
8. Patient with permanent occlusion of lacrimal puncta in any eye
9. Patient with temporary punctal plug within two months before selection in any eye
10. Patients with other diseases or characteristics judged by the investigator to be incompatible with the frequent assessments needed in this study or with reliable instillation of the products (for example disability of the upper limbs)
11. Patients who participated in any other clinical trial within the last 30 days before selection
12. Patients with known hypersensitivity to hyaluronic acid or any component or procedure used in the study
13. Patients who need or intend to wear contact lens during the whole trial
14. Patients with best corrected visual acuity (BCVA) less than 1/10 in any eye
15. Pregnant or lactating females
16. Known human immunodeficiency virus (HIV) positive patients, if they belong to an anamnestic known risk group like drug addicts, etc., or if there is any reasonable doubt about HIV a validated test must be performed
17. Patients with a concomitant diagnosis of sarcoidosis, non-hodgkin lymphoma, bone marrow transplant or any secondary Sjogren's syndrome due to rheumatoid diseases or as an adverse event possibly of any other prior of concomitant medication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dry eye syndrome</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Disorders of lacrimal system</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There were three arms: 
1. SVS20
2. Saline 
3. Carbomer

Patients instilled 2 - 4 times a day one of these eye drops. Treatment duration was 1 month with a previous period of wash-out of 112 to 16 days.

The following parameters were measured at V1 (day 16 to day 12), V2 (day 0) and V3 (day 28):
1. BUT
2. Schirmer I test
3. Lissamine and fluorescein staining
4. BCVA
5. Slit lamp examination
6. Symptoms intensity and frequency</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>SVS20, carbomer</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17492-0</funderId>
      <contactId>Contact55454_17492</contactId>
      <sponsorId>Sponsor54034</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55454_17492">
    <title>Prof</title>
    <forename>Margrit</forename>
    <surname>Zeher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Szent János Kórház
1 Diósárok u.</address>
      <city>Budapest</city>
      <country>Hungary</country>
      <zip>1125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54034">
    <organisation>TRB Chemedica International SA (Switzerland) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>12 rue Michel-Servet </address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487371.e</gridId>
    <rorId>https://ror.org/012pz6314</rorId>
  </sponsor>
  <funder id="Funder17492-0">
    <name>TRB Chemedica International SA (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-08T00:00:00.000Z">86152982</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of Haemate HS for the treatment of severe intraoperative hemorrhage during aortic-valve replacement in patients with aortic-valve stenosis</title>
      <scientificTitle/>
      <acronym>HAVAS-Study</acronym>
      <studyHypothesis>Evaluation of the efficacy and safety of Haemate HS in this clinical setting</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Intra- and postoperative transfusion requirements according to defined transfusion thresholds.</primaryOutcome>
      <secondaryOutcome>1. Requirement of rethoracotomy, assessed during patients stay at the intensive care unit 
2. Surgeons' subjective rating of therapeutic efficacy after application of Haemate HS or placebo (classification of bleeding after therapy as "better", "equal" or "worse") 
3. Survival (perioperative mortality, mortality during hospital stay, mortality within a 90 day period following surgery) 
4. Duration of treatment on intensive care ward 
5. Adverse events and therapy-related side effects, assessed within the first 10 days after surgery. A second assessment is carried out after 3 month (at day 90)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee of the Heinrich Heine University Medical Center (Duesseldorf, Germany) on 25 April 2007. First amendment approved on 28 November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86152982</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BI8021_5101</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Two-arm, randomised, double-blind controlled clinical study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7fa4256a-350f-48e8-a0ae-2fa2ec0d217f">
	  <name>Department of Hemostasis and Transfusion Medicine</name>
	  <address/>
	  <city>Duesseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-40225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with isolated valvular aortic stenosis or combined aortic-valve defect with prevailing stenosis (mean transvalvular gradient &gt;50 mmHg) with severe bleeding during aortic-valve replacement 
2. Age &gt;18 years. 
3. Written informed consent. 
4. All patients that fulfill at least one of the following criteria 15 minutes after the end of extracorporal circulation and application of protamine: 
4.1. Excessive bleeding without surgical explanation according to the surgeons' impression (Classification of bleeding as "normal", "moderate" or "excessive" by the surgeon. Classification as "excessive" bleeding leads to recruitment to the study). 
4.2. Drainage volume &gt;40 ml in 5 minutes following application of protamine and thorax closure.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 patients (20 per arm)</totalTarget>
      <exclusion>1. Participation in other interventional studies that potentially impair the interpretation of results 
2. History suggestive for inherited or acquired bleeding disorder 
3. Written informed consent not to be obtained 
4. Active endocarditis 
5. Concomitant coronary heart disease 
6. Agents impairing platelet function at the time of surgery 
7. Pregnancy 
8. Known or suspected intolerance against Haemate HS 
9. Previous thromboembolic complications 
10. Known hepatitis B, hepatitis C or HIV infection 
11. Known or suspected intolerance against standard medication (e.g., heparin) 
12. Emergency surgery within the last 7 days 
13. Previous chemotherapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe intraoperative hemorrhage during aortic-valve replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Severe intraoperative hemorrhage during aortic-valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Intraoperative infusion Haemate HS 500/1000 IU (vWF/F VIII:C concentrate), time of infusion according to inclusion criteria.  
Control group: Intravenous infusion of 0.9% NaCl solution (100 ml)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Haemate HS (intraoperative infusion)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17333-0</funderId>
      <contactId>Contact55294_17333</contactId>
      <sponsorId>Sponsor53862</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55294_17333">
    <title>Dr</title>
    <forename>Rainer</forename>
    <surname>Zotz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Hemostasis and Transfusion Medicine
Heinrich Heine University Medical Center 
Moorenstrasse 5 </address>
      <city>Duesseldorf</city>
      <country>Germany</country>
      <zip>D-40225 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49(0)211 8117474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Nicola.Moeller@med.uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53862">
    <organisation>Heinrich Heine University Duesseldorf (Germany) </organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>c/o Dr Rainer B. Zotz
Department of Hemostasis and Transfusion Medicine
Heinrich Heine University Medical Center
Moorenstrasse 5</address>
      <city>Duesseldorf </city>
      <country>Germany</country>
      <zip>D-40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)211 8117474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">zotz@med.uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411327.2</gridId>
    <rorId>https://ror.org/024z2rq82</rorId>
  </sponsor>
  <funder id="Funder17333-0">
    <name>CSL Behring GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-02-06T00:00:00.000Z">88422298</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the effectiveness of a nursing intervention aiming at facilitating the hospital to home transition within a cardiologic Emergency Room (ER) [Évaluation de l&#146;efficacité d&#146;un modèle d&#146;interventions infirmières de soutien à la transition hôpital-domicile dans une urgence cardiologique]</title>
      <scientificTitle/>
      <acronym>TRANSIT-ER [TRANSIT-URGENCE]</acronym>
      <studyHypothesis>We are studying the nursing discharge interventions modalities provided in the Emergency Room (ER) of a cardiology tertiary care centre where an important proportion of patients make repeated visits to the ER in the year following their discharge to home (24% of the patients).

It is hypothesised that the return rates to the ER in the month following discharge to home will be less important in the group receiving the intervention than in the control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>'Return to ER: the occurrence of any visits to the cardiologic ER in the month following randomisation. This will be measured using the hospital patient's registry.</primaryOutcome>
      <secondaryOutcome>The secondary outcomes will be measured at baseline and one month following randomisation by a telephone interview and are as followed: 
1. Health care continuity using the Heart Continuity of Care Questionnaire (HCCQ), a 41-item questionnaire using a 5 points Likert scale (score 1 to 5, 1 = strongly disagree, 5 = strongly agree) measuring the patients' perception of continuity of care in regard to eight different dimensions. A higher score indicate a better continuity of care process according to the patient.
2. Patient's self-care management using the Therapeutic Self-Care Tool (TSCT), a 12-item questionnaire using a 5 points Likert scale (score 0 to 5, 0 = not at all, 5 = very much so) measuring the patients' ability to initiate and perform activities aiming at maintaining health, managing health problems and restoring functioning. A higher score indicate better self-care capacities in the patient.
3. Medication adherence scale using the Self-Reported Medication-Taking Scale (SR-MTS), a 4-item questionnaire using a dichotomous (yes or no) scale measuring patients' adherence to prescribed medication. A higher score indicate a poorer adherence to medication.
4. Patients' perception of control over the disease and of its consequences using three subscales of the Illness Perception Questionnaire - Revised (IPQ-R), a 38-item questionnaire using a 5 points Likert scale (score 1 to 5, 1 = totally agree, 5 = totally disagree) measuring the patients' perception of his disease. The three subscales used are: 
4.1. Consequences (6 items)
4.2. Personal control (6 items) 
4.3. Treatment control (5 items)
Higher scores on the consequences subscale represent strongly held beliefs about the negative consequences of the disease. Higher scores on the control subscales represent positive beliefs about the controllability of the illness. 
5. Anxiety and depressing feelings using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire using a 4 points ordinal rating scale and composed of two subscales (anxiety and depression - each score from 0 to 21). A higher score to each of the subscales indicate a higher degree of symptoms (anxiety or depression).
6. Health services utilisation using the medicare provincial registry (Régie de l&#146;assurance maladie du Québec). The occurence of ER visits, hospitalisation or medical consultations by the patient within the province of Québec will be collected at 1, 3, 6 and 12 months following discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the research ethics committee of the Institut de Cardiologie de Montréal on the 7th September 2007 (ref: 07-963).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88422298</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FRSQ 10187</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial - one ER (single centre)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0aa2b2c1-59d5-4402-b6cb-14c7920a19ab">
	  <name>R-1520</name>
	  <address/>
	  <city>Montreal, Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H1T 1C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female aged 18 years old or more presenting both of the following repeated visits to the ER criterion: 
1.1. Taking six medications or more a day
1.2. Having made one visit or more to the cardiologic ER in the last 12 months
2. Visiting the ER for an unplanned visit (i.e. not coming to the ER on a planned basis, e.g. to receive a laboratory or diagnosis procedure result)
3. Being discharged from the ER directly to their home
4. Having the physical and cognitive capacities to answer a written questionnaire and to communicate by telephone
5. Being able to communicate in French or in English</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>462</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>462</totalTarget>
      <exclusion>1. Having already another nursing follow-up in the 10 days following discharge (e.g. from another research project or from a specialised clinic) to avoid duplication of the nursing interventions being provided to the patient
2. Having already been recruited in the study in a precedent visit to the cardiologic ER</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Facilitation of hospital to home transition after a visit to the ER</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Facilitation of hospital to home transition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All eligible patients will meet with the research nurse after discharge care. Then, the study will be presented to the patient. After informed consent, the participants will be randomly assigned to the intervention or control group. The two groups will answer a questionnaire about the secondary outcomes and the baseline characteristics will be recorded.

Intervention group: 
After randomisation, the nurse will proceed with an assessment of the patient's risks of repeated visits to the ER following discharge to home. The evaluation will include the following themes: 
1. Patient's perception in regard to his discharge to home
2. Patient's self-management of his disease, symptoms and co-morbidities
3. Patient's self-management of his treatment
4. Patient's self-management of his daily living and domestic activities
5. Patient's self-management of his emotions and cognitions
6. Patient's external resources management 
7. Patient's health-services utilisation management

Following the assessment, the nurse will propose tailored interventions to the patient aiming at managing the repeated emergency department visits risk factors identified. Those interventions include: 
1. Teaching
2. Legitimisation and normalisation
3. Listening and empathy
4. Reassurance
5. Reframing
6. Confrontation
7. Recommendations
8. Warnings
9. Reinforcement
10. Referral to external resources 
11. Support to external resources already in place

The research nurse will proceed with this assessment-intervention process thrice: 
1. In person at the patient's discharge from the ER
2. By telephone 4 ± 3 days following discharge 
3. By telephone 10 ± 3 days following discharge

Finally, the patient will be able to contact the nurse by telephone during working hours in the 30 days following discharge for any concerns he would like to address her. 

Control group: 
No specific intervention by the research nurse, the patient will return to home.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17232-0</funderId>
      <contactId>Contact55193_17232</contactId>
      <sponsorId>Sponsor53759</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55193_17232">
    <title>Dr</title>
    <forename>Sylvie </forename>
    <surname>Cossette</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>R-1520
5000, Belanger Street</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H1T 1C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 376 3330 ext. 4012</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sylvie.cossette.inf@umontreal.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53759">
    <organisation>Montreal Heart Institute (MHI) Research Centre (Canada)</organisation>
    <website>http://www.icm-mhi.org/en/index.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>5000, Belanger Street</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H1T 1C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 376 3330</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Richard.Maheu@icm-mhi.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.482476.b</gridId>
    <rorId>https://ror.org/03vs03g62</rorId>
  </sponsor>
  <funder id="Funder17232-0">
    <name>Quebec Health Research Fund (Fonds de recherche en Santé du Québec [FRSQ]) (Canada) (ref: 10187)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">27058472</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in chronic staphylococcal osteomyelitis: a long-term follow-up trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Oral rifampin-cotrimoxazole combination may be as useful as the standard intravenous cloxacillin therapy against chronic osteomyelitis by Staphylococcus aureus.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Treatment failure rate, defined as the number of cases with clinical relapse (appearance or recurrence of local inflammatory signs or sinus tract drainage, with or without microbiological confirmation) during follow-up.</primaryOutcome>
      <secondaryOutcome>1. Treatment tolerability and compliance (number of patients who did not fulfil protocol treatment and reason), from patient inclusion to the end of antibiotic therapy (8 weeks)
2. Length of hospital stay (days) for each treatment schedule; defined as hospitalisation during the diagnosis and treatment of the episode</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Investigation Committee of Hospital de Bellvitge in January 1991.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27058472</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre interventional randomised, active controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="36d5acd5-06a6-4943-92d7-dda5e4b64ab5">
	  <name>Hospital de Bellvitge</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult patients (greater than 18 years old) of any gender with chronic osteomyelitis by Staphylococcus aureus treated with surgery.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Exploratory study. Fifty patients included</totalTarget>
      <exclusion>1. Prosthetic joint infection
2. Methicillin resistant Staphylococcus aureus
3. Allergy to protocol antibiotics
4. Strain resistance to cotrimoxazole or rifampin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non-axial chronic osteomyelitis due to Staphylococcus aureus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Chronic osteomyelitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After surgery and identification of Staphylococcus aureus upon surgical samples, randomisation of patients for antibiotic therapy: 
Group A: intravenous cloxacillin (2 g every four hours [q4h]) for 6 weeks followed by oral cloxacillin (500 mg every six hours [q6h]) for 2 weeks
Group B: oral rifampin-cotrimoxazol combination for 8 weeks (rifampin 600 mg every 24 hours [q24h] plus 7 - 8 mg/kg per day of trimethoprim component, equivalent to three simple strength cotrimoxazole capsules, every 12 hours [q12h])

The total duration of the protocol treatment was 8 weeks for both groups (6 intravenous [iv] and 2 oral [po] in the cloxacillin group and 8 po in the rifampin-cotrimoxazole group). The duration of the follow-up is from the end of antibiotic therapy until 2007 (a median of 10 years).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cloxacillin, rifampin-cotrimoxazole, trimethoprim</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17382-0</funderId>
      <contactId>Contact55343_17382</contactId>
      <sponsorId>Sponsor53913</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55343_17382">
    <title>Prof</title>
    <forename>Javier</forename>
    <surname>Ariza Cardenal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital de Bellvitge
Feixa Llarga s/n
L'Hospitalet de Llobregat</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53913">
    <organisation>Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain) </organisation>
    <website>http://www.idibell.es </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr. Javier Ariza Cardenal
Hospital de Bellvitge 
Feixa Llarga s/n
L'Hospitalet de Llobregat </address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418284.3</gridId>
    <rorId>https://ror.org/0008xqs48</rorId>
  </sponsor>
  <funder id="Funder17382-0">
    <name>Hospital de Bellvitge (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">06127083</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of post-caesarean infections in low resource countries: is a single dose as adequate as a multiple dose antibiotic regiment? A randomised controlled trial</title>
      <scientificTitle>Is the administration of a single prophylactic dose of ampicillin and metronidazole before caesarean section as effective as a multiple day regimen of these antibiotics to prevent postpartum maternal infection in a low resource setting? A randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Single dose antibiotic prophylaxes is as effective as a multiple dose scheme in women undergoing a caesarean section in low resource setting in preventing postoperative infections.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The presence of fever, endometritis, urinary tract infection, wound infection or other serious infections (such as pelvic abscess, peritonitis, sepsis). 

Timepoint of evaluation is on discharge (see interventions section): an independent doctor will review the wound and score the wound healing and record if any complication arose or additional antibiotics were given.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Instritute for Medical Research, Dar es Salaam (Tanzania) on the 12th November 2007 (ref: NIMR/HQ/R.8a/Vol.IX/633).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06127083</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blind randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="15602248-b215-4db9-ba1c-22ed0b319ee2">
	  <name>PO Box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Delivery through caesarean section
2. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Use of antibiotics in the last week
2. Known allergy for any of the antibiotics used
3. Greater than 24 hour rupture of membranes
4. Evident infection or fever pre- or during operation</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Kiswahili)</patientInfoSheet>
      <recruitmentStart>2008-01-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-operative infection after caesareans</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Post-operative infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: ampicillin 1000 mg and metronidazole 500 mg intravenous 20 minutes prior to caesarean section 
Group 2: ampicillin 1000 mg and metronidazole 500 mg intravenous 20 minutes prior to caesarean section followed by ampicillin 500 mg 8-hourly for two more doses and metronidazole 500 mg 8-hourly for two more doses. After completion of the intravenous (iv) doses the patients will receive oral medication for four days (total 12 doses) of amoxicillin 500 mg and metronidazole 400 mg. 

The follow up will be until the patients are discharged: for uncomplicated lower segment caesarean section (LSCS) this will be on day five (in case of pfannenstiel incision) and day seven (in case of median incision). When complications arise, the patient will be followed up longer, until discharge.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17448-0</funderId>
      <contactId>Contact55409_17448</contactId>
      <sponsorId>Sponsor53979</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55409_17448">
    <title>Dr</title>
    <forename>Heleen</forename>
    <surname>van Beekhuizen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO Box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53979">
    <organisation>Sokoine Regional Hospital (Tanzania)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>PO Box 1011</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17448-0">
    <name>Sokoine Regional Hospital (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">90960030</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Functional milk product On the Metabolic Syndrome II</title>
      <scientificTitle>Randomised, controlled, double-blind clinical study on the effect of a functional milk-product on metabolism of men with diagnosed metabolic syndrome: study with extended sample size</scientificTitle>
      <acronym>EFOMS II</acronym>
      <studyHypothesis>The goal of the investigation is the question, to what extent the risk of the metabolic syndrome may be reduced by substances naturally occurring in milk. The pathophysiology of the metabolic syndrome is characterised by an insulin resistance, a dyslipidaemia, an essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus and atherosclerosis. Such metabolic disturbances increase in the industrialised countries and in the developing countries, too, and represent an important economical and public-health cost factor. It is necessary to identify the relevant factors of human nutrition and to develop potential avoidance strategies, e.g. by development of functional food. 

The cow-milk derived substances, which will be used in this study have had influenced individual components of the metabolic syndrome and lowered the risk of components of the metabolic syndrome in own animal and human trials. 

This study is an extension of a previous human study (ISRCTN41474531 - see http://www.controlled-trials.com/ISRCTN41474531).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change of HOMeostasis model Assessment of Insulin Resistance (HOMA-IR) during the intervention period.</primaryOutcome>
      <secondaryOutcome>1. Blood pressure 
2. Body mass index (BMI), waist-to-hip ratio
3. Mean blood glucose during continuously glucose monitoring
4. Postprandial concentration of several hormones and blood parameters linked mainly to carbohydrate metabolism</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University of Kiel (Germany) on the 26th October 2007 (ref: A171/06 - extended sample size).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN90960030</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study is a randomised double-blind placebo-controlled intervention study over 8 weeks.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d31222f0-eb82-4940-bf84-52b9b9dca0c1">
	  <name>Institute for Physiology and Biochemistry of Nutrition</name>
	  <address/>
	  <city>Kiel</city>
	  <state/>
	  <country>Germany</country>
	  <zip>24103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men, 45 - 70 years old
2. A metabolic syndrome as defined by the International Diabetes Federation, 2006 (A new IDF worldwide definition of the metabolic syndrome: the rationale and the results - Diabetes Voice, Vol. 50 Issue 3, 2005)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240 volunteers (120 for each the verum and control group)</totalTarget>
      <exclusion>1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination 
2. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure 
3. Known metabolic or gastro-intestinal diseases, which affects the absorption, metabolism or excretion of food or food components 
4. Condition after operation of the gastro-intestinal tract, which affect gastro-intestinal motility 
5. Haemoglobin less than 12 g/dL 
6. Malfunction of blood coagulation or drugs, leading to malfunction of blood coagulating diabetes 
7. Operation within the last 3 months, which still affects the current state of health 
8. Illness of thyroid gland, which has metabolic and/or cardiovascular effects 
9. Known hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection or chronic liver damage 
10. Kidney insufficiency 
11. Hypercalcaemia 
12. Drug or alcohol abuse 
13. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal tract 
14. Intake of hormone preparations 
15. Vegetarianism, anorexia, bulimia 
16. Known milk protein allergy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic syndrome</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The volunteers of the verum group will take one portion of the functional milk-product (product code 966125, a non-registered product) once a day after lunch with a dessert for 56 days. The product of the control group is based on meat protein and is isoenergetic and isonitrogenous. 

Primary and secondary outcome measures will be analysed before and at the end of the intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Functional milk-product (product code 966125, a non-registered product)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17367-0</funderId>
      <contactId>Contact55328_17367</contactId>
      <sponsorId>Sponsor53897</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55328_17367">
    <title>Prof</title>
    <forename>Juergen</forename>
    <surname>Schrezenmeir</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Physiology and Biochemistry of Nutrition
Federal Reserach Centre for Nutrition and Food
Hermann-Weigmann-Str. 1</address>
      <city>Kiel</city>
      <country>Germany</country>
      <zip>24103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)431 609 2220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juergen.schrezenmeir@bfel.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53897">
    <organisation>Humana GmbH (Germany) </organisation>
    <website>http://www.humana.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bielefelder Strasse 66</address>
      <city>Herford</city>
      <country>Germany</country>
      <zip>32051</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17367-0">
    <name>Humana GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-01T00:00:00.000Z">20442117</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of hemodynamic effects of cascade hemofiltration in septic shock</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of the hemodynamic improvement using cascade hemofiltration in patients treated for septic shock</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of days without catecholamines at the 28th day of randomization</primaryOutcome>
      <secondaryOutcome>1. Rate of decrease of catecholamines during the first 72h 
2. Number of days without mechanical ventilation at the 90th day 
3. Number of days without Renal Replacement Therapy (RRT) at the 90th day 
4. Number of days without ICU requirement at the 90th day 
5. Death or survivor status at the 90th day</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Committee for Protection of Research Subjects (Comité de Protection des Personnes [CPP]) Ile de France VI, approved on 16 July 2007 
2. France's Sanitary Safety in Health Products Agency (AFSSAPS), approved on 30 October 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20442117</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1450</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-center, pilot, prospective, parallel-group, randomised controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9dfb7251-5081-41cd-802c-fb80dbccd2fe">
	  <name>Gambro Industries</name>
	  <address/>
	  <city>Lyon</city>
	  <state/>
	  <country>France</country>
	  <zip>69357</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with a septic shock diagnosed by the medical staff team
2. Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (superior or equal to 1.0 mg/h of norepinephrine or epinephrine) for more than 120 minutes and &lt;24h
Note: Patients with renal failure (treated or not) can be included</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Age (years) &lt;18 or &gt;85 
2. Weight &gt;120 kg 
3. Thrombocytopenia 50&lt; G/l or Neutrophils &lt;0.5 Giga/l 
4. Contra indication to heparin anticoagulation 
5. Patient requiring catecholamines (epinephrine or norepinephrine superior or equal to 1 mg/h) for &gt;24h 
6. Patient admitted to the Intensive Care Unit (ICU) superior or equal to 7 days before the inclusion criteria 
7. Patient with intercurrent disease limiting his/her self-sufficiency (need of help before septic shock) 
8. Inclusion (&lt;28 days) in another study interfering with the goals of the current investigation 
9. Pregnancy and patient under guardianship 
10. Immune compromised patients (e.g., being treated for cancer, treated by immunosuppressors or steroids, AIDS)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Septic shock/ hemofiltration</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Septic shock/ hemofiltration</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Either standard hemofiltration or Cascade hemofiltration (2 types of membrane evaluated)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17411-0</funderId>
      <contactId>Contact55372_17411</contactId>
      <sponsorId>Sponsor53942</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55372_17411">
    <title>Mrs</title>
    <forename>Nathalie</forename>
    <surname>Loughraieb</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Gambro Industries
Clinical Affairs Department
61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53942">
    <organisation>Gambro Industries, Clinical Affairs Department (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder17411-0">
    <name>Gambro Industries (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-01-29T00:00:00.000Z">88931004</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The learning curve for vitreous surgery</title>
      <scientificTitle>The learning curve for primary vitrectomy without scleral buckling for pseudophakic retinal detachment</scientificTitle>
      <acronym/>
      <studyHypothesis>Pseudophakic retinal detachment is a complication in patients after cataract surgery. Although rare, this represents a high number of patients since the number of cataract extractions is on the rise (500,000 in France). This complication may lead to a severe loss of visual acuity. 

In this study we aim to evaluate the learning curve of junior surgeons in performing primary vitrectomy without scleral buckling for pseudophakic retinal detachment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Reattachment rate with a single procedure at 6-month follow-up</primaryOutcome>
      <secondaryOutcome>1. Number of final successes
2. Number of reoperations and complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for the Protection of Human Subjects in Biomedical Research, Bourgogne (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Bourgogne). Date of approval: 4 Marth 2004 (ref: 2004/19)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88931004</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Retrospective interventional case series in two academic centers.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d3108ae-881b-4038-8d13-d4ebb1d7fa08">
	  <name>Service d'Ophtalmologie</name>
	  <address/>
	  <city>Dijon</city>
	  <state/>
	  <country>France</country>
	  <zip>21000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients presenting with a pseudophakic retinal detachment and a Proliferative VitreoRetinopathy (PVR) grade A and B</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>280</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>280</totalTarget>
      <exclusion>Patients presenting with a pseudophakic retinal detachment and a PVR grade C and D</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pseudophakic retinal detachment</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Pseudophakic retinal detachment</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Surgical procedure with pars plana vitrectomy under local anesthesia. Drainage of subretinal fluid through the retinal break or a retinotomy. External cryotherapy on the retinal tears. At the end of the procedure, air-gas exchange with inexpansible gas mixture. No scleral buckling added.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17399-0</funderId>
      <contactId>Contact55360_17399</contactId>
      <sponsorId>Sponsor53930</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55360_17399">
    <title>Prof</title>
    <forename>Catherine</forename>
    <surname>Creuzot-Garcher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Service d'Ophtalmologie
CHU General Hospital </address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53930">
    <organisation>Burgundy Association for Research in Ophthalmology (ABPRO) (France) </organisation>
    <website>http://www.chu-dijon.fr</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Service d'Ophtalmologie
CHU General Hospital</address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17399-0">
    <name>University Hospital Dijon (CHU), General Hospital (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-29T00:00:00.000Z">34357360</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Better Efficacy in Lowering events by General practitioner's Intervention Using remote Monitoring in Heart Failure</title>
      <scientificTitle/>
      <acronym>BELGIUM-HF Registry &amp; Trial</acronym>
      <studyHypothesis>To test the hypothesis that general practitioner's intervention triggered by an alarm generated by an algorithm based on non-invasive vital sign home telemonitoring measurements in moderate to severe heart failure patients may reduce the rate of hospitalisations for heart failure, mortality or both. 

The BELGIUM-HF Registry and Trial is a study that will be conducted in two steps. 
The primary objective of the registry is to identify predictors of death, heart failure recurrence requiring hospitalisation, or both, and to validate simple and robust interventional algorithms based on weight, blood pressure and pulse transmitted by a telemonitoring system and to test those algorithms in subgroups of patients. 

The primary objective of the subsequent randomised trial is to demonstrate a reduction in the incidence of Heart Failure (HF)-related hospitalisations or all-cause mortality in HF subjects managed with the the telemonitoring/interventional algorithm strategy as compared with HF subjects managed with the telemonitoring/usual care strategy over a period of 6 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measures in the Randomised Trial: 
1. Incidence of HF-related hospitalisations (Duration of follow-up: 6 months) 
2. All-cause mortality (Duration of follow-up: 6 months)</primaryOutcome>
      <secondaryOutcome>The following secondary end-points in the Randomised Trial will be assessed at 3 and 6 months except the cost-effectiveness evaluation, which will be carried out after the trial: 
1. To demonstrate a reduction in the combined end-point of cardiac death, HF-related hospitalisations and cardiac-related urgent visits and interventions whichever comes first in HF subjects managed with the TeleMonitoring (TM) strategy compared to the Usual Care (UC) strategy 
2. To demonstrate a reduction in HF-related hospitalisations in the TM arm compared to the UC arm 
3. To demonstrate a reduction in all-cause mortality in the TM arm compared to the UC arm 
4. To demonstrate a reduction in cardiac mortality in the TM arm compared to the UC arm 
5. To demonstrate a reduction in the number of days spent at the hospital for HF-related conditions in the TM arm compared to the UC arm 
6. To determine whether TM intervention improves functional status as assessed by a 6-minute walk test 
7. To demonstrate an improvement in quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the TM arm compared to the UC arm 
8. To report a shift from "in-patient" to "out-patient" healthcare utilisation in the TM arm compared to the UC arm 
9. To conduct a cost-benefit comparison between the two strategies</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for Clinical Trials at the Saint-Jean Clinic (Commission d'éthique Expérimentation Humaine de la Clinique Saint-Jean), Brussels. Date of approval: 10/10/2007 (ref: 2007-284)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34357360</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel-group, prospective, single-centre, phase III, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-12-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75ad38d6-9e3c-4f1b-98b2-198c29fb8b98">
	  <name>Boulevard du Jardin Botanique 32</name>
	  <address/>
	  <city>Brussels</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>BELGIUM-HF will be conducted in two steps: a prospective registry and a subsequent randomised trial. The BELGIUM-HF Registry will be completed before the BELGIUM-HF Randomised Trial starts. Patients who have been included in the Registry are eligible for the subsequent randomised trial if they meet the inclusion criteria at that time and have signed an informed consent regarding the randomised trial. 

Inclusion criteria for both BELGIUM-HF Registry and Randomised Trial: 
1. Subject with left ventricular systolic dysfunction, defined as a left ventricular ejection fraction &lt; or = 40%, documented by echocardiography, contrast ventriculography or radionuclide angioscintigraphy within 6 months prior to inclusion 
2. Subject has been hospitalised within the past 6 months for mild to severe heart failure defined as New York Heart Association (NYHA) class II to IV 
3. Subject has received loop diuretics within 2 weeks prior to inclusion 
4. Subject is at least 18 years of age 
5. Subject or subject's legally representative has signed and dated the study informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Registry: 200 patients; Randomised trial: 500 patients</totalTarget>
      <exclusion>1. Subject who is scheduled for corrective valve surgery or coronary revascularisation, i.e. Coronary Artery Bypass Grafting (CABG) or Percutaneous Coronary Intervention (PCI) in a near future 
2. Subject who has significant concurrent illness or condition not related to heart failure (i.e. terminal malignancy), associated with a life expectancy that is anticipated to be shorter than the expected duration of the trial 
3. Subject on chronic renal dialysis 
4. Pregnancy 
5. Subject who has a health condition or psychic condition associated with poor compliance, including active alcoholism, mental illness or drug dependence 
6. Subject directly involved in the execution of this protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-12-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systolic heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Systolic heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>BELGIUM-HF Registry: No intervention. Duration of the Registry: 6 months. Follow-up visits will take place at 3 and 6 months. 

BELGIUM-HF Trial: General practitioner's intervention based on an alarm generated by a predefined algorithm applied to the telemonitoring system and based on daily measured blood pressure, pulse and weight versus usual care (control). Types of intervention: none, medication changes, cardiologist referral, out-patient clinic referral, emergency room referral, hospitalisation. 

Duration of intervention: 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17314-0</funderId>
      <contactId>Contact55275_17314</contactId>
      <sponsorId>Sponsor53843</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55275_17314">
    <title>Dr</title>
    <forename>Marc</forename>
    <surname>Castadot</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Boulevard du Jardin Botanique 32</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53843">
    <organisation>Saint-Jean Clinic, Department of Cardiology (Belgium)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Boulevard du Jardin Botanique 32</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.490685.6</gridId>
    <rorId>https://ror.org/01dd1x730</rorId>
  </sponsor>
  <funder id="Funder17314-0">
    <name>Institute for the Encouragement of Scientific Research and Innovation of Brussels (Public funding) (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-25T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-25T00:00:00.000Z">83077547</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>ALAP-1 for the attenuation of nasal provocation with histamine in seasonal allergic rhinitis: a randomised, double-blind, placebo-controlled, three-day dosing, cross-over study and dose finding one month cross-over study</title>
      <scientificTitle/>
      <acronym>BB100A and BB100B</acronym>
      <studyHypothesis>1. To evaluate the ability of ALAP-1 compared with placebo to reduce the signs and symptoms of allergic rhinitis (AR) in the presence of a nasal histamine challenge
2. To evaluate the efficacy of chronic dosing of ALAP-1 compared with placebo on reducing the symptoms of AR induced by nasal histamine challenge</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Peak nasal inspiratory flow meter, measured at 0, 10, 20, 30, 45 and 60 minutes post-histamine challenge on the study visit days.</primaryOutcome>
      <secondaryOutcome>Sneeze score, measured at 0, 10, 20, 30, 45 and 60 minutes post-histamine challenge on the study visit days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Copernicus Group Institutional Review Board (IRB) on the 19th September 2006 (ref: MED4-06-238).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83077547</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BB100A and BB100B</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled crossover study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5f1ebd8f-02a4-4741-b745-c8b519fe7177">
	  <name>18250 Roscoe Blvd.</name>
	  <address/>
	  <city>Northridge</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>91325</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 18 - 59 years, either sex
2. A history of seasonal allergic rhinitis</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Atrophic rhinitis
2. Rhinitis medicamentosa
3. Nasal polyps
4. Septal deviation
5. Active bacterial or viral sinusitis
6. Severe asthma
7. Peptic ulcer disease or active gastroesophageal reflux disease (GERD)
8. History of anaphylaxis to any allergen
9. Pregnancy
10. Active bacterial or viral rhinitis
11. Nasal surgery within the last eight weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal allergic rhinitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Seasonal allergic rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>ALAP-1 (herbal combination) versus placebo. ALAP-1 is an herbal combination formulated to prevent and reduce AR symptoms. This proprietary formula is a standardised blend of the following eleven botanical extracts: Cullen corylifolium (Psoralea fruit), Xanthium sibiricum (Xanthium fruit), Scutellaria baicalensis (Chinese skullcap root), Gardenia augusta (Gardenia fruit), Bupleurum chinense (Bupleurum root), Chrysanthemum x moriflolium (Chrysanthemum flower), Areca catechu (Areca husk), Schisandra spp. (Schisandra fruit), Ziziphus jujuba var. spinosa (Jujube seed), Nepeta tenuifolia (Schizonepeta aerial parts) and Plantago asiatica (Asian plantain seed).

Three-day study:
Subjects will consume three capsules of ALAP-1 (1350 mg) or placebo per day for two days and return to the research office on the third day for evaluation. Subjects undergo their baseline peak nasal inspiratory flow (PNIF) measurement and then consume four capsules of ALAP-1 (1800 mg) or placebo. Fifteen minutes later, the nasal histamine provocation is performed. Shortly after the histamine challenge, subjects consume an additional 4 capsules of ALAP-1 (1800 mg) or placebo. This dosing regimen simulates the method in which the formula would be used in practice: daily preventive doses during allergy season and a treatment dose in the event of direct exposure to an environmental allergen. Subjects then wash out for 1 week and are then enrolled into the opposite arm (active or placebo). 

One month study:
Subjects will receive ALAP-1 or placebo for 4 weeks total. Initally, ALAP-1 (or placebo) is provided for 2 weeks at a high dose (1350 mg/day) and subjects undergo nasal histamine provocation and peak nasal inspiratory flow (PNIF) measurements. Then subjects are given ALAP-1 or placebo for 2 weeks at a low dose (900 mg/day). Subjects washout for 1 week and then are enrolled in the opposite arm.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>ALAP-1</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17379-0</funderId>
      <contactId>Contact55340_17379</contactId>
      <sponsorId>Sponsor53910</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55340_17379">
    <title>Dr</title>
    <forename>Jay</forename>
    <surname>Udani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>18250 Roscoe Blvd.
Suite 240</address>
      <city>Northridge</city>
      <country>United States of America</country>
      <zip>91325</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53910">
    <organisation>Radix Bioscience (USA) </organisation>
    <website>http://www.radixbioresearch.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4436 Reeves Road</address>
      <city>Ojai</city>
      <country>United States of America</country>
      <zip>93023</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.505150.4</gridId>
    <rorId>https://ror.org/024hp8310</rorId>
  </sponsor>
  <funder id="Funder17379-0">
    <name>Radix Bioscience (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-23T00:00:00.000Z">37803178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of perioperative patients with obstructive sleep apnoea</title>
      <scientificTitle/>
      <acronym>OSAS</acronym>
      <studyHypothesis>Polysomnographic parameters in patients with obstructive sleep apnoea are influenced by the type of surgery and the type of anaesthesia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Apnoea-hypopnoea index, based on the following: 
1. Continuous polysomnographic measurement. This will be carried out at the following timepoints:
1.1. The night before surgery from 23:00 pm to 7:00 am
1.2. For 2 hours in the recovery room after extubation
1.3. After returning from the recovery room to the ward, until 7:00 am next day 
2. The patients will be asked to rate the intensity/recreative power of the night sleep on a scale, from 1 (not recreative) to 5 (very recreative) the first and second morning 7:00 am</primaryOutcome>
      <secondaryOutcome>1. Patient satisfaction, based on the following: 
1.1. The patients will be asked to rate his contentedness with the anaesthesia on a scale, from 1 (very content) to 5 (not content) the next morning after surgery
1.2. The patients will be asked to rate the pain on a scale from 0 (no pain) to 10 (strongest pain) at the following timepoints:
1.2.1. At the beginning of the anaesthesia
1.2.2. Immediately after extubation
1.2.3. After the first hour in the recovery room
1.2.4. After the second hour in the recovery room
1.2.5. Next morning after surgery
2. Heart rate and blood pressure, measured as part of the continuous polysomnographic measurement (see primary outcome measures)
3. Circulating mediators 
4. Validity of screening</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Charité - Berlin Medical University Ethics Committee on the 18th May 2006 (ref: EA1/016/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37803178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EA1/016/06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eb81e125-6361-4ac6-8c55-ee6a4d0fa1df">
	  <name>Chariteplatz 1</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Obstructive sleep apnoea (the Epworth Sleepiness Scale [ESS] score greater than 9) 
2. Elective surgery with either general or regional anaesthesia, or airway surgery 
3. Aged greater than 18 years, either sex
4. American Society of Anaesthesiologists (ASA) classification I - III</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Significant cardiovascular or pulmonary disease 
2. Significant liver or renal disease 
3. Significant psychiatric disease rendering the subject unable to participate in the trial 
4. Drug dependency 
5. Chronic opioid therapy 
6. Chronic BiPAP (Bi-level Positive Airway Pressure) ventilator therapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obstructive sleep aponea</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Obstructive sleep aponea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 20 patients with surgery with general anaesthesia
Group 2: 20 patients with surgery with regional anaesthesia
Group 3: 20 patients with surgery on the upper airway with general anaesthesia

Randomisation of participants will be carried out between groups 1 and 2. There is no randomisation in group 3.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17209-0</funderId>
      <contactId>Contact55170_17209</contactId>
      <sponsorId>Sponsor53736</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55170_17209">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53736">
    <organisation>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder17209-0">
    <name>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-18T00:00:00.000Z">84220089</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An interventional, randomized, double-blind, placebo-controlled, parallel-assignment, safety/efficacy study for treatment of chronic middle ear infection in adult patients with the antimicrobial peptide OP-145</title>
      <scientificTitle/>
      <acronym>OP-145</acronym>
      <studyHypothesis>The purpose of this study is to determine the safety, tolerability, and efficacy of OP-145 eardrops to the middle ear of patients with chronic otitis media. We hypothesize that OP-145 will improve the middle ear mucosa in patients with chronic otitis media.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety of OP-145 eardrops, which will be determined by the following at baseline and week 1, 2, 4, 8, and 12 (for both Part I and II of the trial): 
1. Hearing levels
2. Blood analysis
3. Antibody detection
4. Bacterial culture of ear and throat swabs
5. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey)</primaryOutcome>
      <secondaryOutcome>Efficacy of OP-145 eardrops, assessed by the following at baseline and week 1, 2, 4, 8, and 12: 
1. Mucosal endoscopic scores (for both Part I and II of the trial)
2. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey) (only for Part II of the trial)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Committee of the Leiden University Medical Center. Approved on the 19th December 2003 (Ref: P02.216/YR/yr)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84220089</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P02.216</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase I/II, double-blind, parallel-assignment, safety/efficacy, randomized placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f78f205a-9198-4106-8aaa-1954d67ac7ff">
	  <name>Leiden University Medical Center</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 ZA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Inclusion criteria for the Part I dose finding study: 
1. Adults &gt;= 18 years, males and females 
2. Legally competent, no psychiatric history 
3. Chronic otitis media with a clear perforation of the tympanic membrane &gt;3 months 
4. Chronic proliferative mucosal changes (confirmed by Computerised Tomography (CT) scan) 
5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for &gt;6 weeks) 

Inclusion criteria for the Part II randomised controlled study: 
1. Adults, both males and females, over 18 years of age 
2. Legally competent, with no history of psychiatric disorders 
3. Chronic otitis media with a clear perforation of the tympanic membrane, lasting longer than 6 months 
4. Chronic proliferative mucosal changes  (confirmed with CT scan)
5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for &gt;6 weeks)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Part I: 16 patients; Part II: 52, with an interim analysis after 26 patients.</totalTarget>
      <exclusion>Exclusion criteria for the Part I dose finding study: 
1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan) 
2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte') 
3. Pregnant and breastfeeding women 
4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days 
5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days 
6. Patients with serious headaches 
7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract 
8. Immunocompromized patients or patients with auto-immune disorders 
9. History of seizures 
10. Patients with deficits at the nervus facialis 

Exclusion criteria for the Part II randomised controlled study: 
1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan)
2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte')
3. Pregnant and breastfeeding women 
4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days
5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days
6. Patients with serious headaches
7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract
8. Immunocompromized patients or patients with auto-immune disorders
9. History of seizures
10. Patients with deficits at the nervus facialis
11. Patients who were included in the Part I dose finding study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic otitis media</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Chronic otitis media</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Part I dose finding study: 

The participants were allocated into four trial arms in the order of inclusion timepoints i.e. the first four participants were allocated to the lowest dose group, second four in the next dose group, etc. 

Arm 1: 0.25 mg/ml OP-145 eardrops twice a day
Arm 2: 0.5 mg/ml OP-145 eardrops twice a day
Arm 3: 1.0 mg/ml OP-145 eardrops twice a day
Arm 4: 2.0 mg/ml OP-145 eardrops twice a day

Duration of intervention: 2 weeks
 
Part II randomised controlled study: 
Based on the results of the Part I study the Part II study was executed with 0.5 mg/ml OP-145 eardops twice a day (control: placebo twice a day) for 2 weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I/II</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16955-0</funderId>
      <contactId>Contact54916_16955</contactId>
      <sponsorId>Sponsor53481</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54916_16955">
    <title>Dr</title>
    <forename>Nanno</forename>
    <surname>F.A.W. Peek</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center
Albinusdreef 2</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 ZA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53481">
    <organisation>OctoPlus N.V. (The Netherlands)</organisation>
    <website>http://www.octoplus.nl/index.cfm/site/OctoPlus/pageid/821DEDEC-E30E-0D4E-CC80F8CDD400753F/index.cfm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ewoud-Jan van Hoogdalem 
Zernikedreef 12</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476342.0</gridId>
    <rorId>https://ror.org/01dn4wg45</rorId>
  </sponsor>
  <funder id="Funder16955-0">
    <name>OctoPlus Inc. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-18T00:00:00.000Z">74707125</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does Acamprosate Decrease Cue-induced Alcohol Craving?</title>
      <scientificTitle>A randomised placebo-controlled trial of acamprosate effects on alcohol cue reactivity and alcohol priming in dependent patients</scientificTitle>
      <acronym>DADCAC</acronym>
      <studyHypothesis>1. Acamprosate attenuates cue-induced subjectively experienced and physiolological correlates of craving
2. Acamprosate attenuates alcohol-induced subjectively experienced and physiolological correlates of craving</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. The difference in subjectively experienced craving post exposure to non-alcohol related stimuli versus alcohol related stimuli
2. The difference in subjectively experienced craving between pre- and post-consumption of an alcoholic drink

For both measures comparisons are made between acamprosate versus placebo treated patients. Measures are collected post 22 days of treatment. Patients then come to the clinic and go through a series of sessions where they are exposed to alcohol versus non-alcohol related stimuli, and also take part in a alcohol priming paradigm. Present alcohol craving is measured in connection to each exposure.</primaryOutcome>
      <secondaryOutcome>Physiological measures of craving:
1. Pulse
2. Blood-pressure
3. Cortisol in blood
4. Galvanic skin response
5. Skin temperature

Measures are collected post 22 days of treatment. Patients then come to the clinic and go through a series of sessions where they are exposed to alcohol versus non-alcohol related stimuli, and also take part in an alcohol priming paradigm. Present alcohol craving is measured in connection to each exposure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial was approved by:
1. The Regional Ethical Review Board in Stockholm on the 23rd March 2005 (ref: 2005/30-31/3)
2. The Swedish Medical Products Agency on the 5th April 2005 (EudraCT number: 2004-004514-17)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74707125</doi>
      <eudraCTNumber>2004-004514-17</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EudraCT number: 2004-004514-17</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study used a randomised, double blind, single-site, placebo-controlled design comparing cue- and alcohol-induced craving for acamprosate and placebo treated patients</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c942a0cf-9319-4efa-bb72-44bcbf1a268c">
	  <name>Department of Clinical Neuroscience</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>17176</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A male or a non-pregnant/non-nursing female between 18 and 65 years of age
2. A goal of controlled drinking
3. An intact sense of smell
4. Fulfilling the criteria for alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
5. Willingness to give informed consent and comply with study procedures
6. Alcohol consumption in 15 of the last 90 days</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>1. Seeking complete alcohol abstinence
2. Current use of any medication that interferes with salivation
3. A diagnosis of an Axis I psychiatric disorder according to DSM-IV criteria (including all forms of substance dependence other than nicotine and alcohol)
4. A current use of psychoactive medications to manage schizophrenia, bipolar disorder, or major depression
5. Inpatient alcohol detoxification within the last 4 days
6. Acamprosate medication during the last year
7. Use of illegal drugs during the course of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Alcohol dependence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Alcohol dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were assigned to 22 days of either acamprosate (1998 mg/day) or placebo treatment according to a randomisation process conducted by the Karolinska University Hospital pharmacy. Medication (150 tablets containing 333 mg acamprosate or placebo) was dispensed once per patient, at the start of the trial, with instructions to intake 6 tablets per day (2 in AM, 2 midday, 2 in PM).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acamprosate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17269-0</funderId>
      <funderId>Funder17269-1</funderId>
      <funderId>Funder17269-2</funderId>
      <funderId>Funder17269-3</funderId>
      <contactId>Contact55230_17269</contactId>
      <sponsorId>Sponsor53798</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55230_17269">
    <title>Dr</title>
    <forename>Johan</forename>
    <surname>Franck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Clinical Neuroscience
Section for Alcohol and Drug dependence Research
Karolinska University Hospital, M4:02</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>17176</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">johan.franck@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53798">
    <organisation>Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)</organisation>
    <website>http://www.beroendecentrum.com</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Box 17914</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>118 95 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476028.f</gridId>
    <rorId>https://ror.org/04g380834</rorId>
  </sponsor>
  <funder id="Funder17269-0">
    <name>AFA insurances (AFA försäkringar) (Sweden) - http://www.afaforsakring.se</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-1">
    <name>Systembolagets Council for Alcohol Research (Systembolagets råd för alkoholforskning) (Sweden) - http://www.can.se/sa/node.asp?node=1663</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-2">
    <name>Milan Valverius Foundation (Sweden) - http://www.salusansvar.se/info/default.aspx?FolderID=3063a24d-26b2-416d-b00a-1d4d06810b2e</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-3">
    <name>Foundation for Research on Psychiatric Diseases (Psykiatrifonden) (Sweden) - http://www.psykiatrifonden.se</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-01-11T00:00:00.000Z">18010960</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Amniocentesis Before rescue Cerclage</title>
      <scientificTitle/>
      <acronym>ABC Trial</acronym>
      <studyHypothesis>We hypothesise that the use of a diagnostic amniocentesis and testing for rapid markers of chorioamnionitis (amniotic fluid lactate dehydrogenase or glucose level) will identify a subset of women without subclinical chorioamnionitis for whom the cerclage is more likely to prolong pregnancy to a viable gestational age and decrease the risk of neonatal and maternal complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary comparison will be the prolongation of gestation to greater than 34 weeks of gestation, defined as rescue cerclage success.</primaryOutcome>
      <secondaryOutcome>1. Maternal morbidity: will include complications of cerclage insertion, through gestation and at the time of the delivery
2. Neonatal morbidity: will include complications during the initial admission to the nursery following the delivery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval is pending as of 31/10/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18010960</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MSH Reference Number # 07-0080-A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7612215e-3013-4743-a54d-c1960b0f3e06">
	  <name>RM 3201</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 1X8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Singleton gestation 
2. Presence of cervical dilatation 
3. Membranes visible at or protruding through the cervical opening 
4. Absence of any uterine activity 
5. Absence of any overt signs of maternal infection:
5.1. Maternal temperature greater than 37.8°C
5.2. Diffuse abdominal pain
5.3. Foul/pus like discharge
5.4. Maternal or foetal tachycardia</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>46</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>46</totalTarget>
      <exclusion>1. Intrauterine foetal demise or distress 
2. Intrauterine growth restriction 
3. Foetal anomaly 
4. Poly- or oligo-hydramnious 
5. Ruptured foetal membranes 
6. Current history of significant antepartum haemorrhage</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cervical incompetence</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Maternal care for cervical incompetence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Women will be randomised to either:
1. Cerclage group 
2. Amniocentesis and cerclage group

Randomisation will be organised by a random numbers table and assigned by telephone. Women randomised to the amniocentesis group will undergo an aseptic aspiration of amniotic fluid under ultrasound guidance by a single operator. Briefly, the abdomen will be prepared with antiseptic solution and draped with sterile towels. The ultrasound transducer probe will be draped with a sterile plastic cover. Using a sterile water-based ultrasound gel to facilitate visualisation, the operator will identify a pocket of amniotic fluid suitably away from the foetus and placenta. A sterile 22 gauge needle will be passed into the uterine cavity under direct visualisation and approximately 15 cc of amniotic fluid will be aspirated. 

Post procedure, Rhogam™ will be administered to Rhesus negative patients as indicated. Amniotic fluid will be tested for lactate dehydrogenase level (2 cc), glucose level (2 cc), cell count (2 cc), haemoglobin level (2 cc) and Gram staining (2 cc). Amniotic fluid will be sent for confirmatory aerobic, anaerobic and myoplasma/ureaplasma culture (4 cc per culture). 

All tests will be performed by the respective Departments of Biochemistry, Haematology and Microbiology (Mount Sinai Hospital, Canada) using established protocols. While waiting for the fluid test results (approximately 90 - 120 minutes), a tocodynometer will be placed over the uterine fundus to confirm the absence of uterine activity. Those women without evidence of subclinical infection following amniocentesis and those women who were randomised to the cerclage group will have a rescue cerclage placed. 

Rescue cerclage placement will be performed under general anaesthesia. Women will be placed in the lithotomy position with a steep Trendelenberg tilt. The prolapsed membranes will be gently pushed back into the uterine cavity with an inflated Foley catheter. A single purse string suture (#5 Ticron™) will be performed using the technique described by MacDonald. Perioperative tocolysis (indomethacin 100 mg per rectum [pr] followed by 25 mg orally every 6 hours for 48 hours) to prevent the uterine contractions that can be precipitated by cervical manipulation and cerclage insertion and prophylactic antibiotics (clindamycin 900 mg intravenous [iv] three times a day [TID] for 7 days) will be administered. A transvaginal ultrasound to evaluate the cervical placement will be done 48 hours postoperatively. 

Following cerclage insertion, women will be restricted to bedrest until 30 weeks of gestation. Cerclages will be removed electively at 36 weeks or before based on foetal or maternal indication. Thromboprophylaxis with enoxaparin (40 mg subcutaneously [sc] once daily [od]) will be administered to all women on prolonged bed rest.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17236-0</funderId>
      <contactId>Contact55197_17236</contactId>
      <sponsorId>Sponsor53763</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55197_17236">
    <title>Dr</title>
    <forename>Wendy</forename>
    <surname>Whittle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>RM 3201 
700 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wwhittle@mtsinai.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53763">
    <organisation>Mount Sinai Hospital (Canada) </organisation>
    <website>http://www.mtsinai.on.ca/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr Wendy Whittle
Department of Obstetrics and Gynaecology
Rm 3201 Ontario Power Generation Building
700 University Avenue </address>
      <city>Toronto </city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wwhittle@mtsinai.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416166.2</gridId>
    <rorId>https://ror.org/05deks119</rorId>
  </sponsor>
  <funder id="Funder17236-0">
    <name>Mount Sinai Hospital (Canada) - Department of Obstetrics and Gynaecology Research Fund ($5000)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-09T00:00:00.000Z">07427212</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of experimental hyperglycemia and AT1 receptor blockade on renal hemodynamics in impaired glucose tolerance</title>
      <scientificTitle/>
      <acronym>IGT-FRA-oo30-I</acronym>
      <studyHypothesis>The study aim is to investigate whether: 
1. Experimental hyperglycemia reduces renal hemodynamics (glomerula filtration rate, renal plasma flow) 
2. Angiotensin II Type 1 (AT1) receptor blocker treatment prevents hyperglycemia induced changes of renal hemodynamics</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at rest (U1 rest, U2 rest) and during hyperglycemic stress testing (U1 stress, U2 stress) with and without AT1 receptor blocker treatment:
1. Glomerular filtration rate (inulin clearance) 
2. Renal plasma flow (Para-AminoHippurate [PAH] clearance) 

U1: Without AT1 receptor blocker
U2: After a 4-week treatment with valsartan</primaryOutcome>
      <secondaryOutcome>The following were assessed at U1 and U2: 
1. High-sensitivity C-Reactive Protein (CRP) 
2. Adiponectin 
3. HbA1c (blood tests) 

U1: Without AT1 receptor blocker 
U2: After a 4-week treatment with valsartan</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Ethical Committee of the Technical University of Munich.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07427212</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, open, prospective, longitudinal, non-randmoised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="de9d23a8-a9e7-4440-ba4b-1b5baaf9d01a">
	  <name>Nephrology Department</name>
	  <address/>
	  <city>Munich</city>
	  <state/>
	  <country>Germany</country>
	  <zip>81675</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males 
2. 18-70 years old
3. Impaired Glucose Tolerance (for the intervention group [IGT-Group]) (tested by the oral glucose tolerance test according to the World Health Organisation) and normoglycemic patients (for control group [healthy subjects])</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Male</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Renal or liver insufficiency 
2. Micro-or macro-albuminuria 
3. Overt diabetes mellitus</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Impaired glucose tolerance/ renal changes in prediabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Impaired glucose tolerance/ renal changes in prediabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>12 participants were recruited in each of the two groups. Statistical calculation was carried out by the Institute of Statistics, Technical University of Munich. 

Participants of both groups (control and IGT-group) received the following two interventions: 
1. Experimental hyperglycemia (clamp technique) 
2. Valsartan (AT1 receptor blocker)(oral, taken once a day in the morning) treatment for 4 weeks. The initial dose was 80 mg/day, and the dosage was increased after 7 +/- 2 days of administration to 160 mg /day. 

A safety visit was made at 5 +/- 2 days after the beginning of the study for the measurement of serum creatintine, potassium and blood pressure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>AT1 receptor blocker</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17381-0</funderId>
      <contactId>Contact55342_17381</contactId>
      <sponsorId>Sponsor53912</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55342_17381">
    <title>Dr</title>
    <forename>Helga</forename>
    <surname>Frank</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nephrology Department
Klinikum rechts der Isar
Ismaninger Strasse 22</address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53912">
    <organisation>Technical University of Munich (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ismaninger Strasse 22 </address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 89 4140 2231</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Helga.Frank@lrz.tum.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6936.a</gridId>
    <rorId>https://ror.org/02kkvpp62</rorId>
  </sponsor>
  <funder id="Funder17381-0">
    <name>Novartis (International)</name>
    <fundRef>http://dx.doi.org/10.13039/100004336</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">56178790</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The MRS study</title>
      <scientificTitle>Sorafenib (NEXAVAR®) monotherapy in patients with inoperable/recurrent germ cell carcinoma refractory to chemotherapy</scientificTitle>
      <acronym>MRS</acronym>
      <studyHypothesis>Sorafenib prolongs Progression-Free Survival (PFS) in patients with inoperable/recurrent germ cell carcinoma refrectory to chemotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Progression Free Survival (PFS)</primaryOutcome>
      <secondaryOutcome>1. Overall Relapse Rate (ORR)
2. Overall Survival (OS)
3. Toxicity
4. Evaluation of panel of biomarkers, will be assessed every 4 weeks
5. Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30] version 3.0 pol and testicular cancer module), will be assessed every 12 weeks</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Submitted, not reviewed yet as of 06/12/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56178790</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>12602</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single arm, non-randomised, single institution, phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8902808c-99d9-4f78-a4ef-24c2b5b14b66">
	  <name>Roentgena 5</name>
	  <address/>
	  <city>Warsaw</city>
	  <state/>
	  <country>Poland</country>
	  <zip>02781</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male patients greater than 18 years of age
2. Patients with histologically proven germ cell neoplasm (gonadal or extragonadal primary)
3. Patients must have the disease not amendable to cure with either surgery or chemotherapy 
4. Patients must have failed at least two cisplatin-based combination chemotherapy regimens
5. Failure on prior regimens will be defined as either:
5.1. A greater than or equal to 25% increase in sum of target lesions, new lesions, or
5.2. An increasing Alpha Fetoprotein (AFP) or Human Chorionic Gonadotropin (HCG) above the nadir level
6. Patients with at least one measurable lesion by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria  
7. Adequate bone marrow, liver and renal function, assessed no longer than 14 days before treatment start, defined by the following laboratory test limits: 
7.1. White Blood Cells (WBC) greater than 2.0 x 10^9/l and platelets greater than 60 x 10^9/l
7.2. Total bilirubin less than 2 x Upper Limit of Normal (ULN)
7.3. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 5 x ULN
7.4. Serum creatinine less than 2 x ULN
8. World Health Organization (WHO) performance status 0, 1, 2 
9. No concurrent chemotherapy or radiotherapy
10. Life expectancy of at least 12 weeks
11. Absence of any physiological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
12. A signed informed consent must be obtained prior to any study specific procedures 
13. All patients must agree to use adequate contraception during the whole study period</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Patients not fulfilling of inclusion criteria 	
2. Primary radiotherapy in the field of target lesion
3. Major surgery (Retroperitoneal Lymph Node Dissection [RPLND]) within 4 weeks before the start of study drug or concurrent serious non-healing wounds, ulcers or bone fractures.
4. Known serious and active bacterial, viral or fungal infection (greater than grade II Common Terminology Criteria for Adverse Events [CTC-AE]) including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) carrier state
5. Previous or concurrent malignancy except for basal cell carcinoma of the skin
6. Uncontrolled hypertension
7. Thrombotic or embolic event in last 6 months prior to inclusion
8. Impairment of Gastrointestinal (GI) tract, or GI disease that may influence the bioavailability of oral sorafenib
9. Substance and alcohol abuse (nicotine use is allowed)
10. Known or suspected hypersensitivity to sorafenib
11. Participance in any other clinical trial using investigational drug within 4 weeks prior to study entry
12. Prior use of investigational or licensed angiogenesis and Raf kinase or Mitogen-activated Extracellular-signal-Regulated Kinase (ERK) (MEK) inhibitors
13. Patient unwilling or unable to give informed consent
14. Any condition that may in the investigator&#146;s opinion jeopardize the safety of the patient or his compliance in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Testicular cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Testicular cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There is only one treatment arm, therefore all participants will receive sorafenib 400 mg (2  tablets of 200 mg twice daily orally) continuously in 4-week cycles till progression or unacceptable toxicity. All patients will be followed/contacted after discontinuation of protocol every 3 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Sorafenib (NEXAVAR®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17331-0</funderId>
      <contactId>Contact55292_17331</contactId>
      <sponsorId>Sponsor53860</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55292_17331">
    <title>Dr</title>
    <forename>Iwona</forename>
    <surname>Skoneczna</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roentgena 5</address>
      <city>Warsaw</city>
      <country>Poland</country>
      <zip>02781</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)22 5462098</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.skoneczna@coi.waw.pl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53860">
    <organisation>Prof. Grzegorz Madej Memorial Foundation "Win the health" (Fundacja "Wygrajmy Zdrowie" im Prof. Grzegorza Madeja) (Poland)</organisation>
    <website>http://www.wygrajmyzdrowie.pl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 20</address>
      <city>Warsaw 10</city>
      <country>Poland</country>
      <zip>00956</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)510 723 802</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.skoneczna@wygrajmyzdrowie.pl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17331-0">
    <name>Bayer Pharmaceuticals Poland Sp. z.o.o. (Poland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">25350905</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Topical use of adrenaline in different concentrations for endoscopic sinus surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vasoconstrictors such as cocaine or epinephrine (adrenaline) are routinely applied during functional endoscopic sinus surgery. The goal is to control bleeding because, when surgery is endoscopic, even minor bleeding can be troublesome if it blocks the small end of the endoscope. Nevertheless vasoconstrictors might cause an increase in blood pressure and heart arrhythmias. The ideal adrenaline concentration should be the one to provide optimal operative field with no cardiovascular side effects. Despite its routine use, that concentration is yet to be determined. Concentrations of adrenaline varying from 1:1000 to 1:200,000 have been used both topically and sub-mucosally. Many studies have used both adrenaline and cocaine, which makes it difficult to establish the individual role of each substance on the outcome. We have decided to work with adrenaline solutions applied only topically. 

We study the effects of topical use of adrenaline solution on the nasal mucosa in three different concentrations on systemic absorption of the drug, blood pressure, heart rhythm, operative bleeding and operative time during endoscopic sinus surgery for nasal polyposis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data were collected during surgery (No assessment was done post-operatively): 
1. Variation of blood pressure during surgery (measured by non-invasive blood pressure measures every 3 minutes)
2. Variation of heart frequency during surgery (measured continuously by 12 lead ECG)
3. Development of heart arrythmias during surgery (measured continuously by 12 lead ECG)
4. Operative bleeding (measured both objectively by the amount of blood aspirated during the procedure and subjectively by visual-analogue scale from 01 = no bleeding to 10 = very high bleeding)
5. Variation of plasma levels of adrenaline measured by three blood samples obtained during each surgery
6. Operative time</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the ethic committee of Federal University of Rio de Janeiro (UFRJ) on 24 November 2004 (ref: 207/04 CEP)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25350905</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind single-centre controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="621fe6be-6b09-4d98-85fb-170c726beeb8">
	  <name>Praia de Botafogo, 422 / 1106</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>+55 22250 040</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Be over 18 years old
2. Need elective endoscopic sinus surgery under general anesthesia for the treatment of nasal polyposis
3. Understand and give written consent to participate in the trial
4. To be classified as grade I or II according to the American Society of Anesthesiology classification of pre-operative assessment</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Patients legally incompetent or unable, for any reason, to read and sign a written consent form 
2. Patients who withdraw their consent in any time during the course of the trial, even if they have signed the consent form 
3. Patients with systemic hypertension, coronary diseases, heart arrythmia, coagulation disorders, collagen disorders, renal or liver insufficiency in any degree, previously diagnosed or detected during pre-operative assessment 
4. Pregnant women 
5. Patients who do not follow the trial protocol for any reason, unless it is related to the use of the adrenaline solution 
6. Patients in use of a number of medications that might interfere with blood pressure or coagulaion, such as anti-inflammatory drugs, oral hypoglicemics, beta agonists, etc</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nasal polyposis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Nasal polyposis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were submitted to endoscopic sinus surgery under general anesthesia for treatment of nasal polyposis using different concentrations of adrenaline solution applied topically to the nasal mucosa. 

Concentrations: 
1. Adrenaline 1:2000 with lidocaine 1% (4 ml)
2. Adrenaline 1:10,000 with lidocaine 1% (4 ml)
3. Adrenaline 1:50,000 with lidocaine 1% (4 ml)

The control group consisted of patients submitted to tonsillectomies using the same anesthetic protocol as the study groups but without the use of adrenaline solution during surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>adrenaline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17366-0</funderId>
      <contactId>Contact55327_17366</contactId>
      <sponsorId>Sponsor53896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55327_17366">
    <title>Dr</title>
    <forename>Krishnamurti</forename>
    <surname>Sarmento Junior</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Praia de Botafogo, 422 / 1106
Botafogo</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>+55 22250 040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krishnamurti.sarmento@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53896">
    <organisation>Federal University of Rio de Janeiro (UFRJ) (Brazil) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Pedro Calmon, nº 550
Prédio da Reitoria
2º andar
Cidade Universitária </address>
      <city>Rio de Janeiro </city>
      <country>Brazil</country>
      <zip>CEP 21941-901</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8536.8</gridId>
    <rorId>https://ror.org/03490as77</rorId>
  </sponsor>
  <funder id="Funder17366-0">
    <name>Federal University of Rio de Janeiro (UFRJ) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">99715969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Immediate in-hospital reactivation of patients with an exacerbation of Chronic Obstructive Pulmonary Disease (COPD): Pulmofit-MST</title>
      <scientificTitle/>
      <acronym>PULMOFIT-MST</acronym>
      <studyHypothesis>Chronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and mortality worldwide. Morbidity and mortality among COPD-patients are strongly related to acute exacerbations of COPD, which can be defined as sustained worsening of the patient&#146;s condition, from stable state and beyond normal day-to-day variations, that is acute in onset and may warrant additional treatment in a patient with underlying COPD. Severe exacerbations may lead to hospital admissions and have a major impact on disease evolution and costs.

Pulmofit-MST, an immediate reactivation programme, will induce a reduction of the length of stay in the hospital, by preventing loss of peripheral muscle force and exercise capacity and thereby initiating a faster recovery of activities of daily living.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Length of hospital stay, defined as number of days between day of admission and day of medical discharge. Day of medical discharge was distinguished from the actual day of discharge because some patients remain in hospital longer than medically necessary (e.g. patients could not yet be referred to a nursing home).</primaryOutcome>
      <secondaryOutcome>1. Walking distance (3 minutes walking test)
2. Dyspnoea (Borg scale)
3. Health status (Clinical COPD Questionnaire)
4. Activities of daily living (Barthel Index)
5. Readmissions due to a COPD-exacerbation (less than 28 days), measured at 28 days

Measurements take place at the day of admission, day 4 and the day of medical discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medisch Etische Toetsingscommissie Medisch Spectrum Twente) on the 16th January 2006 (ref: P06-05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99715969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NT1101</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, two armed trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9995600e-9a5b-46d4-8e0a-4fe5a58e5961">
	  <name>Haaksbergerstraat 55</name>
	  <address/>
	  <city>Enschede</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>7513 ER</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
2. A clinical diagnosis of an exacerbation of COPD for which hospitalisation was required
3. (Ex-) smoker
4. Age above 40 years
5. A life expectancy of at least 3 months
6. Able to understand and read Dutch
7. An informed consent from the subject prior to participation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Pneumonia
2. Fever (greater than 38.5°C)
3. Severe confusion
4. Severe heart failure, New York Heart Association (NHYA) class III or IV
5. Relevant co-morbidity seriously influencing mobility</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Obstructive Pulmonary Disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The protocol of the programme aimed at an active role of COPD-patients during their stay in the hospital. Patients in the intervention group were asked to perform three daily training sessions of 15 minutes each. One daily session was assisted by a physiotherapist, while the other two had to be performed by the patients themselves. 

PULMOFIT-MST consists of four levels of increasing difficulty. Within four hours after admission, level I was started by the nurse who distributed the workbook with the description of all exercises and who instructed the first exercises to the patient. Within 24 hours after admission, the physiotherapist visited the patient and continued the programme by choosing the appropriate follow-up level and determining the intensity of the exercises. Every day the physiotherapist evaluated the exercises and the appropriateness of the training level and training intensity. A workbook functioned as a daily diary in which the intensities of training exercises were noted by the physiotherapist and daily experiences and improvements by the patient. All disciplines (chest physicians, nurses, and physiotherapists) stimulated patients to perform all three daily PULMOFIT-MST sessions. 

Patients in the control group received usual care, meaning treatment the patients would have received prior to this study. 

The duration of the treatment depends on the length of the hospitalisation. Patients of the intervention group are treated according to the PULMOFIT-MST protocol during the whole hospitalisation period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17272-0</funderId>
      <contactId>Contact55233_17272</contactId>
      <sponsorId>Sponsor53801</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55233_17272">
    <title>Mrs</title>
    <forename>Tanja </forename>
    <surname>Effing</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Haaksbergerstraat 55
Poli 12</address>
      <city>Enschede</city>
      <country>Netherlands</country>
      <zip>7513 ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53801">
    <organisation>Dutch Asthma Foundation (The Netherlands) </organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Postbus 5 </address>
      <city>Leusden</city>
      <country>Netherlands</country>
      <zip>3830 AA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.483859.b</gridId>
    <rorId>https://ror.org/00ddgbf74</rorId>
  </sponsor>
  <funder id="Funder17272-0">
    <name>Dutch Asthma Foundation (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-03T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-01-03T00:00:00.000Z">48092875</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>N3 fatty acids as adjuvant therapy in rheumatoid arthritis (N3-fettsäuren als adjuvante therapie bei rheumatoider arthritis)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Omega-3 fatty acids infusions may show earlier and superior antiinflammatory effects in patients with rheumatoid arthritis than oral administered ones (as shown in earlier trials), and we presumed the beneficial effects may be maintained by following oral omega-3 fatty acid administration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed at baseline, during infusion phase (after week 1 and after week 2) and during capsule phase (after two weeks [end of month 1] and then monthly until the end of month 6):
1. Swollen joints
2. Tender joints
3. Erythrocyte Sedimentation Rate (ESR)
4. C-Reactive Protein (CRP)</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline, during infusion phase (after week 1 and after week 2) and during capsule phase (after two weeks [end of month 1] and then monthly until the end of month 6):
1. Disease Activity Score (DAS)
2. Rheumatoid Arthritis Disease Activity Index (RADAI) 
3. Health Assessment Questionnaire (HAQ)
4. 36-item Short Form health survey (SF-36)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This trial was approved by the ethics committee of the Medical University of Graz on 10th July 2000.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48092875</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>10-184 ex 99/00</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, double-blinded, placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a9dfa791-fddb-48e3-9746-7c5965360601">
	  <name>State Hospital Muerzzuschlag</name>
	  <address/>
	  <city>Muerzzuschlag</city>
	  <state/>
	  <country>Austria</country>
	  <zip>8680</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients at least 19 years of age and should not be older than 85 years
2. Patients suffering from Rheumatoid Arthritis (RA), according to American College of Rheumatology (ACR) criteria, for at least (&gt;=) 6 months 
3. Patients with active RA who meet following criteria:    
3.1. &gt;= 6 swollen joints 
3.2. &gt;= 6 tender joints
3.3. &gt;= 1 of following criteria: 
a. Joint morning stiffness &gt;= 45 minutes 
b. Erythrocyte Sedimentation Rate (ESR) &gt;= 28 mm 
c. C-Reactive Protein (CRP) &gt;=  20 mg/l (normal range: 0 - 9)
4. No pregnant or breast feeding women allowed; monthly negative pregnancy test in women of reproductive age 
5. Participant doesn't have a severe concomitant physical or mental illness  
6. Participant has to be able to follow the study procedures   
7. No severe malfunctioning of the liver, kidneys, bone marrow, blood clotting system 
8. Stable dosages of RA medication for at least 1 month prior to baseline:  
8.1. DMARD therapy with methotrexate of at least 10 mg per week over 4 months
8.2. Prednisone &lt;=10 mg daily 
9. No injection of glucocorticoids into a joint within 3 month prior to baseline 
10. Participant must not have legal conflict 
11. Participant must not have alcohol or drug abuse problems 
12. Written informed consent signed by the participant</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known allergy against fish oil or any other substance of the study medication 
2. Participant is younger than 19 years of age 
3. Patient simultaneously participates in another trial  
4. Participant doesn't sign the written informed consent. 
5. No stable dosage of RA medication 1 month prior to baseline 
6. Injection of glucocorticoids into a joint within 3 month prior to baseline 
7. Pregnant or breast feeding women; positive pregnancy test in women of reproductive age 
8. Patient has legal conflicts
9. Patient has alcohol or drug abuse problems 
10. Severe concomitant physical or mental illness  
11. Participant is physically or mentally unable to follow the study procedures  
12. Hereditary disorder of lipid metabolism 
13. Blood triglyceride levels &gt;300 mg/dl 
14. Patients with uncontrolled diabetes mellitus
15. Severe malfunctioning of the liver, kidneys, bone marrow, blood clotting system: 
15.1. Creatinin clearance &lt;=30 ml/min
15.2. Elevated levels of ALanine aminoTransferase (ALT) 2 fold above the upper normal range 
15.3. Leucopenia &lt;=2,500/ml, red blood cells &lt;=2.5 mill/ml, hemoglobin &lt;=9 mg/dl, platelets &lt;=70,000/ml 
16. Severe cardiovascular disease 
17. Known neoplasms</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Infusions of omega-3 fatty acids once daily for 14 days (Infusion speed: 0.5 ml/kg body weight and hour), followed by oral administration of omega-3 fatty acids up to 6 months. 

Control group: Placebo infusions once daily for 14 days (Infusion speed: 0.5 ml/kg body weight and hour), followed by oral administration of placebo up to 6 months. 

Verum:   
Infusions: Fish oil emulsion (Omegaven® Fresenius). 100 ml Omegaven® contained 10 g fish oil with 2.03 g EicosaPentaenoic Acid (EPA) and 2.26 g DocosaHexaenoic Acid (DHA) (and 0.02 mg a-tocopherol as antioxidat) 
Capsules: Fish oil. One capsule contained 1 g fish oil with 0.20 g EPA and 0.23 g DHA (and 0.02 mg a-tocopherol as antioxidant) 

Placebo: 
Infusions: NaCl 0.9% (physiological sodium chloride solution)
Capsules: Paraffin wax

Randomisation was done by a hospital pharmacist who prepared the bottles and other infusion material, so that neither the patients nor the staff could identify them as verum or placebo. Additionally, the study conducting staff was not allowed to enter the inpatient area while the patients received their infusions.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Omega-3 fatty acids</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17316-0</funderId>
      <funderId>Funder17316-1</funderId>
      <contactId>Contact55277_17316</contactId>
      <sponsorId>Sponsor53845</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55277_17316">
    <title>Dr</title>
    <forename>Babak</forename>
    <surname>Bahadori</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>State Hospital Muerzzuschlag
Department of Internal Medicine
Grazerstr. 63-65</address>
      <city>Muerzzuschlag</city>
      <country>Austria</country>
      <zip>8680</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.bahadori@gmx.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53845">
    <organisation>Medical University of Graz (Austria)</organisation>
    <website>http://www.meduni-graz.at/englisch/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Universitätsplatz 3</address>
      <city>Graz</city>
      <country>Austria</country>
      <zip>A-8010 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11598.34</gridId>
    <rorId>https://ror.org/02n0bts35</rorId>
  </sponsor>
  <funder id="Funder17316-0">
    <name>Investigator-funded (This trial is a physician initiated study) (Austria)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17316-1">
    <name>Fresenius Kabi Austria (Provided Omega-3 infusions only)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">76293435</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the effectiveness of endoscopic and microscopic removal of cerumen (wax) from the ear canal</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>What is the best preparation to use for otitis externa in the first instance?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76293435</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0212177259</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="563a1fcd-6767-4778-9b84-bb2997da2fe5">
	  <name>ENT</name>
	  <address/>
	  <city>Bath</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BA1 3NG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with otitis externa</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ear, Nose and Throat: Otitis externa</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Otitis externa</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Dewaxing using microscope
2. Dewaxing using endoscope</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17014445 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3d1cb828-f3d4-4b99-985d-35f98f8f341e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17014445"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17027-0</funderId>
      <contactId>Contact54988_17027</contactId>
      <sponsorId>Sponsor53553</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54988_17027">
    <title>Mr</title>
    <forename>David</forename>
    <surname>Pothier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>ENT
Royal United Hospital
B&amp;NES
</address>
      <city>Bath</city>
      <country>United Kingdom</country>
      <zip>BA1 3NG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">David.Pothier@ruh-bath.swest.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53553">
    <organisation>Record Provided by the NHSTCT Register - 2007 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17027-0">
    <name>Royal United Hospital Bath NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">75155444</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Which intravenous fluid should be given for hospitalized patients?: A prospective randomised study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesize of the study is that in sick children, moderately hypotonic fluids (such as fluids contain 77 mmol/L sodium) are better tolerated (i.e. induce less hyponatraemia without the risk of hypernatraemia) than conventional intravenous fluids that contain 34 mmol/L sodium.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Association between administration of hypotonic fluids and hospital-acquired hyponatraemia, assessed by the following:
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24</primaryOutcome>
      <secondaryOutcome>To determine contributive factors that may increase hyponatraemia risk, assessed by the following: 
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy. 
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24. 
3. Plasma AntiDiuretic Hormone (ADH), measured at T0. Abnormal ADH function was assessed by serum osmolality and serum sodium determinations.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical Board of Istanbul University, Istanbul Faculty of Medicine, approved on 13 June 2005. Ref: 2005/526.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75155444</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f4d6d98c-6794-4047-a043-44cc3da8e711">
	  <name>Istanbul University</name>
	  <address/>
	  <city>Istanbul</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>34390</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All children aged between 3 months to 16 years old who received intravenous fluids</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="16.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Dehydration
2. Cerebral oedema
3. Nephrotic syndrome
4. Hepatorenal syndrome
5. Plasma sodium level below 135 mmol/L
6. Congestive heart failure
7. Renal failure
8. Inborn error of metabolism
9. Protein energy malnutrition
10. Patients receiving mannitol or diuretics
11. Patients whose fluid therapy was started before admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hyponatraemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomized to one of the three study arms prospectively. Stratified block randomization was performed, with each one-week block featuring a different intravenous solution. Randomization was performed separately for children on the ward and children in the Paediatric Intensive Care Unit (PICU).

Arm 1: 0.2% sodium in 5% dextrose
Arm 2: 0.3% sodium in 3.3% dextrose
Arm 3: 0.45% sodium in 5% dextrose

When hyponatraemia developed in any group during the therapy intravenous fluid sodium composition was increased and fluid therapy was decreased to 80% of the initial volume.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Intravenous Fluid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16511-0</funderId>
      <contactId>Contact54469_16511</contactId>
      <sponsorId>Sponsor53024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54469_16511">
    <title>Prof</title>
    <forename>Metin </forename>
    <surname>Karaböcüoğlu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Istanbul University
Istanbul Faculty of Medicine 
Department of Paediatric Intensive Care
Millet Cad
Fındıkzade	  </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+01190 5332341818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mkara63@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53024">
    <organisation>Istanbul University, Faculty of Medicine (Turkey)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Paediatric Intensive Care 
Millet Cad
Fındıkzade </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.9601.e</gridId>
    <rorId>https://ror.org/03a5qrr21</rorId>
  </sponsor>
  <funder id="Funder16511-0">
    <name>Mainly investigator-funded with support from Ege Medical Company (Turkey)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-09-12T00:00:00.000Z">15330757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the efficacy and tolerability of nabilone with dihydrocodeine when used in the treatment of neuropathic pain based upon the following null hypotheses:
1. The analgesic activity of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
2. The patient tolerability of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
3. The antidepressant effect of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
4. Anxiety reducing effects of nabilone are not different from dihydrocodeine when used in the treatment of neuropathic pain over a six-week period</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mean pain score as measured by VAS 0 - 10 for the last two weeks on treatment.</primaryOutcome>
      <secondaryOutcome>1. Sleep was measured as hours slept and if the sleep was interrupted or not in the diary
2. Depression and anxiety were measured with the Hospital Anxiety and Depression Score (HAD) at baseline and after each treatment period
3. Quality of life was measured with the 36-item Short Form questionnaire (SF-36) at baseline and after each treatment period
4. Six psychometric tests were performed at baseline and after each treatment period on a Apple Newton device
5. Side effects were assessed every two weeks with a eight-point questionnaire rating the severity of the side effects on a five point scale plus a field for open comments</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from:
1. South Tees Local Research Ethics Committee on the 20th April 2001 (ref: 00/53)
2. West Ethics Committee Glasgow on the 23rd November 2001 (ref: 01/95)
3. Newcastle and North Tyneside Joint Ethics Committee on the 20th June 2001 (ref: 2000/137)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15330757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CL0014 Version 5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2441c365-7dc1-4e9c-a0fc-d2200bc2cbeb">
	  <name>Pain Management Unit</name>
	  <address/>
	  <city>Adelaide</city>
	  <state/>
	  <country>Australia</country>
	  <zip>5042</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients entering the study will be recruited following written informed consent from pain clinics at participating centres
2. Patients will be in the age range 18 - 90 years with a diagnosis of neuropathic pain made according to the criteria set out below
3. Patients may be taking stable dose regimens of paracetamol, anticonvulsants, antidepressants, opioids or Non-Steroidal Anti-Inflammatory Srugs (NSAIDs)
4. Patients taking excluded medications (see exclusion criteria below) may enter the study after a two week period without these medications

Diagnosis of neuropathic pain:
The term "neuropathic pain" is loosely applied to a variety of heterogeneous conditions and strict diagnostic criteria are difficult to apply. However, for the purposes of this study, the diagnosis will be made on the basis of the following:
1. Pain secondary to an identifiable injury or disease process where damage to the central or peripheral nervous system is suspected
2. Pain persisting for more than three months in the absence of any continuing nociceptive stimulus
3. Pain that is documented as responding poorly to either opioid analgesics or NSAIDs
4. Pain associated with at least two of the following signs/symptoms:
4.1. Abnormal sensation on clinical examination, including sensory loss, paraesthesia, dysaesthesia
4.2. Mechanical allodynia (static or dynamic)
4.3. Pain of a burning character
4.4. Pain of a stabbing or lancinating character
4.5. Signs of sympathetic dysfunction (discolouration, abnormal vasomotor activity, skin trophic changes)

Many conditions may present with neuropathic pain. However, in some conditions the
distinction between primary nociceptive and neuropathic pain is extremely difficult. An
important example of this is in mechanical low back pain where radiation of pain into the legs is commonly reported in the absence of identifiable nerve injury. Given this diagnostic difficulty, for the purpose of this study, patients with lumbar radiculopathy will not be recruited to the study.

The Central Post-Stroke Pain Syndrome seems to have features that are significantly different to other types of neuropathic pain. For this reason, patients with this syndrome will not be included in this study.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Patients may not enter the study if they have a history of any of the following conditions:
1. Epilepsy
2. Liver disease
3. Psychosis
4. Bipolar disorder
5. Substance misuse
6. Renal failure
7. Adverse reactions to either dihydrocodeine or nabilone
8. Pregnant women, lactating women or women of childbearing potential not using effective methods of contraception
9. Patients involved in ongoing legal action against a third party in which financial compensation is being sought for personal injury alleged to be the cause of the presenting condition

Excluded medications:
Patients may not take the following medications during the study:
1. Dihydrocodeine
2. Antipsychotic drugs
3. Benzodiazepine drugs (excepting stable doses of night-time sedatives)
4. Monoamine oxidase inhibitors

Patients taking dihydrocodeine may enter the study after a washout period of two weeks. Analgesia during this time will be provided with co-proxamol. Patients taking cannabinoid preparations of any kind may not be included in the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mixed neuropathic pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The medication was given in identical tablets either containing 240 µg nabilone or 30 mg dihydrocodeine. The dose schedule was one capsule in the first week, two capsules in the third week, four capsules in the third and fourth week and then eight capsules in week five and six. After a two week washout the treatment was crossed over. If there were side effects the dose was not increased further. During the washout rescue medication in the form of eight tablets 30/500 codeine with paracetamol was permitted. So each treatment arm was six weeks with a two week washout after six weeks and in the end. Patients with benefit went then into the open label trial (see ISRCTN38408594: A one year open label assessment of the use of nabilone in the treatment of chronic neuropathic pain). Visual Analogue Scale (VAS) scores and hours slept were recorded in a diary daily and then averaged per week. Only pain scores for the last two weeks were used for the analyses.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nabilone, dihydrocodeine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18182416 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9147c260-9dbb-48dd-8b6b-8e8ca292983e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18182416"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16745-0</funderId>
      <funderId>Funder16745-1</funderId>
      <contactId>Contact54703_16745</contactId>
      <sponsorId>Sponsor53259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54703_16745">
    <title>Dr</title>
    <forename>Dilip</forename>
    <surname>Kapur</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Pain Management Unit
Flinders Medical Centre
Flinders Drive
Bedford Park</address>
      <city>Adelaide</city>
      <country>Australia</country>
      <zip>5042</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Dilip.Kapur@fmc.sa.gov.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53259">
    <organisation>Cambridge Laboratories Ltd (UK)</organisation>
    <website>http://www.camb-labs.com/index.html</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Deltic House Newcastle
Kingfisher Way
Silverlink Business Park</address>
      <city>Wallsend</city>
      <country>United Kingdom</country>
      <zip>NE28 9NX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487149.7</gridId>
    <rorId>https://ror.org/001zd1d95</rorId>
  </sponsor>
  <funder id="Funder16745-0">
    <name>Cambridge Laboratories Ltd (UK) - supported by a grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder16745-1">
    <name>The sponsors/funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-10T00:00:00.000Z">99270116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is laser treatment or surgery the best way of treating varicose veins?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Endovenous laser ablation (EVLA) produces comparable short-term results to surgery (abolition of great saphenous vein [GSV] reflux and improvement in symptoms) for the treatment of primary varicose veins due to sapheno-femoral incompetence with greater saphenous vein reflux.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Abolition of GSV reflux at three months (duplex ultrasound) 
2. Improvement in disease-specific quality of life (Aberdeen Varicose Vein Questionnaire)</primaryOutcome>
      <secondaryOutcome>1. Time to return to work and to normal activity
2. Pain and analgesia use during first week following treatment
3. Overall satisfaction and satisfaction with cosmetic outcome
4. Generic quality of life (36-item Short Form health survey [SF-36]) at 1 and 12 weeks following treatment
5. Complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from Leeds (West) Research Ethics Committee in May 2003 (ref: 03/052).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99270116</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VS03/2281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel group, non-blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9cfbfbd3-f2c9-4de3-a383-9f1bd0ab14ff">
	  <name>Leeds Vascular Institute</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS1 3EX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Symptomatic varicose veins 
2. Primary sapheno-femoral incompetence with greater saphenous vein reflux</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>342</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>342</totalTarget>
      <exclusion>1. Unable to consent
2. Children (under 18 years)
3. Unfit for general anaesthesia
4. Recurrent varicose veins
5. Patients on long-term anticoagulation
6. Patients with anterior thigh branch of greater saphenous vein arising within 10 cm of groin and competent GSV distal to this</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Varicose veins</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Varicose veins</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endovenous laser treatment (810 nm diode laser, Diomed) versus sapheno-femoral ligation, greater saphenous vein stripping and avulsions (surgery).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18278775 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c53e0951-6902-41b7-baa3-d782cc85afe7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18278775"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16614-0</funderId>
      <funderId>Funder16614-1</funderId>
      <contactId>Contact54572_16614</contactId>
      <sponsorId>Sponsor53127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54572_16614">
    <title>Mr</title>
    <forename>Michael</forename>
    <surname>Gough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53127">
    <organisation>Leeds Teaching Hospitals NHS Trust (UK)</organisation>
    <website>http://www.leedsteachinghospitals.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415967.8</gridId>
    <rorId>https://ror.org/00v4dac24</rorId>
  </sponsor>
  <funder id="Funder16614-0">
    <name>Leeds Teaching Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16614-1">
    <name>Diomed Ltd (UK) - part of research fellow salary paid (£15,000 pa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-05-02T00:00:00.000Z">48222371</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study on the effects on plasma insulin and glucose after a single meal replacement in patients with type two diabetes mellitus</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A single oral doses of amino acids may play a role as insulin secretagogues.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Insulin and glucose response</primaryOutcome>
      <secondaryOutcome>Hormones involved in glucose homeostasis</secondaryOutcome>
      <trialWebsite>http://www.chdr.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48222371</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9802d8e7-18ec-4b64-9120-d3bab077a0f9">
	  <name>Center for Human Drug Research</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 CL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult Type two Diabetes Mellitus (T2DM) patients</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Insulin use
2. Significant clinical abnormalities</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes, insulin response</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention with single meals with different composition of amino acids in a double-blind placebo controlled trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Plasma insulin, glucose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16479-0</funderId>
      <contactId>Contact54437_16479</contactId>
      <sponsorId>Sponsor52992</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54437_16479">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>Burggraaf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Human Drug Research
Zernikedreef 10</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52992">
    <organisation>Dutch State Mines (DSM) (The Netherlands)</organisation>
    <website>http://www.dsm.com/en_US/html/about/about_us_home.htm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 6500</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 JH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10760.30</gridId>
    <rorId>https://ror.org/00k01kt20</rorId>
  </sponsor>
  <funder id="Funder16479-0">
    <name>Dutch State Mines (DSM) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-04-25T00:00:00.000Z">27453314</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical evidence continuous medical education: randomised educational trial of an e-learning program for transferring evidence based information in primary and secondary care</title>
      <scientificTitle/>
      <acronym>ICEKUBE (Italian Clinical Evidence Knowledge Utilisation Behaviour Evaluation)</acronym>
      <studyHypothesis>This trial is designed to test the effectiveness of ECCE (the Italian acronym for Continuing Education Clinical Evidence) e-learning program for transferring evidence based information to medical doctors after three months of ECCE usage and the retention of the transferred information after six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is the basic knowledge of Clinical Evidence contents assessed through the scoring of clinical vignettes selected from ECCE. The test will consist of fixed and multiple choice questions of the selected valid and reliable vignettes and will be administered before (pre-test), immediately after (12 weeks post-test one), and six months after the intervention (post-test two).</primaryOutcome>
      <secondaryOutcome>Satisfaction with the information source and its perceived value for the medical education and clinical practice.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local research ethics committee (Research Ethics Board Azienda Sanitaria Locale &#147;Città di Milano&#148;, Milano) on the 15th December 2007 (ref: 43-06 SO).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27453314</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>43-06 SO</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A before and after pragmatic educational randomised controlled trial utilising a two by two incomplete block design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="595541a4-729a-4656-955e-731234e1778a">
	  <name>Italian Cochrane Centre</name>
	  <address/>
	  <city>Milano</city>
	  <state/>
	  <country>Italy</country>
	  <zip>20156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All Italian doctors naïve to ECCE who voluntarily adhere to participate. New users to ECCE who connect to ECCE are automatically invited to participate.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>A sample size of 54 practitioners per study arm</totalTarget>
      <exclusion>There are no exclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knowledge of the best available evidence for effective healthcare.</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Healthcare knowledge</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that as of 20/07/2007 the anticipated end date has been extended to 31/09/2007 due to a low recruitment rate. The previous end date of this trial was 31/07/2007. On 18/12/2007 the anticipated end date was extended again to 01/04/2008 due to a continued low recruitment rate. On the 05/03/2008 the anticipated end date was again amended to show the end date as the 29/02/2008 - this is the date this trial was closed to enrolment. 

Sample size/power calculation:
Based on a preliminary examination, we determined that the &#147;minimal&#148; important difference for this intervention to be considered useful was a 20% absolute improvement.

Based on a preliminary test of 300 doctors, we determined that the &#147;mean&#148; improvement due to the intervention, was a 28% absolute improvement. Therefore we calculated our sample size to detect a 0.7 standardised difference in the primary outcome, set the α error rate at 0.05 (two-sided), and the β error at 0.10 (power 90%) &#150; this yielded a sample size of 45 practitioners per study arm. If the accrual period is two months and the maximum follow-up period is six months with a loss during follow-up of 20% at the end of the study, the total number of practitioners to be randomised has been adjusted upwards to 162 (54 per intervention group).

Intervention:
ECCE is an e-learning tool that uses interactive clinical vignettes based on chapters in Clinical Evidence and a predefined sequence of questions. ECCE has four components: 
1. The Clinical Evidence chapter (e.g. headache, chronic tension-type), a clinical vignette derived from the Clinical Evidence chapter gives a plausible medical scenario (e.g. Margaret says to her family doctor: &#147;This time I didn&#146;t come for me, but to talk about Rachel, my 25-year-old daughter&#133;)
2. The lead-in for the clinical vignette and related questions that gives the doctors instructions on what to do (e.g. "more than one answer may be correct&#148;)
3. The questions addressing the recall of Clinical Evidence facts or the application of Clinical Evidence facts to the medical scenario, based on which the doctor is to select the correct answer
4. And finally the potential answers (e.g. a list of potential efficacy descriptors for a therapeutic regimen relevant to the theme) 

Group one access to ECCE for Clinical Evidence chapters and vignettes lot A and provides control data for Clinical Evidence chapters and vignettes lot B.
Group two access to ECCE for lot B and provides control data for lot A. 

To determine the possible Hawthorne effect of this trial, we added to the two-block design arms a third control arm (classical design), in which a minimal intervention was defined. The minimal intervention consisted of one of the elements of the complete intervention, namely the concise printed version of Clinical Evidence and access to the on-line full-text version.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16347-0</funderId>
      <contactId>Contact54304_16347</contactId>
      <sponsorId>Sponsor52857</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54304_16347">
    <title>Dr</title>
    <forename>Lorenzo</forename>
    <surname>Moja</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Italian Cochrane Centre
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52857">
    <organisation>Italian Cochrane Centre (Italy)</organisation>
    <website>http://www.icc.cochrane.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o  Dr Lorenzo Moja 
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7548.e</gridId>
    <rorId>https://ror.org/02d4c4y02</rorId>
  </sponsor>
  <funder id="Funder16347-0">
    <name>Italian Drug Agency (AIFA) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-04-11T00:00:00.000Z">54960762</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>LIMIT-1: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose Tolerance and a recent transient ischaemic attack or minor ischaemic stroke: a phase II randomised, controlled trial</title>
      <scientificTitle/>
      <acronym>LIMIT-1</acronym>
      <studyHypothesis>Metformin will be tolerated in patients with Transient Ischaemic Attack (TIA) or minor ischaemic stroke and will result in blood glucose lowering.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Tolerability of metformin treatment (measured as number of patients still on treatment after three months)
2. The safety of metformin treatment (which will be continuously monitored) 
3. The adjusted difference in two-hour post-load glucose levels at three months

Primary outcomes will be measured at three months for feasability (safety will be continuously monitored). Primary outcome on effect on post-load glucose level will be measured at three months, expressed as a for baseline adjusted difference in mean two-hour post-load glucose levels at three months between treatment groups.</primaryOutcome>
      <secondaryOutcome>1. Differences in fasting glucose levels
2. Insulin resistance
3. Body mass index
4. Percentage of patients with a normal glucose tolerance at three months

Secondary outcomes will be measured at three months, as a for baseline adjusted difference between groups.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from the Medical Ethics Committee of Erasmus Medical Centre on the 5th December 2006 (ref: NL15011.078.06 [local METC number MEC-2006-303]).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54960762</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-label, multicentre, controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b57f755c-57b2-4d06-b9c3-12697e9e00e9">
	  <name>Stroke Research Assistant</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 DR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men or women 18 years and over
2. TIA/minor ischaemic stroke (modified Rankin Score three or less) within six months
3. Impaired fasting glucose (fasting glucose level of 5.6 to 6.9 mmol/L) and/or impaired glucose tolerance (two-hour post-load glucose level of 7.8 to 11.0 mmol/L)
4. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known or newly diagnosed diabetes mellitus
2. Contraindication for metformin:
2.1. Renal impairment (serum creatinine greater than 135 micromol/L for men, and greater than 110 micromol/L for women)
2.2. Hepatic disease (liver enzymes increased twice the upper limit of normal)
2.3. A past history of lactic acidosis
2.4. Cardiac failure requiring pharmacological therapy
2.5. Chronic hypoxic lung disease
2.6. Pregnancy
2.7. Breast feeding
3. Severe comorbidity interfering with follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Transient ischaemic attack or minor ischaemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Vascular complications</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised for metformin or no oral anti-diabetic drug (open-label) on top of optimal standard treatment, including lifestyle advice aimed at weight reduction and regular physical exercise.

Patients allocated to metformin will be treated with metformin for three months from the day of randomisation until study end. They will start with a daily dose of 500 mg that will be slowly increased in one-month time to a daily dose of 2,000 mg in two gifts. All patients will be followed for three months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Metformin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16389-0</funderId>
      <contactId>Contact54347_16389</contactId>
      <sponsorId>Sponsor52901</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54347_16389">
    <title>Ms</title>
    <forename>Esther</forename>
    <surname>van der Heijden</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Stroke Research Assistant
Erasmus Medical Centre
Room Ee 22.42
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 408 7818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stroke-research@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52901">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Neurology
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16389-0">
    <name>Erasmus Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-03-27T00:00:00.000Z">26123577</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic Gabapentin for Prevention of Acute Mountain Sickness: a double blind, randomised, placebo controlled, clinical trial</title>
      <scientificTitle/>
      <acronym>GPAMS</acronym>
      <studyHypothesis>Prophylaxis with gabapentin will slow or stop the progression of Acute Mountain Sickness (AMS) compared to those taking a placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. AMS incidence (Lake Louise acute mountain sickness score of equal or more than three with headache and at least one other symptom) 
2. AMS severity (score of five or more)</primaryOutcome>
      <secondaryOutcome>1. Duration of high-altitude headache free phase after prophylaxis initiation
2. Duration of moderate to severe high-altitude headache free phase after prophylaxis</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the institutional review board of the Neurology Research Centre, Imam Hospital, Tehran University of Medical Sciences (Iran) on the 11th Januray 2007 (ref: 85-04-54-4708).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26123577</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>86-01-54-5304</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised, parallel group, two-armed, placebo controlled, participants/outcome assessor blinded, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b362415-80e7-4c6f-b437-4f58e07e8499">
	  <name>No. 15, Shabtab Street</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>19389</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 15 to 65 years
2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres using cable cars (within 45 to 90 minutes)
3. Consenting participant
4. May reasonably be expected to complete a 24 hour trial</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>204</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>204</totalTarget>
      <exclusion>1. Severe cardiac, pulmonary, or liver disease
2. Severely impaired kidney function
3. Current history of alcohol or drug abuse
4. Pregnancy
4. Known allergy to gabapentin
5. Treatment with anticonvulsants or tricyclic antidepressants</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute mountain sickness</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Mountain sickness</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group one: gabapentin 600 mg orally; single dose within first two hours of ascent.
Treatment group two: mono-hydrate lactose (same shape and weight to gabapentin capsules); single dose within first two hours of ascent.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gabapentin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17965148 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cf867bdb-7c3c-46a4-97ac-03068105e646" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17965148"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16208-0</funderId>
      <funderId>Funder16208-1</funderId>
      <contactId>Contact54163_16208</contactId>
      <sponsorId>Sponsor52717</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54163_16208">
    <title>Dr</title>
    <forename>Sirous</forename>
    <surname>Jafarian</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No. 15, Shabtab Street
Gheytarieh Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)91 2215 6750</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jafarian_s@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52717">
    <organisation>Tehran University of Medical Sciences (Iran)</organisation>
    <website>http://www.tums.ac.ir/index.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Professor Ghaffarpour
Neurology Research Centre
Imam Hospital
Faculty of Medicine 
Keshavarz Blvd</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder16208-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16208-1">
    <name>Darou Darman Pars Pharmaceuticals (DDP) (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-03-14T00:00:00.000Z">88259320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Recent studies have demonstrated the effectiveness of cisplatin-based combinations in patients with advanced Transitional Cell Carcinoma (TCC) of the urothelium. Concern over cisplatin toxicity instigated a search for alternative regimens. The aim of the study was to evaluate the activity and tolerability of gemcitabine plus carboplatin combination as first-line treatment in patients with advanced transitional cell carcinoma of the urothelium.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Objective response rate
2. Tolerability</primaryOutcome>
      <secondaryOutcome>1. Overall survival
2. Progression-free survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The First Affiliated Hospital Ethical Review Board, School of Medicine, Zhejiang University. Approved on 10/12/2002. Ethics Review No. 26 (2002)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88259320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ZJWST491010G20518</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An open label, multi-centre, phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2f9e4fd2-a1d9-44df-b681-76546b42c0e5">
	  <name>79 Qingchun Road</name>
	  <address/>
	  <city>Hangzhou</city>
	  <state/>
	  <country>China</country>
	  <zip>310003</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with locally advanced or metastatic transitional cell carcinoma of the bladder, ureter or renal pelvis were eligible for this study
2. Patients were required to have histologically or cytologically proven locally advanced or metastatic transitional cell carcinoma of the bladder, ureter or renal pelvis
3. Prior cytotoxic treatment either in the adjuvant setting or for metastatic disease was permitted if the treatment had been completed at least six months prior to enrollment in the study
4. Prior radiotherapy was permitted but must have been completed at least six weeks prior to enrollment
5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
6. A life expectancy at least 3 months
7. Age between 18 and 75 years
8. Adequate bone marrow: absolute neutrophil count more than or equal to 1.5  x 10^9/L, platelet count more than or equal to 100 x 10^9/L, and hemoglobin more than or equal to 100 g/L
9. Adequate hepatic functions: aspartate aminotransferase/alanine aminotransferase, AST/ALT less than or equal to 3.0 times the Upper Normal Limit (UNL) and serum bilirubin less than or equal to 1.5 x UNL
10. Adequate renal functions: serum creatinine less than or equal to 1.5 x UNL and creatinine clearance more than or equal to 30 ml/min based on the Calvert formula
11. Adequate normal cardiac function</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>39</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>39</totalTarget>
      <exclusion>1. Second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma
2. Central nervous system (CNS) involvement
3. Prior radiotherapy in parameter lesions
4. Concurrent uncontrolled medical illness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Advanced transitional cell carcinoma of the urothelium</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Advanced transitional cell carcinoma of the urothelium</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with advanced TCC were treated with gemcitabine 1200 mg/m2 on days 1 and 8 and carboplatin area under the concentration-time curve (AUC) 5 on day 1 every 21 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Gemcitabine, carboplatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17559681 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a6bf69c-46ef-4116-9272-143021f336c2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17559681"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16206-0</funderId>
      <contactId>Contact54161_16206</contactId>
      <sponsorId>Sponsor52715</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54161_16206">
    <title>Dr</title>
    <forename>Nong</forename>
    <surname>Xu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>79 Qingchun Road</address>
      <city>Hangzhou</city>
      <country>China</country>
      <zip>310003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+86 571 56731277</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">xunong@medmail.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52715">
    <organisation>School of Medicine, Zhejiang University (China)</organisation>
    <website>http://www.cmm.zju.edu.cn/english/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>338 Yuhangtang Road</address>
      <city>Hangzhou</city>
      <country>China</country>
      <zip>310058</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+86 571 88208019</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Chyx@zju.edu.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.13402.34</gridId>
    <rorId>https://ror.org/00a2xv884</rorId>
  </sponsor>
  <funder id="Funder16206-0">
    <name>Health Bureau of Zhejiang Province (China)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-21T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-03-07T00:00:00.000Z">72245261</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomised double-blind controlled trial in patients with haematological malignancies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Urokinase rinses will lead to less Coagulase-Negative Staphylococcal (CoNS) infections in patients with haematological malignancies and central vein catheters.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The main endpoints of the study were the occurrence of any Central Venous Catheter (CVC)-related infection by CoNS. According to previously described criteria these infections were classified as local CVC related infection (insertion site infection or significant CVC colonisation) and systemic CVC­related infections.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints in this study were:
1. CVC-related infections caused by other microbial pathogens
2. Premature CVC removal
3. Secondary CVC-related complications (metastatic infection, CVC-related thrombosis)
4. Non-CVC related septicaemia bleeding
5. Death</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72245261</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="511c64af-6c37-4de8-9359-276248c83d83">
	  <name>Leiden University Medical Centre (LUMC)</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 18 years or older
2. Admission to undergo intensive cytotoxic treatment associated with disruption of the mucosa and deep granulocytopenia (Polymorphonuclear cells [PMNs] less than 0.1 x 10^9/L) for at least 14 days</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>161</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>161</totalTarget>
      <exclusion>1. Patients with pre-existing bleeding disorders
2. Patients treated with intravenous unfractionated heparin to prevent veno-occlusive disease
3. Patients with documented septicaemia prior to the start of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coagulase-negative staphylococcal central venous catheter-related infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Central venous catheter-related infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Urokinase rinses of central vein catheter three times weekly (25,000 IU, 5 ml of 5,000 IU/ml).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Urokinase</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18202420 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c495c126-c7ff-4eb1-b988-a768c32f9dab" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18202420"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16286-0</funderId>
      <contactId>Contact54243_16286</contactId>
      <sponsorId>Sponsor52795</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54243_16286">
    <title>Dr</title>
    <forename>M V</forename>
    <surname>Huisman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Centre (LUMC)
Department of General Internal Medicine, C2-R
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 625 9111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.v.huisman@lumc.nl </email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52795">
    <organisation>Leiden University Medical Centre (LUMC) (The Netherlands)</organisation>
    <website>http://www.lumc.nl/english/start_english.html</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Haematology
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder16286-0">
    <name>Leiden University Medical Centre (LUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">21473387</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Biochemical efficacy and tolerability of allopurinol, benzbromarone and probenecid in GOUT</title>
      <scientificTitle/>
      <acronym>GOUT-1</acronym>
      <studyHypothesis>1. Allopurinol has a poor efficacy and tolerability profile to lower serum urate to target levels less than 0.30 mmol/l
2. Benzbromarone is more potent and is better tolerated than probenecid to lower serum urate to target levels less than 0.30 mmol/l</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Success rate on study medication consisting of patient tolerability and attainment of target level serum urate less than 0.30 mmol/l after eight weeks treatment.</primaryOutcome>
      <secondaryOutcome>1. Serum urate lowering effect (% decrease) of the antihyperuricemic agent
2. Tolerability of the antihyperuricemic agent (adverse drug reactions)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received by the Medical Centre Leeuwarden on the 7th February 2005 (ref: TPO-357).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21473387</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9dce9a50-fd9a-4ad7-99b9-c3121c4b6a77">
	  <name>Medical Centre Leeuwarden</name>
	  <address/>
	  <city>Leeuwarden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8901 BR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Diagnosis gout based on crystal evidence or American Rheumatism Association (ARA) criteria
3. Eestimated creatinine clearance more than 50 ml/min
4. Baseline values measured: serum urate, urinary urate excretion, serum creatinine</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>96</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>96</totalTarget>
      <exclusion>1. Contra-indication for allopurinol, benzbromaron or probenecid
2. Prior treatment with allopurinol, benzbromaron or probenecid</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperuricemia, gout</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Stage 1: allopurinol 1dd 300 mg (eight weeks)
Stage 2:
1. Benzbromarone 1dd 200 mg (eight weeks), or 
2. Probenecide 2dd 1000 mg (eight weeks)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Allopurinol, benzbromarone, probenecide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18250112 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="80b02b92-3425-46a1-b3a7-1fb6fbb911c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2009-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18250112"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16226-0</funderId>
      <contactId>Contact54181_16226</contactId>
      <sponsorId>Sponsor52735</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54181_16226">
    <title>Dr</title>
    <forename>M K</forename>
    <surname>Reinders</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Centre Leeuwarden
Department of Clinical Pharmacy and Pharmacology
P.O. Box 888</address>
      <city>Leeuwarden</city>
      <country>Netherlands</country>
      <zip>8901 BR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)58 286 6610</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.reinders@znb.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52735">
    <organisation>Medical Centre Leeuwarden (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Clinical Pharmacy and Pharmacology
P.O. Box 888</address>
      <city>Leeuwarden</city>
      <country>Netherlands</country>
      <zip>8901 BR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414846.b</gridId>
    <rorId>https://ror.org/0283nw634</rorId>
  </sponsor>
  <funder id="Funder16226-0">
    <name>Medical Centre Leeuwarden (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-08T00:00:00.000Z">45381163</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal haemorrhage admitted in intensive care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Describing the pharmacokinetics of nimodipine, especially the variability of the bio-availability of orally administred nimodipine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pharmacokinetics of nimodipine in this specific group of patients
2. Variability of bio-availability of orally administred nimodipine</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45381163</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, non-randomised, pharmacokinetic study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="559b9792-ab3a-4cf1-bc06-151558b4b2de">
	  <name>VU University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. All patients admitted to the Intensive Care Unit (ICU) with subarachnoidal bleeding/haemorrhage (SAB), treated according to our SAB-protocol
2. Adults aged 18 to 70 years old</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12</totalTarget>
      <exclusion>1. Pregnancy
2. Expected mortality in less than 24 hours
3. Severe hepatic function disorders
4. Use of medication with known interaction in relation to nimodipine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subarachnoidal haemorrhage</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cerebrovascular diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Blood samples according to strict time protocol during treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nimodipine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16142-0</funderId>
      <contactId>Contact54088_16142</contactId>
      <sponsorId>Sponsor52643</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54088_16142">
    <title>Dr</title>
    <forename>B M</forename>
    <surname>Kors</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Centre 
Afdeling intensive care volwassenen
Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+ 31 (0)20 444 3900</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bm.kors@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52643">
    <organisation>VU University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Intensive Care
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16142-0">
    <name>VU University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-29T00:00:00.000Z">85092388</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of continuous femoral analgesia after anterior cruciate ligament repair on postoperative pain and range of motion: a pilot study</title>
      <scientificTitle/>
      <acronym>FemoX</acronym>
      <studyHypothesis>Patients with a catheter-based analgesia at the femoral nerve have less pain compared to patients receiving a Patient-Controlled Analgesia (PCA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain levels.</primaryOutcome>
      <secondaryOutcome>Physiotherapeutic options.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received, no details provided as of 29/01/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85092388</doi>
      <eudraCTNumber>2005-000237-37</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-blinded, randomised study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b02c58be-9b59-4432-b89e-46bc5426cdbb">
	  <name>Charité Universitätsmedizin Berlin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10098</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients receiving a anterior cruciate ligament repair.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Pregnancy
2. Redo-Surgery
3. Neurologic or psychiatric diseases
4. Other diseases potentially putting the patient at risk
5. Body Mass Index of more than 35
6. Allergic to local anesthetics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ruptured anterior cruciate ligament</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Ruptured anterior cruciate ligament</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Peripheral nerve catheter at the femoral nerve versus PCA.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15320-0</funderId>
      <contactId>Contact53236_15320</contactId>
      <sponsorId>Sponsor51781</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53236_15320">
    <title>Dr</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité Universitätsmedizin Berlin
Department of Anesthesiology and Intensive Care Medicine
Charitéplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (030) 450 531012</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anaesth@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51781">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de/ch/anaest/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o PD Dr Thomas Volk
Department of Anesthesiology and Intensive Care Medicine
Charitéplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder15320-0">
    <name>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin),  Medical School Research Grant (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-01-22T00:00:00.000Z">43202606</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fatty Acid Absorption Study</title>
      <scientificTitle/>
      <acronym>FAAS</acronym>
      <studyHypothesis>The biochemical importance of dietary lipids to human physiology and nutrition is now firmly established and research continues to show potential health benefits of polyunsaturated fatty acids (PUFAs) and in particular the omega 3 fatty acids from fish and precursors of the same family found in many plant oils. Current UK recommendations advise the public to eat at least two portions of fish every week including one of oily fish, which is rich in omega-3 PUFAs, or take more than 200 mg/day of omega-3 PUFAs.  According to the World Health Organization (WHO), one portion should provide an equivalent of 200-500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In fact most people in the UK consume considerably less than one portion per week indicating that the recommended levels are not being achieved leaving fish oil supplementation as the most convenient route to augment dietary intake.  However, reaching recommended intake levels may require taking several capsules of fish oil per day. An alternative is to use a more palatable version of liquid fish oils presented as a flavoured emulsion, which may offer a more flexible route to achieve the required level of intake.

Approximately 95% of dietary lipids ingested from foods consist of triacylglycerols (TAGs) and lipid digestion is initiated by the action of lingual/gastric lipases which, together with the physical mixing action of the stomach, produces small partially emulsified droplets containing mainly TAGs but also free fatty acids (FFA) and diacylglycerols. Further emulsification together with the action of pancreatic lipase results in the production of 2-monoacylglycerols (sn2-MAG) and free fatty acids and these are incorporated into mixed micelles before passive diffusion into the enterocyte. Once inside the enterocyte the fatty acids with less than 12 carbon atoms pass directly into the hepatic portal vein. However, most dietary fatty acids have a chain length greater than 12 and these are re-synthesised into TAG and incorporated into the chylomicron (CM) family of lipoproteins which are secreted into the lymphatic system and transported to the thoracic lymphatic duct where they enter the circulation. The fatty acid composition of the core of the CM - TAG generally reflects the dietary fatty acid profile, particularly in the first four to six hours postprandial period. The CM-TAG are rapidly hydrolysed by lipoprotein lipase (LPL) releasing between 70 and 90% of the total TAG and leaving CM remnants which are removed from the plasma via low density lipoprotein (LDL) receptors in the liver. There have been conflicting observations that the use of emulsified forms of fish oils in some studies has led to improved digestion and absorption of EPA and DHA with other studies showing no differences in absorption.

Preliminary research in our laboratory has indicated that both the rate and extent of absorption of the fatty acids EPA and DHA improve if the oil is pre-emulsified prior to ingestion. This cross over absorption study was designed to establish whether pre-emulsification of an oil mixture leads to improved absorption of fatty acids, particularly DHA and EPA, compared with the non-emulsified form of the oil mixture.

The hypothesis of this trial is that absorption of fatty acids occurs more rapidly and extensively in a pre-emulsified form than in the straight oil.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Plasma fatty acid concentrations.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received by the local research ethics committee (Lechyd Morgannwg Health) on the 2nd October 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43202606</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2002.112</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised cross-over study with oral ingestion of a fatty acid mixture in the form of an oil mixture or a water miscible oil emulsion.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b6f1d0e-2985-46e1-9b80-bf8d7e9d0fed">
	  <name>Obsidian Research Limited</name>
	  <address/>
	  <city>Port Talbot</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SA12 7BZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Healthy volunteers, male or female
2. Body mass index (BMI) less than 30
3. Capable of providing written informed consent
4. Not pregnant or subject to medication</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Involved in dietary control
2. Obese/very low body weight
3. Hypercholesterolemic
4. Taking dietary fatty acid supplements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Absorption of fatty acids as part of a healthy dietary lifestyle</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Absorption of fatty acids</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In a cross-over study, participants were randomly assigned to receive either the oil mixture or oil emulsion mixture, with thirteen subjects receiving oil and eleven subjects receiving oil emulsion in the first stage. The mixtures of oils (comprising concentrated fish oil 43%, borage oil 31% and flaxseed oil 26%) in both the natural form and in the emulsified form were supplied by Cultech Ltd., Port Talbot, United Kingdom.

The participants fasted for 12 hours prior to the study. Subjects consumed 30 ml of oil as part of a meal comprising fat free cereal (37.5 g), skimmed milk (230 ml), sugar (4 g) and apple juice (150 ml). For the remainder of the nine hour collection period the participants ate only boiled rice (100 g), boiled pasta (100 g) and fresh fruit (large apple). Apple juice or water was available to drink throughout the day. The average energy intake was 3596 kJ (859 kcal) comprising 147 g carbohydrate, 23 g protein and 32 g total fat. Twenty days later (washout period), the procedure was repeated with the assignments reversed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17254329 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d6f0da26-8a35-4162-b098-b2b16676b090" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17254329"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16035-0</funderId>
      <contactId>Contact53981_16035</contactId>
      <sponsorId>Sponsor52530</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53981_16035">
    <title>Dr</title>
    <forename>Sue</forename>
    <surname>Plummer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Obsidian Research Limited
Unit 2 Christchurch Road
Baglan Industrial Park</address>
      <city>Port Talbot</city>
      <country>United Kingdom</country>
      <zip>SA12 7BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52530">
    <organisation>Obsidian Research Limited (UK)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Unit 2 Christchurch Road
Baglan Industrial Park</address>
      <city>Port Talbot</city>
      <country>United Kingdom</country>
      <zip>SA12 7BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16035-0">
    <name>Funded in-house by Cultech Limited with financial support from Welsh Development Agency as part of Technology Exploitation Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">87678078</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and security of low toxicity immunosuppressive regimen using basiliximab, mycophenolate mofetil, neoral or tacrolimus and corticosteroids versus full doses of  neoral, thymoglobulin, azathioprine and corticosteroids</title>
      <scientificTitle/>
      <acronym>Immuno99</acronym>
      <studyHypothesis>To compare efficacy and security of low toxicity immunosuppressive regimen using basiliximab, mycophenolate mofetil (MMF), neoral (cyclosporin A [CsA]) or tacrolimus and corticosteroids versus full doses of  neoral, thymoglobulin, azathioprine and corticosteroids.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine renal function evaluated by calculated creatinine clearance at 6 and 12 months.</primaryOutcome>
      <secondaryOutcome>To assess acute rejection rate at 6 and 12 months, patient and graft survival rate at 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received in May 1999 from two sources:
1. The Ethics Committee of the University Hospital of the Canary Islands (ref: Inmuno/99)
2. Agencia Española del Medicamento from Spanish Ministry of Health (ref: 99-0296)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87678078</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, open-label, single centre, three parallel therapeutic armed trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-10-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5c17f9de-741d-4acf-a67e-102784d6c69e">
	  <name>Nephrology Service</name>
	  <address/>
	  <city>Tenerife</city>
	  <state/>
	  <country>Spain</country>
	  <zip>38320</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 18 years
2. Accepted informed consent
3. Primary kidney allograft 
4. Cadaveric donor</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Panel Reactive Antibody (PRA) over 50%
2. History of malignancy
3. History of infection
4. Previous treatment with polyclonal antibodies or basiliximab</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-10-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Kidney transplant</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Kidney transplant</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one: thymoglobulin (1 to 1.5 mg/k/day for seven days), CsA (8 mg/k/day; levels: 175 to 225 ng/ml), azathioprine (1.5 mg/k/day) and corticosteroids
Group two: basiliximab (20 mg days zero and four), CsA (4 mg/k/day, levels: 125 to 175 ng/ml), MMF (2 g/day) and corticosteroids
Group three: basiliximab (20 mg days zero and four), tacrolimus (0.1 mg/k/day, levels: 8 to 12 ng/ml), MMF (2 g/day) and corticosteroids</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Basiliximab, mycophenolate mofetil (MMF), neoral (cyclosporin A [CsA]), tacrolimus, corticosteroids, thymoglobulin, azathioprine.</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17893603 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="81bb378d-5713-4945-9f1f-fdddd0a7361d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17893603"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15383-0</funderId>
      <contactId>Contact53315_15383</contactId>
      <sponsorId>Sponsor51862</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53315_15383">
    <title>Dr</title>
    <forename>Domingo</forename>
    <surname>Hernandez</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nephrology Service
Hospital Universitario de Canarias
Ofra s/n La Laguna</address>
      <city>Tenerife</city>
      <country>Spain</country>
      <zip>38320</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 922 678 545</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">domingohernandez@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51862">
    <organisation>Hospital Universitario de Canarias (Spain)</organisation>
    <website>http://www.hecit.es</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Fundation Rafael Clavijo
Research Unit 
Ofra s/n La Laguna </address>
      <city>Tenerife</city>
      <country>Spain</country>
      <zip>38320</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 922 678 545</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">domingohernandez@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411220.4</gridId>
    <rorId>https://ror.org/05qndj312</rorId>
  </sponsor>
  <funder id="Funder15383-0">
    <name>Fundation Rafael Clavijo, Research Unit, Hospital Universitario de Canarias (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">85744812</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Alternative Intra Osseous Devices: randomised controlled trial comparing three intraosseous methods</title>
      <scientificTitle/>
      <acronym>AIOD</acronym>
      <studyHypothesis>The aim of this study is to analyse whether or not it is possible to created a fast, reliable intraosseous entrance using the BIG and/or FAST bone needles, with less complications compared with the traditional bone needle Jamshidi.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Primary endpoint: aspiration of bone marrow upon successful placement of a bone needle.
2. Primary parameter is time required for successful placement.</primaryOutcome>
      <secondaryOutcome>Secondary endpoint: Complications encoured using an intraosseous device
Secondary parameters:
1. Adverse events
2. Success rate (%)
3. User friendliness (Visual Analogue Scale [VAS])
4. Pain scored by the patient (VAS)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethical review board, Erasmus Medical Centre, Rotterdam, The Netherlands. The approval was completed at 15th June 2006 with reference number MEC-2006-109.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85744812</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, single blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="54f620ec-a652-4038-8812-36c07c8132fb">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients in acute life threatening situations, requiring assistance of a mobile medical team
2. Intravascular medical or fluid resuscitation is necessary and intravascular access cannot be obtained after two attempts</inclusion>
      <ageRange>Other</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Children under the age of one year
2. Patients with suspected sternumanomaly (only FAST1)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe injury, life threatening</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Severe injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consists of the application of a randomised instraosseous needle:
1. In people over 14 years: BIG versus FAST versus conventional bone needle
2. In children more than one and less than 14 years: BIG versus conventional bone needle</description>
	<interventionType>Device</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15956-0</funderId>
      <contactId>Contact53902_15956</contactId>
      <sponsorId>Sponsor52451</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53902_15956">
    <title>Dr</title>
    <forename>I B</forename>
    <surname>Schipper</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
Trauma Center ZWN
Room Z-9.15
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 5034</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.schipper@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52451">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Trauma Center ZWN
P.O. Box 2040</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15956-0">
    <name>Medirisk (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">32882895</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The variations in small vascular function and arterial compliance during the menstrual cycle in young healthy women (De cyclus afhankelijke variatie in de microcirculatie bij jonge gezonde ovulerende vrouwen)</title>
      <scientificTitle/>
      <acronym>MCycle</acronym>
      <studyHypothesis>It has been suggested in literature that insulin sensitivity and determinants of the blood pressure vary according to the past ovulation cycle. Since microcirculation plays a large role in the transport and supply of insulin to the muscle fibres, it can be assumed that the microcirculatory function cycle will be dependent on the ovulation cycle. Indeed from literature it has been suggested that this is true, however another group of researchers found no cycle dependent pattern. Moreover in the Vrije University the most unique method has been developed to measure the microcirculation (capillary microscope) and this measuring has never been examined in women in their ovulation cycle. The results of this research are very important for the interpretation of cardiovascular events in women during their ovulation cycle.

Hypothesis:
Microcirculatory function is cycle dependent in healthy ovulating women.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Microcirculatory function measured in three phases of the cycle (early and late follicular, and luteal).</primaryOutcome>
      <secondaryOutcome>Blood pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32882895</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bee72f5b-9219-42b2-b062-41b5aa6db158">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy as judged by history and physical examination
2. Regular ovulatory menstrual cycles between 21 - 35 days (proven by biphasic basal temperature curve [BTC] or midluteal progesterone more than 10 nmol/l)
3. Aged 18 to 35 years
4. No medication including oral conceptive or hormonal intra-uterine device (IUD) for at least three months
5. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Cardiovascular disease (hypertension [more than 160/90 mmHg], stroke, coronary artery disease, peripheral vascular disease, heart failure)
2. Diabetes mellitus (according to American Diabetes Association [ADA] criteria)
3. Smoking for the last three months
4. Alcohol use more than 4 units/day
5. Pregnancy
6. Diseases that influence reproductive hormone status</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Small vascular function, arterial compliance</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Small vascular function, arterial compliance</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Microcirculation measured by means of:
1. Microscopic examination of the nail bed (assessment of the refill after temporary occlusion of the finger) 
2. Ionthophoresis with acetylcholine (ACH) (endothelium dependent) and sodiumnitroprusside (SNP) (endothelium independent vasodilatation)
3. Blood pressure</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15970-0</funderId>
      <contactId>Contact53916_15970</contactId>
      <sponsorId>Sponsor52465</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53916_15970">
    <title>Dr</title>
    <forename>I J G</forename>
    <surname>Ketel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Department of Reproductive Medicine (Poli H)
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 0041</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ijg.ketel@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52465">
    <organisation>VU University Medical Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Reproductive Medicine
Postbus 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder15970-0">
    <name>Institute for Cardiovascular Research of the Vrije University of Amsterdam (ICaR-VU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-12-14T00:00:00.000Z">87201238</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic sumatriptan for prevention of Acute Mountain Sickness: a double blind, randomised, placebo controlled, clinical trial</title>
      <scientificTitle/>
      <acronym>SAMS</acronym>
      <studyHypothesis>Prophylaxis with sumatriptan will slow or stop the progression of acute mountain sickness (AMS) compared to those taking a placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>AMS development due to Lake Louise criteria within 24 hours (International Hypoxia Symposium)</primaryOutcome>
      <secondaryOutcome>1. AMS severity (score more than or equal to five) due to Lake Louise protocol after 24 hours (self-report and clinical assessment)
2. Altitude headache occurrence and severity</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Review Board of Neurology Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87201238</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised, two-armed, placebo controlled, participants/outcome assessor blind, clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="274352eb-ca1f-4dda-92e5-2fd5bb122312">
	  <name>No15, Shabtab Street</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>19389</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 18 to 60 years
2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres
3. Consenting participant
4. May reasonably be expected to complete a 24 hour trial</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>102</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>102</totalTarget>
      <exclusion>1. Other neuro-vascular disease such as cerebrovascular accident, and hypoxic cerebral damage
2. Cardiovascular disease such as ischaemic heart disease, coronary artery disease, significant valvular disease, congestive heart failure, and uncontrolled hypertension with systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg
3. Pregnancy 
4. Hypersensitivity to either sumatriptan or acetazolamide or their components</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute mountain sickness</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Acute mountain sickness</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Sumatriptan succinate 50 mg plus orally, once at early ascent 
2. Placebo: similar color, shape, and weight to interventional group</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sumatriptan succinate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17557349 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="434f927f-920c-4b64-bde8-af9c749e1ba2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17557349"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15862-0</funderId>
      <contactId>Contact53802_15862</contactId>
      <sponsorId>Sponsor52356</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53802_15862">
    <title>Dr</title>
    <forename>Sirous</forename>
    <surname>Jafarian</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No15, Shabtab Street
Gheytarieh Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52356">
    <organisation>Imam Neurology Research Center (Iran)</organisation>
    <website>http://iro.tums.ac.ir/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Tehran University of Medical Sciences
No. 23, Dameshgh Street
Vali-e Asr Street</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder15862-0">
    <name>Imam Neurology Research Center, Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-06T00:00:00.000Z">64070727</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Augmented Community-based Perinatal Care</title>
      <scientificTitle/>
      <acronym>CPC Study</acronym>
      <studyHypothesis>It was hypothesised that additional community-based prenatal support from nurses and home visitors would improve the use of prenatal resources among women at low medical risk, including those experiencing challenges such as poverty, language barriers, abuse, and low self esteem.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Resource utilisation
2. Provision of information</primaryOutcome>
      <secondaryOutcome>1. Mental health
2. Lifestyle choices
3. Satisfaction with care</secondaryOutcome>
      <trialWebsite>http://www.calgaryhealthregion.ca/dsrt/studycpcs.htm</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Conjoint Health Ethics Research Board, Calgary Health Region and University of Calgary.  Approval date: June 7, 2001(ref: #15763).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64070727</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>10</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="903601ca-a9ea-432a-aca3-113033576f37">
	  <name>Alberta Children's Hospital</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T3B 6A8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. More than or equal to 18 years
2. Speak English, French, Punjabi, Urdu, Arabic, Cantonese, Mandarin
3. Live in city limits
4. Not attended first prenatal class prior to intake interview</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>1800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1,800</totalTarget>
      <exclusion>1. Less than 18 years
2. Could not speak English, French, Punjabi, Urdu, Arabic, Cantonese, or Mandarin
3. Live outside city limits 
4. Attended first prenatal class prior to intake interview</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pregnancy</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pregnant women randomised to:  
1. Standard of prenatal care,
2. Standard of prenatal care plus supplementary nurse, or 
3. Standard of care plus supplementary nurse and home visitor.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16948718 Results:
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17118044 Results:
2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17617914 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="32db2230-db2b-4e6c-8832-2edb2a196bd7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16948718"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="939a1f6d-c82b-4799-8cca-9edce804be57" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17118044"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="87e4b736-8e9a-4c9d-bcb2-07c0509348c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17617914"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15744-0</funderId>
      <funderId>Funder15744-1</funderId>
      <funderId>Funder15744-2</funderId>
      <funderId>Funder15744-3</funderId>
      <funderId>Funder15744-4</funderId>
      <contactId>Contact53682_15744</contactId>
      <sponsorId>Sponsor52236</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53682_15744">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Tough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Alberta Children's Hospital
2888 Shaganappi Trail NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T3B 6A8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52236">
    <organisation>Calgary Children's Initiative (Canada)</organisation>
    <website>http://www.childrensinitiative.ca/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Suite 600
1202 Centre Street S.E.</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2G 5A5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder15744-0">
    <name>Calgary Children's Initiative (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15744-1">
    <name>Physician Partnership Steering Committee (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15744-2">
    <name>Added as of 07/02/2008:</name>
    <fundRef/>
  </funder>
  <funder id="Funder15744-3">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
  <funder id="Funder15744-4">
    <name>Child and Women's Health Portfolio, Calgary Health Region (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-03T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-12-01T00:00:00.000Z">89278733</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and efficacy of mycophenolate mofetil in pediatric renal transplantation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Mycophenolate Mofetil (MMF)/prednisolone is as efficacious in prevention of acute rejections as Cyclosporin A (CsA)/prednisolone
2. MMF/prednisolone is safer than CsA/prednisolone, in renal function, lipids, and blood pressure</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Glomerular filtration rate
2. Incidence of acute rejections
3. Serum lipids
4. Blood pressure and number of antihypertensive drugs</primaryOutcome>
      <secondaryOutcome>1. Graft survival
2. Incidence of malignancies
3. Incidence of viral infections
4. Incidence of anemia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN89278733</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR800</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre parallel armed, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="169e4847-4c76-4659-a170-2c8bc7a1c3e4">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 GJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. All Dutch children, receiving a first kidney transplant after 01/01/2000
2. Treated with initial immunosuppression corticosteroids, MMF and CsA, during the latter part of the study with addition of basiliximab</inclusion>
      <ageRange>Child</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. Not on triple therapy (prednisolone/CsA/MMF) at the end of the first year
2. More than one acute rejection episode
3. Rejection episode being not steroid sensitive
4. No written informed consent</exclusion>
      <patientInfoSheet>Nor ptovided at time of registration</patientInfoSheet>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal transplant</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal transplant</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Start trial is one year after transplantation. Randomisation between two groups: continuing with MMF/prednisolone or CsA/prednisolone by withdrawal over three months of the third immunosuppressive drug. 

During the three months of withdrawal, the prednisolone dosage is doubled. Follow-up is two years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mycophenolate mofetil (MMF), prednisolone and cyclosporin A (CsA)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17452893 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f4446880-aaf1-466f-9c95-caeb7060c249" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17452893"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15879-0</funderId>
      <contactId>Contact53819_15879</contactId>
      <sponsorId>Sponsor52373</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53819_15879">
    <title>Dr</title>
    <forename>Karlien</forename>
    <surname>Cransberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
Sophia Children's Hospital
Dr Molewaterplein 60</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4636363</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.cransberg@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52373">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Sophia Children's Hospital
Dr Molewaterplein 60</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GJ </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15879-0">
    <name>Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002997</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-09-29T00:00:00.000Z">03252849</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised trial of a vibrating bladder stimulator to induce urine flow in acute paediatrics</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does use of a vibrating bladder stimulator alter the time taken to pass urine in children?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to pass urine from taking the nappy off to urine flow.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03252849</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0264171565</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f21e0d66-08be-4006-b547-117465f815da">
	  <name>C/O Research and Effectiveness Department</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8HW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All children to give a urine sample who are not continent of urine (by day or night) attending to the Paediatric Emergency Department at the Bristol Children's Hospital will be asked to take part.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>97</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>97</totalTarget>
      <exclusion>1. Children too unwell, in the opinion of the doctor treating
2. Those who do not need a clean sample of urine (so could have a urine bag)
3. Those who in the opinion of the consent taker, have insufficient understanding (due to language or other factors) of the trial process
4. Those who do not have a legal guardian with them
5. Those who have abnormalities in their anatomy or nerves which affect their ability to pass urine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urological and Genital Diseases:</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>RCT:
1. Advice
2. Device

The patients will be assigned to one of two groups: the 'advice' and the 'device' groups. The advice group will be given an advice leaflet which has some tips on how to try to stimulate urine flow. The device group will be shown the use of a bladder stimulator. This is a hand-held vibrating disk which is non-painful and has no known side effects. It is pressed on to the lower abdomen and vibrates the bladder, with the aim of stimulating urine flow. The idea behind this stimulator is that the vibrations of the bladder cause a reflex reaction which leads to urine flow. 

Half of the patients will be in each group: which group the individuals go in to is decided at random. This is to minimise the possible effects of patients becoming frustrated at perceived preferential treatment within the waiting room area. Full informed consent will be obtained. 

The parents would be given a clock and asked to write down when the urine is passed. If a sample is passed and is missed by the parents, this still counts as a time to pass urine. A questionnaire is also given which will ask some questions on the child and their illness, as well as how they think the child coped with the urine collection process.

This is then the end of the study and there will be no further input for the child or their parents.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18192318 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d40b09b7-c0b0-4317-810f-f9213fca8463" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18192318"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15617-0</funderId>
      <funderId>Funder15617-1</funderId>
      <contactId>Contact53550_15617</contactId>
      <sponsorId>Sponsor52097</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53550_15617">
    <title>Dr</title>
    <forename>Patrick</forename>
    <surname>Davies</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>C/O Research and Effectiveness Department
Level 1 Old Building
Bristol Royal Infirmary
Marlborough Street</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8HW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 0117 928 3473</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">R&amp;Eoffice@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52097">
    <organisation>Record Provided by the NHSTCT Register - 2006 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15617-0">
    <name>United Bristol Healthcare NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15617-1">
    <name>NHS R&amp;D Support Funding (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">92152389</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical feasibility study to evaluate the effectiveness and safety of VivescOs™ as bone graft for reconstruction of intra-oral osseous defects</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Cultured mesenchymal stem cells differentiated into osteoblasts and seeded on scaffolds can induce bone formation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety of VivescOs™ has been confirmed.</primaryOutcome>
      <secondaryOutcome>Efficacy of VivescOs™ is doubted.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92152389</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Clinical feasability study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Other</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="249a2c1c-6aff-411c-bfab-83163d6a43b2">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Repair of the intra-oral defect was indicated as preparation for dental implant placement in a secondary stage.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Presence of local or systemic disease;
2. Pregnancy, cancertherapy; 
3. Previous participation in another trial within 30 days; 
4. Known hypersensitivity for penicillin, streptomycin.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intra-oral bone defects, loss of teeth/molars</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Intra-oral bone defects, loss of teeth/molars</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>VivescOs™ versus tissue engineered bone.

Preoperatively, four weeks before the implantation procedure, a aspiration biopsy will be taken.

Post-operatively patients will be evaluated using radiographic analysis by OphtoPantomoGrams (OPG), histological analysis by biopsy specimens and clinical evaluation of functionality at three months, six months, nine months, 12 months and 15 months after surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>VivescOs™</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15415-0</funderId>
      <contactId>Contact53348_15415</contactId>
      <sponsorId>Sponsor51895</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53348_15415">
    <title>Dr</title>
    <forename>Gert</forename>
    <surname>Meijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
AZU
Department of Oral Maxillofacial Surgery
Heidelberglaan 100
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gmeijer@azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51895">
    <organisation>IsoTis NV (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Prof. Bronkhorstlaan 10-D</address>
      <city>Bilthoven</city>
      <country>Netherlands</country>
      <zip>3723 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.422884.0</gridId>
    <rorId>https://ror.org/04qce9v53</rorId>
  </sponsor>
  <funder id="Funder15415-0">
    <name>IsoTis NV (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">47031769</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study of the efficacy of topically applied cyclosporin solution on psoriatic nails</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the study is to establish and evaluate the affectivity of topical application of cyclosporin in psoriasis of the fingernails.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Nail Psoriasis Severity Index (NAPSI) scores.</primaryOutcome>
      <secondaryOutcome>1. Prevention 
2. Does the NAPSI correlate with patient satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47031769</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32d5c572-1626-42ff-b9bc-25aa0fe29742">
	  <name>Postbus 2040</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinical diagnosis of  psoriasis of fingernails in both hands
2. In cases of oral treatment with  methotrexate, prednisone or fumarates, the dose of medication before the start  has to be constant for eight weeks and it may be reasonably expected that the dose shall not be altered during the treatment phase of the study
3. A minimum of at least two affected nails on the left hand and the right hand, and the number of affected nails may differ by one nail at the maximum on the left hand compared with those on the right hand</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Systemic treatment with cyclosporine or a biological agent (efaluzimab, etanercept or related medication)
2. Change of oral medication eight weeks before the start of the trial
3. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psoriatic nails</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Psoriatic nails</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>On left and right fingernails either placebo, or 100 mg/ml cyclosporin application, twice daily.
The duration of the treatment is till complete cure or for a maximum of 16 weeks.
Control group maximal 28 weeks</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cyclosporin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15416-0</funderId>
      <contactId>Contact53349_15416</contactId>
      <sponsorId>Sponsor51896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53349_15416">
    <title>Dr</title>
    <forename>Annik</forename>
    <surname>van Rengen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Postbus 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4634569</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.vanrengen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51896">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15416-0">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">07851536</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Information processing, neuropsychological, and neurobiological processes in pediatric obsessive-compulsive disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Information-processing:
1. Changes in measures of severity of Obsessive-Compulsive Disorder (OCD) are explained (partially) by changes in measures of meta-cognitions (explicit and/or implicit)
2. Changes in measures of meta-cognitions (explicit and implicit) precede changes in measures of severity of OCD

Neuropsychological processes:
1. Changes in measures of severity of OCD are explained (partially) by changes in measures of inhibition of attentional processes
2. Changes in measures of inhibition precede changes in measures of severity of OCD

Neurobiological processes:
1. Volumes of prefrontal cortex and striatum, activity of anterior cingulate, orbitofrontal region and striatum differ from healthy controls and change during treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Severity of OCD (CY-BOCS, measured at the start of the waitlist condition, directly before start of the CBT, session eight, 16 and follow up after 16 weeks)
2. Anxiety/Depression (Revised Child and Anxiety Depression Scale [RCADS]) measured at the start of the waitlist, directly before start of the CBT, at the end of the therapy (session 16) and follow up after 16 weeks)</primaryOutcome>
      <secondaryOutcome>1. Information-processing (explicit: Revised 44 item version of the Obsessive-Beliefs Questionnaire scale [OBQ-44 R], Meta-Cognitions Questionnaire for Adolescents [MCQ-A], Implicit: Implicit Association Procedure [IAP]) (measured at the start of the waitlist, directly before start of the CBT, session eight and 16 and follow up after 16 weeks)
2. Inhibition/selective attention (dot-probe, measured at the start of the waitlist, directly before start of the CBT, session eight and 16 and follow up after 16 weeks)
3. Neuroimaging data: volumes grey and white matter, activity on planning (tower of London), selective attention (Flanker) and inhibition (dot-probe) task in fMRI</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07851536</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="47cb03c5-9dc2-4d84-a711-40c4219c4e85">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children and adolescents eight to 18 years
2. Primary diagnosis: Obsessive Compulsive Disorder (OCD)
3. OCD symptoms for more than six months
4. Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) total score more than 16
5. IQ (Intelligence Quotient) more than 80
6. Informed consent of parents and child</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>45</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>45</totalTarget>
      <exclusion>Use of the following medication: 
1. Selective Serotonin Reuptake Inhibitor (SSRI)
2. Tricyclic Antidepressant (TCA)
3. Anti-psychotic medication

For neurobiological measures (functional Magnetic Resonance Imaging [fMRI]): 
1. Claustrophobia
2. Metal on body</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obsessive-Compulsive Disorder  (OCD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Obsessive Compulsive Disorder (OCD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 16 weekly sessions Cognitive Behavioral Therapy (CBT)
2. Waitlist (eight weeks) followed by 16 weekly sessions CBT</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15417-0</funderId>
      <contactId>Contact53350_15417</contactId>
      <sponsorId>Sponsor51897</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53350_15417">
    <title>Ms</title>
    <forename>L H</forename>
    <surname>Wolters</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
Department of Child and Adolescent Psychiatry
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5662242</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.h.wolters@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51897">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15417-0">
    <name>Academic Medical Center (AMC) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003180</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-25T00:00:00.000Z">67906788</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Proof of principle study of the effect of individual and team drill on the ability of labour ward staff to manage acute obstetric emergencies</title>
      <scientificTitle/>
      <acronym>SaFE study</acronym>
      <studyHypothesis>The use of mock drills in simulation centres and labour wards (fire drills) has increased in response to issues of patient safety and the Clinical Negligence Scheme for Trusts (CNST) requirements. These provide opportunities for staff to practise emergency obstetric scenarios. However, there has been little evaluation of the effects of such training on individuals or obstetric teams. The Department of Health has funded this work, to establish proof of principle of the effect of individual and team drill training on the ability of labour ward staff to manage acute obstetric emergencies. The study evaluates training involving simulation centre and local in-house labour ward drills, so that future policies and studies can be based on the most promising methods.

The aim of this study is to evaluate the effect of individual and team drill for the management of acute obstetric emergencies. The specific research questions are:

1. Primary questions
a. Does the use of a high fidelity setting improve clinical skills in obstetric emergencies?
b. Does including team training in emergency drills improve clinical skills in dealing with obstetrics emergencies?

2. Secondary questions
a. Does team training in obstetric emergency drills improve team working?
b. Does the use of a high fidelity setting improve team working in obstetric emergencies?
c. Does team training in emergency drills improve knowledge in obstetric emergencies?
d. Does the use of a high fidelity setting improve knowledge in obstetric emergencies?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Global rating scores of individual clinical skills
2. Time taken to execute procedures
3. Number of actions, omissions and inappropriate actions</primaryOutcome>
      <secondaryOutcome>1. Knowledge assessed by a multiple choice questionnaire
2. Applied delivery force in shoulder dystocia skill station
3. Communication - as assessed by a content analysis of a sub sample of skill stations
4. Global rating scores of teamwork behaviours on a sub sample of skill stations</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Southwest Devon Medical Research Ethics Committee (reference number: 04/Q2103/68), approval gained on September 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67906788</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>0270030</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II exploratory trial within the format of a factorial 2 x 2 randomised trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="02475b0e-a8ee-48fa-8886-2be2b2b2a996">
	  <name>St Michael's Hospital</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8UG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All hospital and community midwives and obstetric medical staff (junior and senior) who provide care to mothers and babies are eligible to enter the study.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>144</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>144</totalTarget>
      <exclusion>Staff who have attended addition accredited training course in the management of obstetric emergencies (Advanced Life Support in Obstetrics [ALSO], Managing Obstetric Emergencies and Trauma [MOET], South West Obstetric Emergency Course) within the past 12 months will be excluded from the study, and also:
1. Staff who have taken part in the Simulation and Fire drill Evaluation study (SaFE) pilot study
2. Staff involved in the delivery of the training interventions
3. Local staff involved in assisting the research team
4. Staff currently on maternity leave or long term sick leave</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute obstetric emergencies</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Acute obstetric emergencies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Phase II exploratory trial of two aspects of the training intervention, high versus low fidelity and team training versus no team training, will be assessed within the format of a factorial 2 x 2 randomised trial.

The participants will be randomly allocated to one of the four training interventions.
Group A1: One day obstetric emergency training course. This will be within the low fidelity setting in the local participating hospitals and will exclude specific team training.
Group B1: One day obstetric emergency training course. This will be within the high fidelity setting of the Bristol Medical Simulation Centre and will exclude specific team training.
Group A2: Two day obstetric emergency training course. This will be within the low fidelity setting of the local participating hospitals and will include specific team training.
Group B2: Two day obstetric emergency training course. This will be within the high fidelity setting of the Bristol Medical Simulation Centre and will include specific team training.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18310377 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="54cc7507-8c93-4ddc-9e33-ac2aea462f73" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18310377"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15346-0</funderId>
      <contactId>Contact53274_15346</contactId>
      <sponsorId>Sponsor51823</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53274_15346">
    <title>Dr</title>
    <forename>Bryony</forename>
    <surname>Strachan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Michael's Hospital
Southwell Street</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8UG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 117 9285594</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bryony.strachan@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51823">
    <organisation>United Bristol Healthcare Trust (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Research and Effectiveness Department
Marlborough Street</address>
      <city>Bristol</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>BS1 3NU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 117  923 0000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">maria.palmer@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410421.2</gridId>
    <rorId>https://ror.org/04nm1cv11</rorId>
  </sponsor>
  <funder id="Funder15346-0">
    <name>The trial is funded by Policy Research Programme of the Department of Health as part of the Patient Safety Research Portfolio (PSRP) (reference number: 0270030).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-13T00:00:00.000Z">25825250</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy</title>
      <scientificTitle/>
      <acronym>IM-VIT100</acronym>
      <studyHypothesis>To determine the safety and efficacy of VIT100 (VitrenAse), a proliferating cell nuclear antigen (PCNA) ribozyme (Immusol, Inc. San Diego, CA), in preventing recurrent proliferative vitreoretinopathy (PVR) in patients with established PVR who undergo vitrectomy for retinal reattachment repair.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy variables included:
1. Failure rate of retina repair surgery secondary to PVR
2. All cause of failure rate of retina repair surgery
3. Retinal status</primaryOutcome>
      <secondaryOutcome>Safety variables included:
1. ETDRS best corrected visual acuity
2. Lens status
3. Intraocular pressure
4. Biomicroscopy findings
5. Adverse effects
6. Serum Blood Urea Nitrogen (BUN) and creatinine</secondaryOutcome>
      <trialWebsite>http://www.immusol.com/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Columbia University Institutional Review Board reviewed and approved research on the 31st July 2003 (reference number: AAA8110).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25825250</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>IM-VIT 100-01 (IND # 63,756)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, double-masked, placebo controlled, randomised clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1699ea0-d135-46c6-bcf7-3a21f1b87b8b">
	  <name>635 West 165th Street</name>
	  <address/>
	  <city>New York</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>10032</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with retinal detachment with Grade C or worse PVR who undergo vitrectomy for retinal reattachment:
1. Retinal detachment
2. Proliferative vitreoretinopathy (PVR) grade C or worse under direct visualisation
3. Visual acuity greater than no light perception
4. Aged at least 18 years
5. Patient willing and able to sign informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>170</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>170</totalTarget>
      <exclusion>1. Vision of no light perception
2. Presence of any uncontrolled, sight threatening concomitant eye disease
3. Severe non proliferative diabetic retinopathy or proliferative diabetic retinopathy according to Early Treatment Diabetic Retinopathy Study (ETDRS) criteria
4. Other pre-existing vaso-proliferative retinopathy
5. History of intraocular inflammatory disease
6. Retinoschisis detachment
7. Heredity vitreoretinopathies
8. Best corrected visual acuity less than 20/200 prior to onset of retinal detachment due to permanent pre-existing condition
9. Vision less than 5/200 or visual field less than 20 degrees in the fellow eye
10. Pregnant or nursing women or women of childbearing potential not using a reliable form of contraception
11. Concurrent participation in any other research study within 30 days of entry into the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Proliferative Vitreoretinopathy</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Proliferative Vitreoretinopathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients undergo retinal reattachment surgery with pars plana vitrectomy. Additional intraoperative procedures including scleral buckle placement or revision, pars plana lensectomy or limbal cataract extraction, Intraocular Lens (IOL) implantation or removal, temporary keratoprosthesis and penetrating keratoplasty, retinotomy, and/or gas or silicone oil tamponade could be performed at the discretion of the operating surgeon and required the assistance of an anterior segment specialist in certain cases.

All patients were to be randomly assigned to one of the three treatment groups: 0.75 mg or 0.15 mg VitrenAse and placebo (ratio 1:1:1). A single intravenous administration of VitrenAse or placebo was administered after the completion of the vitrectomy procedure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>VitrenAse (VIT100)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17846353 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c03cc984-b5ff-4406-a8da-44814ec9bb93" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17846353"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15341-0</funderId>
      <contactId>Contact53268_15341</contactId>
      <sponsorId>Sponsor51817</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53268_15341">
    <title>Dr</title>
    <forename>William</forename>
    <surname>Schiff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>635 West 165th Street</address>
      <city>New York</city>
      <country>United States of America</country>
      <zip>10032</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 212 305 5922</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wms13@columbia.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51817">
    <organisation>Immusol, Inc. (USA)</organisation>
    <website>http://www.immusol.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>10790 Roselle Street</address>
      <city>San Diego, CA</city>
      <country>United States of America</country>
      <zip>92121</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 858 824 1100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bsimon@immusol.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420473.6</gridId>
    <rorId>https://ror.org/03q43d318</rorId>
  </sponsor>
  <funder id="Funder15341-0">
    <name>Immusol, Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-07-14T00:00:00.000Z">33728802</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Labour support and evidence  based medicine: a randomised controlled trial of implementation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Providing women with evidence based maternity care, with provision of labour support as a focus, will improve the care of women during childbirth.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Whether women had a labour support person with them during labour.</primaryOutcome>
      <secondaryOutcome>Whether women during labour were:
1. Offered food or fluids
2. Left alone for long periods of time
3. Allowed to move during labour and delivery
4. Given an episiotomy
5. Given an enema
6. Shouted at
7. Struck or slapped
8. Unhappy with their care or percieved their care was bad</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Committee for Research on Human Subjects (Medical), University of the Witwatersrand on the 1st August 1998 (ref: M960512).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33728802</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>M960512</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="74bc46ec-6ffe-49b4-8cef-1f618d01ea0a">
	  <name>Effective Care Research Unit</name>
	  <address/>
	  <city>East London</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>5201</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Maternity units within Gauteng Province, South Africa, that delivered a minimum of 150 women per month.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10 maternity units</totalTarget>
      <exclusion>Maternity units within Gauteng Province, South Africa, that were directly linked to a university teaching scheme.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Support during labour and evidence based medicine</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Labour</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two educational interventions for maternity staff: one focused on provision of labour support and the other on accessing evidence based maternity care information.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17470267 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ddbdea08-bf7d-404f-b55b-396859ea2d88" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17470267"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15217-0</funderId>
      <funderId>Funder15217-1</funderId>
      <funderId>Funder15217-2</funderId>
      <funderId>Funder15217-3</funderId>
      <contactId>Contact53115_15217</contactId>
      <sponsorId>Sponsor51657</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53115_15217">
    <title>Prof</title>
    <forename>Justus</forename>
    <surname>Hofmeyr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Effective Care Research Unit
University of the Witwatersrand/University of Fort Hare/East London Hospital Complex
P Bag X9047</address>
      <city>East London </city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51657">
    <organisation>Effective Care Research Unit (South Africa)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>University of the Witwatersrand/University of Fort Hare/East London Hospital Complex
P Bag X9047</address>
      <city>East London</city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11951.3d</gridId>
    <rorId>https://ror.org/03rp50x72</rorId>
  </sponsor>
  <funder id="Funder15217-0">
    <name>Department for International Development (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15217-1">
    <name>Medical Research Council (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
  <funder id="Funder15217-2">
    <name>International Childbirth Educators Association (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15217-3">
    <name>Johnson and Johnson (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-07-10T00:00:00.000Z">26610787</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Impact of Laboratory-based Prompts on the Management of Patients with Chronic Kidney Disease</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A laboratory prompt, which identifies a patient with chronic kidney disease (CKD) as being at high risk for cardiovascular disease and progression to kidney failure, improves the management of cardiovascular disease risk factors and kidney disease by physicians.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Use of ACEi or ARB in patients &gt;65 years of age with CKD who have a clear indication for ACEi or ARB use as defined by the presence of diabetes or significant albuminuria.</primaryOutcome>
      <secondaryOutcome>1. Use of an ACEi or ARB in patients &gt;65 years of age with CKD
2. Subsequent measurement of lipids, hemoglobin A1C (in patients with diabetes, if not done in previous six months), urine protein or urine albumin, and subsequent frequency of measurement of serum creatinine
3. Referral to a specialist
4. Addition of cholesterol-lowering drugs in patients &gt;65 years of age
5. Addition of new blood pressure medication(s) in patients &gt;65 years of age
6. Health care costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Bioethics Committess at the University of Calgary and the University of Alberta, 2005, reference number: 18050</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26610787</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomized trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a517e612-28e1-4b1f-b873-a601568c4f16">
	  <name>1403-29th St NW</name>
	  <address/>
	  <city>Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T2N 2T9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients &gt;18 years of age who are registered with one of the participating general practices and have a GFR measured at &lt;60 ml/min during the one-year study period will be included.  All participating general practices will be geographically separated (not located in the same office building), and staffed by &gt;1 full time practitioners who do not see outpatients in another general practice unit (to reduce the risk of contamination).</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>92</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>46 Family Practices per group (92 total)</totalTarget>
      <exclusion>Those patients not meeting the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic kidney disease</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Kidney disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The following prompt will be added to laboratory reports for patients who meet the inclusion criteria and are seen by a physician practice randomized to receive the prompt:
This patient has reduced kidney function and is at risk for cardiovascular events and progression to kidney failure. The National Kidney Foundation recommends:
1. Measure random urine albumin to creatinine (Alb:Cr) ratio
2. Institute an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in patients with diabetes, or those with an Alb:Cr &gt;35 mg/mmol
3. Referral to a nephrologist if GFR &lt;30 ml/min/1.73 m^2
4. Assess  and treat modifiable risk factors for cardiovascular (CV) and renal disease:
a. Target blood pressure (BP) less than 130/80 mmHg
b. Target low-density lipoprotein cholesterol(LDL-C) &lt;2.5 mmol/l
c. If diabetic, target hemoglobin A1C (HbA1C) &lt;7.0%

The above recommendations are general in nature and may not apply to all patients. Further information is available at  http://www.akdn.info
The control group will receive usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14759-0</funderId>
      <contactId>Contact52528_14759</contactId>
      <sponsorId>Sponsor51051</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52528_14759">
    <title>Dr</title>
    <forename>Bruce</forename>
    <surname>Culleton</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1403-29th St NW
Calgary</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T2N 2T9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1403 944 8166</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bruce.culleton@calgaryhealthregion.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51051">
    <organisation>Alberta Heritage Foundation for Medical Research (Canada)</organisation>
    <website>http://www.ahfmr.ab.ca</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Suite 1500
10104-103 Avenue</address>
      <city>Edmonton</city>
      <country>Canada</country>
      <zip>T5J 4A7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 780 423 5727</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ahfmrinfo@ahfmr.ab.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.484182.3</gridId>
    <rorId>https://ror.org/006b2g567</rorId>
  </sponsor>
  <funder id="Funder14759-0">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-29T00:00:00.000Z">29920470</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Patients with chronic idiopathic axonal polyneuropathy: relationships in the disablement process</title>
      <scientificTitle/>
      <acronym>EXAMPLE part II</acronym>
      <studyHypothesis>1. A specific set of variables of impairments are related or predictive of functional limitations and disabilities
2. A specific set of variables of functional limitations are related or predictive of disabilities
3. Psychological variables (defined by theory of planned behaviour [TPB], anxiety and depression) add to impairment variables in the prediction of functional limitation (in self-report and performance measures)
4. These psychological variables mediate the relationship between impairment and functional limitations</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Parameters of four domains of the disablement process will be measured:
1. Impairment: muscle strength (hand-held dynamometry), balance (Berg balance scale), sensory function (sensory modality score), pain (McGill pain questionnaire), fatigue (fatigue severity scale)
2. Functional limitations: walking (modified shuttle walk test), physical functioning (physical functioning performance 10 test), hand functioning (button test and disabilities of the arm, shoulder, and hand questionnaire), physical activity (DigiWalker stepcounter), problematic activities (McMaster-Toronto arthritis patient function preference questionnaire)
3. Disability: autonomy and participation (impact on participation and  autonomy questionnaire and Rankin score)
4. Intra-individual risk factor: cognitions; intentions and perceptions of control (TPB questionnaire), emotions (hospital anxiety and depression scale)</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN29920470</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Longitudinal study; one patient group with CIAP in which the health status will be monitored</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e586c4d4-6226-4dc0-94b7-ee0545d7b078">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic idiopathic axonal polyneuropathy (CIAP), diagnosed on established criteria
2. Patients who write and speak the Dutch language well
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Relevant co-morbidity, expected to influence the test results
2. Anticipated health risks during performance-based testing</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic idiopathic axonal polyneuropathy (CIAP)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Chronic idiopathic axonal polyneuropathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>None: this is a longitudinal study with one patient group with chronic idiopathic axonal polyneuropathy (CIAP), in which the health status will be monitored</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15193-0</funderId>
      <contactId>Contact53075_15193</contactId>
      <sponsorId>Sponsor51625</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53075_15193">
    <title>Dr</title>
    <forename>N.L.U.</forename>
    <surname>van Meeteren</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht
Department of Neurology and Neurosurgery
Rudolf Magnus Institute of Neuroscience
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">n.vanmeeteren@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51625">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Rehabilitation
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15193-0">
    <name>University Medical Center Utrecht (UMCU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-06-26T00:00:00.000Z">12814243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Self-help parent-training for conduct problems in children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Children in the treatment group will show significantly fewer behavioural problems than children in the control group at post-treatment and six-month follow-up as measured by parent and teacher report.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Child behaviour problems as measured by parent's report and teacher's report post-treatment and at six-month follow-up</primaryOutcome>
      <secondaryOutcome>1. Utilisation of mental health services after treatment
2. Parental mental health
3. Parents' sense of competence in parenting
4. Parent's self-report of parenting practices
5. Families' satisfaction with treatment
6. Parent report of parental relationship quality</secondaryOutcome>
      <trialWebsite>http://www.apsoc.ox.ac.uk/EBIG.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by National Health Service (NHS) Oxfordshire Research Ethics Committee C, reference number 05/Q1606/57.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12814243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00299442</clinicalTrialsGovNumber>
      <protocolSerialNumber>05/Q1606/57</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="315a2ae3-3e7f-4560-8ce1-4229eaa35653">
	  <name>University of Oxford</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX1 2ER</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families with children aged 2-5, on the waiting lists of child and adolescent mental health service clinics, and scores in the clinical range on the standardised measure of child behavioural problems. At least one parent in each family must be literate and a fluent English speaker to participate because the self-administered intervention will primarily consist of written instructions and information in English.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="2.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 (100 subjects will be recruited to allow for dropout)</totalTarget>
      <exclusion>1. Clients whose children score below a clinical cut-off score on a standardised measure of child behaviour problems. This is to ensure that participants are appropriate for an intervention aiming to reduce behaviour problems.
2. Non-English speakers or those who are unable to read cannot be included because reading English is required to complete the self-administered intervention
3. Children or parents with severe disabilities and children with a developmental disorder (e.g. autism) will be excluded because the version of the parent-training programme that will be implemented is not designed for families with these types of problems
4. Children who live with a temporary carer will be excluded because the intervention is designed for full-time parents and follow-up will be after one year
5. Children or parents who are currently receiving treatment for psychological problems will be excluded because outcomes may be influenced by interventions not affiliated with this project</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Behavioural problems in children</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that, as of 18/03/2008, the anticipated end date was updated from 01/10/2007 to 31/08/2008. 

This project will introduce a self-help parent-training programme for families on NHS waiting lists for child mental health services. It will examine whether access to treatment can be increased by providing an intervention that requires fewer resources and by releasing clinician time for more serious cases. This intervention will be tested in a randomised, controlled trial in which 35 subjects will receive treatment and 35 will not. All families will also complete questionnaires before and after treatment in order to measure changes in child behaviour, parenting, and parental-mental health. Cost-effectiveness of this programme will also be analysed. Intention-to-treat analyses will be conducted. 

The control group will receive the self-help intervention after the intervention group completes their post-treatment outcome assessments. The treatment intervention is a self-help version of the Triple P parenting programme and will consist of six parent-training videos and a workbook that will be divided into 10 weeks of treatment, to be completed at home by the families. This intervention is based on social learning theory and provides information about preschoolers' development, promoting acceptable behaviour and responding to unacceptable behaviour in effective ways, promoting children's self-esteem and coping with stress. The control group will receive no treatment during this period. 

Both groups will remain on the waiting list for treatment in a clinic and will commence that treatment if they still wish to do so when they reach the end of the waiting list, regardless of their position in the trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16437442&amp;query_hl=1&amp;itool=pubmed_docsum Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="565431c3-5d83-4364-8fbd-065ddc6533bd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-01-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16437442&amp;query_hl=1&amp;itool=pubmed_docsum"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12882-0</funderId>
      <contactId>Contact50388_12882</contactId>
      <sponsorId>Sponsor48757</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50388_12882">
    <title>Ms</title>
    <forename>Gretchen</forename>
    <surname>Bjornstad</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Oxford
Department of Social Policy and Social Work
Barnett House
32 Wellington Square</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX1 2ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 270342</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gretchen.bjornstad@socres.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48757">
    <organisation>University of Oxford (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Paul Montgomery
Deparment of Social Policy and Social Work
Barnett House
32 Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 280325</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.montgomery@socres.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder12882-0">
    <name>University of Oxford Research Development Fund and Oxfordshire Health Services Research Committee (OHSRC) Grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-22T00:00:00.000Z">25438351</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, active-controlled, randomized, parallel group multicentric study to investigate the safety, tolerability and efficacy of reparagen - a dietary supplement compared to glucosamine sulphate in patients with moderate osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym>REPVGLUOA</acronym>
      <studyHypothesis>That reparagen is safe and effective in patients with moderate osteoarthritis, and compared to glucosamine sulphate, reparagen has a faster onset of action with an overall greater response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain visual analogue score
2. Modified Western Ontario and McMaster University osteoarthritis index (WOMAC)</primaryOutcome>
      <secondaryOutcome>1. Serum insulin-like growth factor-1 (IGF-1)
2. Global assessment of therapy
3. Patient's opinion
4. Consumption of rescue medication</secondaryOutcome>
      <trialWebsite>http://www.santerra-pharma.com</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Ethics Committee of KJ Somaiya Medical College and Hospital, Mumbai, India, submitted on 30/12/2005, approved on 08/02/2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25438351</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VL/050421/SP</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, active-controlled, randomized, parallel group multicentric study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1b347a48-8896-4a84-a6cc-ef500b11b40f">
	  <name>Vedic Lifesciences</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400 053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ambulatory adult patients of either sex &gt;20 years of age
2. Patients with moderate osteoarthritis of the knee, clinically detected and/or diagnosed as per radiological examination and American Rhematology Association (ARA) functional classification
3. ARA functional class II or III
4. Kellgren Lawrence for knee osteoarthritis grade II, grade III
5. Patient's assessment of overall pain score between 40 and 100 mm on a pain-visual analogue scale after washout period</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Arthritis other than osteoarthritis
2. Arthroscopy of either knee in the past year
3. Administration of intraarticular steroids within the past three months or hyaluronic acid in the last nine months
4. Known adverse responses to non-steroidal anti-inflammatory drugs (NSAIDs), suspected hypersensitivity, allergy or other contraindication to any compounds present in the study medication
5. Significant gastrointestinal (GI) diseases or previous GI upset to NSAID administration
6. Pregnant or lactating women or woman of child-bearing age not following adequate contraception
7. Evidence of severe renal, hematopoetic disease or severe cardiac insufficiency as revealed by laboratory investigations and other tests
8. Moderate to severe peripheral neuropathy or other neurological disorders
9. Unwilling or unable to come to regular follow-up studies
10. Any condition which in the opinion of the investigator does not justify patient inclusion in the study
11. Inability to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Moderate osteoarthritis of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Reparagen, a combination of a cat's claw extract (Uncaria guianensis), a herbal medicine from the Amazon, and RNI 249, an extract of maca (Lepidium meyenii) a vegetable native to the Andes compared to glucosamine sulphate</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Reparagen, glucosamine sulphate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17974032 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="30d4c240-17ba-4dba-b961-4a907f196053" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-31T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17974032"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15074-0</funderId>
      <contactId>Contact52911_15074</contactId>
      <sponsorId>Sponsor51461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52911_15074">
    <title>Mr</title>
    <forename>Jayesh</forename>
    <surname>Chaudhary</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vedic Lifesciences
118 Morya House
Off Link Road
Andheri (West)</address>
      <city> Mumbai</city>
      <country>India</country>
      <zip>400 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 5693 9757</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jayesh@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51461">
    <organisation>Santerra Pharmaceuticals LLC (USA)</organisation>
    <website>http://www.santerra-pharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Santerra Pharmaceuticals LLC
12721 Strickland Road</address>
      <city>Raleigh</city>
      <country>United States of America</country>
      <zip>27613</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 919 847 2221</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pbobrowski@santerra-pharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15074-0">
    <name>Santerra Pharmaceuticals LLC (USA)  - contracted by Rainforest Nutritionals, Inc.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-06-19T00:00:00.000Z">34091554</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, randomised, crossover study to investigate the difference in frequency of episodes of hypoglycaemia during treatment with Biphasic Insulin Aspart 30 (NovoMix®30) compared to Biphasic Human Insulin 30 (Mixtard® 30) in patients with well-controlled, type 2 diabetes</title>
      <scientificTitle/>
      <acronym>REACH</acronym>
      <studyHypothesis>The trial is a double-blind, two-period cross-over, randomised, multicentre trial in insulin-treated subjects with type-2 diabetes comparing the efficacy and safety of NovoMix® 30 and Mixtard® 30.
Patients will first complete a screening and run-in period lasting eight weeks during which their current insulin dose will be adjusted to achieve pre-breakfast and pre-evening meal blood glucose levels of 5-7 mmol/l.
Patients who achieve an HbA1c of 6.5-8.5% at the end of the run-in period will be randomly allocated to treatment with either NovoMix® 30 or Mixtard® 30 for a 16-week treatment period.
At the end of this period patients will be crossed over to the alternative treatment. The second crossover period will also last for 16 weeks. Both insulin regimens will involve administration just before meals. Total duration of the trial will be 40 weeks. Patients will self-check blood-glucose levels daily. Insulin total dosage will be adjusted by a maximum of either plus or minus 10% using the following algorithm in order to improve blood-glucose profiles, based on the targets stated above. The primary assessment variable will be the number of glucose readings below 3.5 mmol/l as measured by continuous glucose monitoring system overview (CGMS) during two 72-hour periods mid-way through and at the end of each treatment period.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Frequency of hypoglycaemic episodes measured by CGMS for three days.</primaryOutcome>
      <secondaryOutcome>1. Frequency of reported severe hypoglycaemic episodes, minor hypoglycaemic events and nocturnal hypoglycaemia, during the last 12 weeks of each treatment period
2. HbA1c
3. Diabetes treatment satisfaction questionnaire 
4. Adverse event recording</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by South East Multicentre Research Ethics Committee (MREC) on 03/05/2002 reference number: MREC 01/1/67</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34091554</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BIAsp-1466</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, randomised, crossover study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-11-07T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8cd93d74-89eb-4534-b89b-af8e7b8fae7f">
	  <name>Department of Diabetes and Endocrinology</name>
	  <address/>
	  <city>Leicester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LE1 5WW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 160 male or female, adult subjects, with type 2 diabetes and treated with 1 - 3 injections of insulin daily for at least six months
2. HbA1c less than 9.5% at screening and 6.5 - 8.5 at randomisation
3. Judged by the investigator to be eligible for a twice a day (BID) mixed-insulin treatment regimen</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Impaired hepatic, renal or cardiac function
2. Concomitant oral hypoglycaemic agents
3. History of frequent severe hypoglycaemic episodes requiring external assistance within the last six months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-11-07T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 diabetes requiring insulin</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Crossover trial comparing the glucose control of using NovoMix® 30 to Mixtard® 30.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Biphasic Insulin Aspart 30 (NovoMix® 30), Biphasic Human Insulin 30 (Mixtard® 30)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17277042 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a2c8e56c-dc35-46ff-9406-1f39445eb270" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17277042"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15110-0</funderId>
      <contactId>Contact52963_15110</contactId>
      <sponsorId>Sponsor51512</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52963_15110">
    <title>Prof</title>
    <forename>Paul</forename>
    <surname>McNally</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Diabetes and Endocrinology
Leicester Infirmary Close</address>
      <city>Leicester</city>
      <country>United Kingdom</country>
      <zip>LE1 5WW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51512">
    <organisation>Novo Nordisk Ltd (UK)</organisation>
    <website>http://www.novonordisk.co.uk</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Broadfield Park
Brighton Road</address>
      <city>Crawley</city>
      <country>United Kingdom</country>
      <zip>RH11 9RT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1293 613555</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gcom@novonordisk.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.436696.8</gridId>
    <rorId>https://ror.org/0415cr103</rorId>
  </sponsor>
  <funder id="Funder15110-0">
    <name>Novo Nordisk Ltd (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-05-23T00:00:00.000Z">77101807</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, controlled, multicenter, pilot study comparing qigong and back school for elderly patients with chronic neck pain</title>
      <scientificTitle/>
      <acronym>QIBANE</acronym>
      <studyHypothesis>Primary hypothesis: there is a significant difference between the qigong and the waiting list groups for the primary outcome (visual analogue scale [VAS]) after 3 months.
Secondary hypothesis: there is a significant difference between the qigong and the back school groups for the primary outcome (VAS) after 3 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain measured on the VAS (visual analogue scale) after three months</primaryOutcome>
      <secondaryOutcome>1. Neck pain (Neck Pain and Disability Scale, Wheeler)
2. Depression (Depression Scale, Hautzinger)
3. Quality of life (Short-form Questionnaire-36 [SF-36], Bullinger)
4. Frequency of falls and anxiety to fall
5. Sleep quality and satisfaction
6. Overall treatment effect (OTE) (Wiklund)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Yes, date of approval: 23/02/06; reference number: EA1/265/05</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77101807</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicenter, three-armed, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41001a1b-3ff5-4639-9b23-1513da4cd7a8">
	  <name>Institute for Social Medicine</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10098</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age ≥55 years of age
2. Chronic neck pain (duration &gt;6 months)
3. Average pain during the last 7 days before randomisation ≥20 mm on 100 mm VAS
4. Informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 (40 per group)</totalTarget>
      <exclusion>1. Serious acute or chronic disease which would not allow the exercises to be performed
2. Planned start of physiotherapy for chronic neck pain during study participation
3. Participation in another study during the last 6 months before study entry</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic neck pain</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Chronic neck pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomized into the qigong and back school exercise groups (each 24 sessions of 45 min over a period of three months)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15058-0</funderId>
      <contactId>Contact52883_15058</contactId>
      <sponsorId>Sponsor51433</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52883_15058">
    <title>Dr</title>
    <forename>Claudia </forename>
    <surname>Witt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Social Medicine
Charité University Medical Center</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51433">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de/epidemiologie</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Medical Center 
Institute for Social Medicine</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder15058-0">
    <name>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin), Institute for Social Medicine, University Medical Center (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-15T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-03-31T00:00:00.000Z">95821329</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre prospective randomised clinical trial to compare the safety and efficacy of outpatient treatment with oral amoxicillin with that of injectable ampicillin in children aged 3 to 59 months: APPIS II Randomised Controlled Trial (RCT), Pakistan</title>
      <scientificTitle/>
      <acronym>APPIS II</acronym>
      <studyHypothesis>The proportion of children aged 3 to 59 months with World Health Organization (WHO) defined severe pneumonia who fail treatment in the oral amoxicillin group will not be greater than the proportion of those who fail in the parenteral ampicillin group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical deterioration occurring any time after enrolment
2. Inability to take oral medication due to persisting vomiting as assessed by study physician
3. Change or addition of antibiotics</primaryOutcome>
      <secondaryOutcome>1. Treatment failure between day 6 and 14
2. Clinical deterioration (development of danger signs) between day 6 and 14
3. Development of lower chest indrawing or fast breathing, which is non responsive to three trials of nebulisation with bronchodilator between day 6 and 14</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from:
1. Local ethics board on the 2nd December 2004
2. WHO Ethics Research Committee (ERC) on the 23rd March 2005</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95821329</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00227331</clinicalTrialsGovNumber>
      <protocolSerialNumber>RPC116</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="209b5f7d-d67a-4b5f-a0a8-2f9eb8528bf9">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 3 to 59 months with severe pneumonia. Severe pneumonia is defined as Lower Chest Indrawing (LCI) in children with cough and/or difficult breathing, who are able to drink and do not have central cyanosis, regardless of the respiratory rate
2. Known Human Immunodeficiency Virus (HIV) infected patients in clinical category N or A (Centers for Disease Control [CDC]) will be included
3. Informed consent by a legal guardian</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>2100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2100</totalTarget>
      <exclusion>Children with any of the following conditions will be excluded:
1. Very severe pneumonia/disease
2. Known prior episodes of asthma or three or more prior episodes of wheezing
3. LCI that resolves after three doses of bronchodilator therapy
4. Severe malnutrition (visible severe wasting or oedema)
5. Known anaphylactic reaction to penicillin or amoxicillin
6. Hospitalisation in the last two weeks
7. Other diseases requiring antibiotic therapy at presentation, such as meningitis, dysentery, osteomyelitis, septic arthritis, evident tuberculosis etc.
8. Persistent vomiting
9. Previous inclusion in the study
10. Living outside a pre-defined area
11. Parental or caretaker refusal to participate in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>World Health Organization (WHO) defined severe pneumonia</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Parenteral Ampicillin for 2 days then sent home on oral amoxicillin for 3 days
2. Oral Amoxicillin for 5 days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Amoxicillin, ampicillin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18177775 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a9a4ab8-01fd-4876-aedf-5f5ae396864c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18177775"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14959-0</funderId>
      <funderId>Funder14959-1</funderId>
      <contactId>Contact52762_14959</contactId>
      <sponsorId>Sponsor51305</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52762_14959">
    <title>Dr</title>
    <forename>Shamim Ahmad</forename>
    <surname>Qazi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4853</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.in</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51305">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4853</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14959-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14959-1">
    <name>US Agency for International Development (USAID) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-03-30T00:00:00.000Z">42445141</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective, randomised trial comparing fluids and dobutamine optimisation of oxygen delivery in high-risk surgical patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We aimed to investigate the effect of oxygen delivery index (DO2I) optimisation with fluids versus with fluids and dobutamine on 60-day hospital mortality and incidence of complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the effect of both DO2I optimisation with fluids compared to with fluids and dobutamine on 60-day mortality in high-risk general surgery patients.</primaryOutcome>
      <secondaryOutcome>The incidence of complications, particularly adverse cardiovascular events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics board on the 13th May 2002 (ref: 2611/2002).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42445141</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2611/2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbb7f3b6-21e3-4b48-ac00-f0a97c44c9fc">
	  <name>Av Faria Lima 5416</name>
	  <address/>
	  <city>São Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>15091/000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients older than 18 years old undergoing elective surgeries with greater than or equal to three points according to a risk scoring system adapted from the American College of Cardiology (ACC) or the American Heart Association (AHA) guidelines</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>98</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>98</totalTarget>
      <exclusion>1. Refusal of consent
2. Haemodynamic instability prior to surgery
3. Congestive heart failure
4. Presence of infection
5. Acute myocardial ischaemia prior to enrolment
6. Life expectancy lower than 60 days
7. Disseminated malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>High-risk patients undergoing prolonged surgery</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>High-risk surgical patients</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Therapy consisted of pulmonary artery catheter (PAC)-guided haemodynamic optimisation during the operation and 24 hours postoperatively, using either fluids alone or fluids and dobutamine with the aim of achieving supranormal values (oxygen delivery index [DO2I] greater than 600 ml/min/m^2).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dobutamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16696864 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eb6370aa-1d7b-4662-90b8-caa7272906cf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16696864"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14940-0</funderId>
      <contactId>Contact52739_14940</contactId>
      <sponsorId>Sponsor51278</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52739_14940">
    <title>Prof</title>
    <forename>Suzana</forename>
    <surname>Lobo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av Faria Lima 5416
Jardim Universitário
São José do Rio Preto</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>15091/000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51278">
    <organisation>Faculty of Medicine of São José do Rio Preto (FAMERP) Foundation (Brazil)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Av. Brigadeiro Faria Lima, 5416
Vila São Pedro</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>15091/000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419029.7</gridId>
    <rorId>https://ror.org/052e6h087</rorId>
  </sponsor>
  <funder id="Funder14940-0">
    <name>Faculty of Medicine of Sao Jose do Rio Preto Foundation (Fundacao Faculdade de Medicina de Sao Jose do Rio Preto [FAMERP] - Hospital de Base) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-03-08T00:00:00.000Z">10791836</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of an educational program on the prevention of complicated infections in patients with diabetes</title>
      <scientificTitle/>
      <acronym>DELPHI</acronym>
      <studyHypothesis>A health education program for both patients and general practitioners will change behaviour by 15%.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Self-reported behaviour with regard to the uptake of measures relevant to patients and healthcare providers on the basis of the developed educational program.</primaryOutcome>
      <secondaryOutcome>The following outcomes are assessed both in persons with diabetes and in primary health care providers:
1. Awareness of the possibility of an abnormal course and a specific treatment of common infections in persons with diabetes
2. Knowledge about infections and prevention of an abnormal course in persons with diabetes
3. Attitude towards infections in persons with diabetes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10791836</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>U03/175-P230</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2625d266-a6f4-4008-b0d2-df93244c5e27">
	  <name>University Medical Center Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 AB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with type 2 diabetes
2. Aged 45 years or older 
3. Able to attend a meeting and without a Dutch language barrier</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2400</totalTarget>
      <exclusion>Patients greater than or equal to 85 years.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urinary tract infections, lower respiratory tract infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention group of patients and general practitioners participates in an educational program on urinary tract and lower respiratory tract infections. The control group doesn&#146;t receive any intervention, but is managed according to usual care. The intervention period is five months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18056887 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fa0830ac-401a-409d-b432-d78f58664a36" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18056887"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14883-0</funderId>
      <funderId>Funder14883-1</funderId>
      <contactId>Contact52663_14883</contactId>
      <sponsorId>Sponsor51196</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52663_14883">
    <title>Ms</title>
    <forename>Leonie M.A.J.</forename>
    <surname>Muller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht (UMCU)
Julius Center for Health Sciences and Primary Care
Str. HP. 6.131
P.O. Box 85060</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2538181</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.a.muller@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51196">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14883-0">
    <name>Public Health Fund (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14883-1">
    <name>Diabetes Fund (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-03-07T00:00:00.000Z">87656977</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intravenous and oral administration of amiodarone for the management of recent onset atrial fibrillation (AF): a randomized, digoxin and disopyramide controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To confirm if oral amiodarone is as effective as intravenous amiodarone in restoring sinus rhythm in patients with recent AF.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Restoration of sinus rhythm</primaryOutcome>
      <secondaryOutcome>Blood pressure monitoring</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Provided by the Ethics Committee of the Medical School of the University of Athens on 12/03/1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87656977</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-04-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1ed34b82-020f-43a4-95e1-fd3dc499ec3e">
	  <name>15B Agiou Thoma street</name>
	  <address/>
	  <city>Athens</city>
	  <state/>
	  <country>Greece</country>
	  <zip>11527</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with recent onset atrial fibrillation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>223</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>223</totalTarget>
      <exclusion>1.  Age &lt;18 years
2.  Baseline systolic blood pressure &lt;100 mmHg
3.  Known thyroid disease
4.  Serum potassium &lt;3.5 mmol/l
5.  Pre-treatment with any antiarrhythmic drug
6.  Documented permanent AF
7.  Atrial flutter and corrected heart rate (QTc) interval &gt;440 msec
8.  The duration of tachyarrhythmia estimated by medical history
9.  The current guidelines regarding prevention of thromboembolism are also followed</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-04-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Atrial fibrillation</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Atrial fibrillation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients, a total number of 338 received digoxin and disopyramide and if this restored sinus rhythm within two hours, they were excluded from the study.
Patients were randomized into two groups. One group received intravenous amiodarone
and the other group received oral amiodarone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>amiodarone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17434635 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="234302d4-4145-4ce1-aaad-b2823cf9c6ad" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17434635"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14738-0</funderId>
      <contactId>Contact52503_14738</contactId>
      <sponsorId>Sponsor51018</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52503_14738">
    <title>Dr</title>
    <forename>Theodoros</forename>
    <surname>Xanthos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>15B Agiou Thoma street</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 (0)2107462550</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">theodorosxanthos@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51018">
    <organisation>Greek National Health Service (Greece)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>15B Agiou Thoma street</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 (0) 2107462501</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dperrea@med.uoa.gr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14738-0">
    <name>Greek National Health Service</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-02-14T00:00:00.000Z">25180151</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab</title>
      <scientificTitle/>
      <acronym>HOVON 68 CLL</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm B is better than in arm A.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Progression free survival (i.e. time from registration to disease progression, relapse or death due to CLL whichever occurs first)</primaryOutcome>
      <secondaryOutcome>1. Event free survival (i.e. time from registration to induction failure, progression, relapse or death whichever occurs first); the time to failure of patients with induction failure is set at one day
2. Clinical, flow cytometric and molecular response rate
3. Overall survival
4. Disease free survival (i.e. time from CR to relapse)
5. Toxicity</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25180151</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO68</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, multicenter, randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4b05e13a-f146-499a-9481-4be2bb68f570">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Biological high-risk CLL
2. Patients with symptomatic stage A, symptomatic stage B or stage C
3. Age 18-75 years inclusive
4. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="75.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. WHO performance status &gt;/= 3, unless related to CLL
2. Intolerance of exogenous protein administration
3. Severe cardiac dysfunction (New York Heart Association [NYHA] classification III-IV)
4. Significant renal dysfunction (serum creatinine &gt;/= 150 micromol/l or creatinine clearance &lt;30 ml/min)
5. Significant hepatic dysfunction (total bilirubin or transaminases &gt;2 times upper limit of normal [ULN]), unless related to CLL
6. Suspected or documented central nervous system (CNS) involvement by CLL
7. Known HIV positivity
8. Active, uncontrolled infections
9. Uncontrolled asthma or allergy requiring systemic steroid treatment
10. Previously treated with chemotherapy, radiotherapy or immunotherapy for CLL
11. History of active cancer during the past 5 years, except non-melanoma skin cancer or stage 0 cervical carcinoma
12. Clinically significant auto-immune hemolytic anemia (AIHA)
13. Female patients who are pregnant or nursing
14. Male and female patients of reproductive potential who are not practicing effective means of contraception, these include oral contraceptives, intrauterine device, depot injection of gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot plaster. These methods must be applied for the entire protocol treatment period, and for patients treated with alemtuzumab until at least 6 months after the end of alemtuzumab administration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Lymphocytic Leukemia (CLL)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All eligible patients will be randomized on entry between:
Arm A: 6 cycles of oral FC 
Arm B: 6 cycles of oral FC combined with sc alemtuzumab</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Fludarabine and cyclophosphamide (FC) and low-dose alemtuzumab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14786-0</funderId>
      <contactId>Contact52556_14786</contactId>
      <sponsorId>Sponsor51080</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52556_14786">
    <title>Prof</title>
    <forename>M.H.J.</forename>
    <surname>Oers, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Department of Hematologie
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5665785</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.h.vanoers@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51080">
    <organisation>Rigshospitalet (Denmark)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Hematology</address>
      <city>Copenhagen</city>
      <country>Denmark</country>
      <zip>DK-2100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.475435.4</gridId>
    <rorId>https://ror.org/03mchdq19</rorId>
  </sponsor>
  <funder id="Funder14786-0">
    <name>Dutch Cancer Society and Schering AG (Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-01-30T00:00:00.000Z">07286796</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness and cost-effectiveness of public access defibrillation in urban and rural populations in Northern Ireland</title>
      <scientificTitle/>
      <acronym>Northern Ireland Public Access Defibrillation (NIPAD)</acronym>
      <studyHypothesis>Training laypersons such as first responders and police officers to carry and use automated external defibrillators to attend the scene of out-of-hospital sudden cardiac arrests will result in the resuscitation of additional patients by a reduction in the response time compared to the existing emergency medical service response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Survival after hospital discharge following out-of-hospital sudden cardiac arrest
2. Cost-effectiveness of public access defibrillation in the study areas</primaryOutcome>
      <secondaryOutcome>1. Reduction in response time compared to existing emergency medical services
2. Return of spontaneous circulation
3. The modelling of the results to Northern Ireland as a whole using a spatial modelling approach
4. The modelling of the effectiveness and cost-effectiveness of public access defibrillation across Northern Ireland</secondaryOutcome>
      <trialWebsite>http://www.med.qub.ac.uk/nipad</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Northern Ireland Research Ethics Committee on the 26th March 2003 (ref: 47/03).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07286796</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>COM/2371/03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An observational study for one year followed by an intervention using public access defibrillation on the cohort</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-03T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7a4040e6-3a07-41bf-b4c3-62c61018cd42">
	  <name>QUB Centre For Clinical and Population Science</name>
	  <address/>
	  <city>Belfast</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT12 6BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients with a presumed out-of-hospital sudden cardiac arrest over the age of 14 in Antrim, Ballymena, Magherafelt and North and West Belfast district council areas of Northern Ireland.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300,000 people in study area, expected 300 cardiac arrests</totalTarget>
      <exclusion>Out-of-hospital sudden deaths due to non-cardiac causes including trauma, drowning, overdose, poisoning and fire.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-03T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Out-of-hospital sudden cardiac arrest</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cardiac arrest</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Training lay cardiac first responders and police officers to carry and use automated external defibrillators in response to sudden out-of-hospital cardiac arrest in fixed and mobile locations.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17540690 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7836ea51-5d18-48ca-bc90-e78be31b0a25" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17540690"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14619-0</funderId>
      <contactId>Contact52375_14619</contactId>
      <sponsorId>Sponsor50885</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52375_14619">
    <title>Prof</title>
    <forename>Frank</forename>
    <surname>Kee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>QUB Centre For Clinical and Population Science
1st Floor Mulhouse building
Royal Victoria Hospital
Grosvenor road</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)28 90632746</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.kee@qub.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50885">
    <organisation>The Research and Development Office for Health and Personal Social Services in Northern Ireland (UK)</organisation>
    <website>http://www.centralservicesagency.n-i.nhs.uk/display</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>R&amp;D Office
12-22 Linenhall street</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT2 8BS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)28 90553617</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joanne.O'Neill@rdo.n-i.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412915.a</gridId>
    <rorId>https://ror.org/02tdmfk69</rorId>
  </sponsor>
  <funder id="Funder14619-0">
    <name>The Research and Development Office for Health and Personal Social Services in Northern Ireland (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-01-27T00:00:00.000Z">14751416</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clopidose trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>150 mg/day maintenance dose will increase the biological effect of clopidogrel in clopidogrel low responders</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Biological effect of clopidogrel</primaryOutcome>
      <secondaryOutcome>Genetic association study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This protocol has been approved by the ethics committee of the internal medicine department in November 2005</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14751416</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled clinical study with patients admitted for coronary angioplasty</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3464b3b5-cd29-4d0e-8788-242768423001">
	  <name>Geneva University Hospital</name>
	  <address/>
	  <city>Geneva</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cardiovascular outpatients on 75 mg/day clopidogrel</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>Anticoagulation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular outpatients</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After a loading dose of clopidogrel (600 mg), patients will take a standard dose of clopidogrel 75 mg once a day for 15 days.


At day 15, adenosine diphosphate (ADP) induced platelet aggregation and measurement of phosphorylated vasodilator-stimulated phosphoprotein (VASP-P) by a flow cytometric technique will be performed. If patients are clopidogrel resistant, they will receive 150 mg (2x75) once a day during the next 15 days. ADP-induced platelet aggregation and measurement of VASP-P will be performed at day 30.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Clopidogrel</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14633-0</funderId>
      <funderId>Funder14633-1</funderId>
      <contactId>Contact52391_14633</contactId>
      <sponsorId>Sponsor50904</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52391_14633">
    <title>Prof</title>
    <forename>François</forename>
    <surname>Mach</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Geneva University Hospital
Cardiology Division
24 Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 382 7234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">francois.mach@medecine.unige.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50904">
    <organisation>Geneva University Hospital (Switzerland)</organisation>
    <website>http://www.cardiology-geneva.ch</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Cardiology Division
24 Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 382 7234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marjorie.burkhard@hcuge.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.150338.c</gridId>
    <rorId>https://ror.org/01m1pv723</rorId>
  </sponsor>
  <funder id="Funder14633-0">
    <name>University of Geneva Cardiology Foundation (GECOR)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14633-1">
    <name>Geneva University Hospital Internal Medicine Department</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-13T00:00:00.000Z">91576704</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Intranasal calcitonin can be effective in the treatment of acute Charcot foot.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Effect on bone remodeling markers
2. Markers of disease activity - skin temperature</primaryOutcome>
      <secondaryOutcome>1. Prevention of deformities
2. Shortening of the treatment
3. Recurrence of Charcot foot</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethics committee, and all participants gave written informed consent.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91576704</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MZO00023001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Czech Republic</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cde2359c-64fb-4dc1-8ee7-7196d95f4bff">
	  <name>Videnska 1958/9</name>
	  <address/>
	  <city>Prague 4</city>
	  <state/>
	  <country>Czech Republic</country>
	  <zip>14021</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute Charcot foot
2. Type 1 or Type 2 Diabetes</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Foot ulcer
2. Acute osteomyelitis</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetic Foot</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Acute charcot foot</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intranasal Calcitonin 200 IU + Calcium 1000 mg per day or Calcium 1000 mg per day in monotherapy; two years follow-up period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Calcitonin, calcium</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14563-0</funderId>
      <contactId>Contact52297_14563</contactId>
      <sponsorId>Sponsor50784</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52297_14563">
    <title>Dr</title>
    <forename>Robert</forename>
    <surname>Bem</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Videnska 1958/9</address>
      <city>Prague 4</city>
      <country>Czech Republic</country>
      <zip>14021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50784">
    <organisation>Institute for Clinical and Experimental Medicine (Czech Republic)</organisation>
    <website>http://www.ikem.cz</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Videnska 1958/9</address>
      <city>Prague 4</city>
      <country>Czech Republic</country>
      <zip>14021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418930.7</gridId>
    <rorId>https://ror.org/036zr1b90</rorId>
  </sponsor>
  <funder id="Funder14563-0">
    <name>Institute for Clinical and Experimental Medicine MZO00023001 (Czech Republic)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">28577651</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intervention project Osteogenesis Imperfecta (OI) type I and IV: home based training program to increase exercise capacity, muscle strength and aspects of quality of life in children with Osteogenesis Imperfecta</title>
      <scientificTitle/>
      <acronym>ETOI</acronym>
      <studyHypothesis>Children with Osteogenesis Imperfecta type I and IV would benefit from a gradual training program. Increased exercise capacity and muscle strength could increase quality of life.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Exercise capacity and muscle strength.</primaryOutcome>
      <secondaryOutcome>Health related quality of life.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28577651</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>04/331-k (METC UMCU)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, single-blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-08-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b35c6d21-d68c-4848-9a7d-b032e2897b40">
	  <name>KB 02.056.0, 3508 AB</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 EA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Osteogenesis Imperfecta Type I and IV
2. Between 8 and 18 years of age 
3. Ambulatory</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Osteogenesis Imperfecta type II and III
2. Retardation
3. Non-walking</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-08-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteogenesis Imperfecta</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteogenesis imperfecta</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Training program for 12 weeks (two times/week).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18154911 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ba9bc6ae-da99-44b1-b5e0-d2d6835aa3bf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18154911"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14339-0</funderId>
      <funderId>Funder14339-1</funderId>
      <contactId>Contact52225_14339</contactId>
      <sponsorId>Sponsor50753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52225_14339">
    <title>Dr</title>
    <forename>R.H.H.</forename>
    <surname>Engelbert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>KB 02.056.0, 3508 AB
P.O. Box 85090</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2504030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.engelbert@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50753">
    <organisation>University Medical Centre Utrecht (UMCU) (Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>PO Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder14339-0">
    <name>Johanna Child Fund (Johanna Kinderfonds) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14339-1">
    <name>Foundation for paediatric rehabilitation (Stichting Bio-Kinderrevalidatie) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">33274262</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dutch Acarbose Intervention Trial (DAISI)</title>
      <scientificTitle/>
      <acronym>DAISI</acronym>
      <studyHypothesis>Approximately 1/3 of persons with impaired glucose tolerance (IGT) develops type 2 diabetes mellitus in 5 - 10 years time. Acarbose is an alpha-glucosidase inhibitor decreasing post-prandial glucose levels, without the risk of hypoglycemia. The prevention of diabetes with acarbose in this study was considered a feasible approach.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Venous plasma glucose level two hours after oral intake (in five minutes) of 75 g glucose dissolved in 300 ml water at study end (ie, after three years). A difference in two hour post-load glucose level between placebo and acarbose group of 0.5 mmol/L was regarded as being clinically relevant.</primaryOutcome>
      <secondaryOutcome>1. Fasting venous glucose level
2. Appearance of type 2 diabetes mellitus and normal glucose tolerance, according to WHO criteria
3. B-cell function and insulin sensitivity as assessed via the method of the hyperglycaemic clamp
4. Level of cardiovascular risk factors: cholesterol, high density lipoprotein (HDL)cholesterol, triglycerides, lipoprotein (a) (later deleted by amendment no. 4), albumin/creatinine ratio in time assessed urine sample</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33274262</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33df032e-443f-4929-b611-f8347f5cbcd6">
	  <name>Department of general practice</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Persons with impaired glucose tolerance on the basis of two oral glucose tolerance tests (World Health Organization [WHO] 1985 criteria).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>119</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>119</totalTarget>
      <exclusion>1. Not having side effects of acarbose in the qualification period of three months
2. Persons having endocrinological diseases, or having a malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes Mellitus type II (DM type II)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Acarbose used at a fixed dose of 50 mg. The daily maintenance dose was 50 mg three times a day (tid), which was reached as from week 3 after two weeks of up-titration with 50 mg once a day (od) (week 1) and 50 mg twice daily (bid) (week 2).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14369-0</funderId>
      <contactId>Contact52136_14369</contactId>
      <sponsorId>Sponsor50549</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52136_14369">
    <title>Dr</title>
    <forename>Giel</forename>
    <surname>Nijpels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of general practice
EMGO Institute
VU University Medical Center
Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 4449659</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.nijpels@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50549">
    <organisation>Bayer Medical B.V. (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 80</address>
      <city>Mijdrecht</city>
      <country>Netherlands</country>
      <zip>3640 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491169.2</gridId>
    <rorId>https://ror.org/01442sk86</rorId>
  </sponsor>
  <funder id="Funder14369-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-19T00:00:00.000Z">61223447</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective (sero-)epidemiological study on contact transmission and chemoprophylaxis in leprosy</title>
      <scientificTitle/>
      <acronym>COLEP</acronym>
      <studyHypothesis>Rifampicin is an effective chemoprophylactic intervention method to prevent leprosy among close contacts of leprosy patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure is the number of new leprosy patients emerging from the contact groups. The proportions between the rifampicin and the placebo group will be compared at two-years intervals.</primaryOutcome>
      <secondaryOutcome>Analysis will be carried out in order to define special groups at risk. The results of the serological tests will also be compiled and analysed. The number of leprosy patients found in the referent group will be used to calculate the prevalence rate (at intake) and the incidence rate (during follow-up) in the general population, allowing for calculation of relative risks among the contacts.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61223447</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Bangladesh</country>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dac36d64-78cb-4dbe-a0a8-f82a39ef6744">
	  <name>Erasmus Medical Centre Rotterdam</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 DR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients should give consent for approaching their contacts for the trial.
Inclusion criteria for contacts:
1. Those living in the same house
2. Those living in a house sharing the same kitchen
3. First neighbours
4. Close business or social contacts, including other relatives. To be included into this category one has to be in contact with the patient on a daily base (five or more days a week) and during several hours a day.
5. Second neighbours

All divided into spouse, child, parent, sibling, other relative, relative-in-law, non-relative.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20,000</totalTarget>
      <exclusion>Exclusion criteria for contacts:
1. Any contact who refuses to be included
2. Any contact being pregnant
3. Any contact currently on tuberculosis (TB) or leprosy treatment (however, released from treatment [RFT] patients should be included)
4. Any contact below 5 years of age
5. Any contact suffering from jaundice
6. Any contact living only temporarily in the area
7. Any contact found to suffer from leprosy at the initial survey
8. Any contact already enrolled in the study via the contact</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Leprosy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Leprosy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All close contacts of 1000 consecutive new leprosy patients in the districts of Nilphamari and Rangpur (Bangladesh) who are recruited for the study are considered for inclusion. A contact group consists of around 20 individuals. 

A single dose of rifampicin or a placebo is given to all included contacts. The rifampicin comes in capsules of 150 mg and the dosage is the same as recommended in the guidelines of the national leprosy control programme of Bangladesh and DBLM. According to bodyweight and age, two to four capsules are taken by the contact under direct supervision of a DBLM staff member. All the contacts of one patient receive medication from the same container.

Dosage of rifampicin according to age and body weight: 
Adult greater than 35 kg: 600 mg
Adult less than 35 kg: 450 mg
Child 10 - 14 years:  450 mg
Child 5 - 9 years: 300 mg</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rifampicin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18332051 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4d2f561d-be32-4879-8e20-f350fa545fff" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18332051"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14302-0</funderId>
      <funderId>Funder14302-1</funderId>
      <contactId>Contact52049_14302</contactId>
      <sponsorId>Sponsor50513</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52049_14302">
    <title>Dr</title>
    <forename>F.J.</forename>
    <surname>Moet</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre Rotterdam
Department of Public Health
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.moet@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50513">
    <organisation>Erasmus Medical Centre (The Netherlands) </organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Public Health 
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder14302-0">
    <name>The Leprosy Mission International (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14302-1">
    <name>American Leprosy Missions (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-16T00:00:00.000Z">28317455</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A controlled trial of the effectiveness of a diabetes education programme in a multi-ethnic community in Glasgow</title>
      <scientificTitle/>
      <acronym>KAP (knowledge-attitude-practice)</acronym>
      <studyHypothesis>Educational intervention could improve the knowledge and attitudes of people from ethnic minority group with diabetes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Knowledge-attitude-practice.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Greater Glasgow Community/Primary Care local Research Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28317455</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial (block design)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b750205e-fc90-41a4-9e6c-9d8088f1fc96">
	  <name>Educational &amp; Development Centre</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>14496</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All people with diabetes from ethnic minority group aged over 30 years.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>329</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>329</totalTarget>
      <exclusion>1. Disabled
2. Blind
3. Not willing to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Educational programme compared to usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16709243 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="208cb9ff-5d98-4296-8d6a-2efdcd4239b0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16709243"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14271-0</funderId>
      <funderId>Funder14271-1</funderId>
      <funderId>Funder14271-2</funderId>
      <contactId>Contact52008_14271</contactId>
      <sponsorId>Sponsor50441</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52008_14271">
    <title>Dr</title>
    <forename>Hamid Reza</forename>
    <surname>Baradaran</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Educational &amp; Development Centre
Iran University of Medical Sciences
P.O. Box 14155-5983</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14496</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 8805 2252</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">baradaran@iums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50441">
    <organisation>Iran University of Medical Sciences (Iran) </organisation>
    <website>http://www.iums.ac.ir</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Educational &amp; Development Centre
Iran University of Medical Sciences
P.O. Box 14155-5983</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14496</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 8805 2252</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">baradaran@iuma.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411746.1</gridId>
    <rorId>https://ror.org/03w04rv71</rorId>
  </sponsor>
  <funder id="Funder14271-0">
    <name>Iran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14271-1">
    <name>University of Glasgow (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000853</fundRef>
  </funder>
  <funder id="Funder14271-2">
    <name>NHS Scotland (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-02T00:00:00.000Z">13964268</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>FIC - Training in malaria research in Uganda</title>
      <scientificTitle/>
      <acronym>FIC</acronym>
      <studyHypothesis>The proportion of convulsions terminated by buccal midazolam is higher than the proportion of convulsions terminated by rectal diazepam in children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time taken to terminate convulsion within 10 minutes without re-occurence of the convulsion in an hour.</primaryOutcome>
      <secondaryOutcome>1. Time taken to re-occurence of convulsion after initial control
2. Time taken to terminate the convulsion within 10 minutes
3. Proportion of children who get respiratory depression within one hour after adminstration of the study drug</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approved received from: 
1. The Makerere University Medical School Research and Ethics Review Board (Uganda)
2. National Council of Science and Technology Institutional Review Board (IRB) (Uganda)
3. University of California San Francisco Institutional Review Board (IRB) (USA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13964268</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double blind clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Uganda</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1fc5c10e-b5eb-4239-9514-054476f4e806">
	  <name>Makerere Univeristy</name>
	  <address/>
	  <city>Kampala</city>
	  <state/>
	  <country>Uganda</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 3 months to 12 years
2. Admission to Acute Care Unit during the study period
3. A child who presents to the Acute Care Unit with convulsions
4. Provision of informed consent to continue participation in the study</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="12.0"/>
      <gender>Both</gender>
      <targetEnrolment>350</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>350</totalTarget>
      <exclusion>1. Documented evidence of having recieved parenteral anticonvulsant in the past 24 hours
2. Cessation of convulsion before adminstration of study drug
3. Parent/caretaker verbally declines to participate in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prolonged convulsions</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rectal diazepam versus buccal placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Midazolam, diazepam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18166545 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a93498cb-f2b4-4363-9945-a1a79119a78a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18166545"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14195-0</funderId>
      <contactId>Contact51909_14195</contactId>
      <sponsorId>Sponsor50338</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51909_14195">
    <title>Dr</title>
    <forename>Justus</forename>
    <surname>Byarugaba</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Makerere Univeristy
Faculty of Medicine
Department of Pediatrics and Child Health
P.O. Box 7072</address>
      <city>Kampala</city>
      <country>Uganda</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+256 75 696 633</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">byarugabaj@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50338">
    <organisation>Fogarty International Center (FIC) (USA)</organisation>
    <website>http://www.fic.nih.gov/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>National Institutes of Health
Office of Communications
Building 31, Room B2C29
31 Center Drive
MSC 2220</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20892-2220</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 301 496 2075</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ficinfo@nih.gov</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453035.4</gridId>
    <rorId>https://ror.org/02xey9a22</rorId>
  </sponsor>
  <funder id="Funder14195-0">
    <name>Fogarty International Centre (FIC) (USA) (grant ref: TW007375)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-11-28T00:00:00.000Z">86717853</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Inhaled Fluticasone in Wheezy Infants</title>
      <scientificTitle/>
      <acronym>IFWIN</acronym>
      <studyHypothesis>1. Can the early introduction of inhaled corticosteroids (ICS) prevent the progressive fall in lung function seen in asthmatics?
2. Can early introduction of inhaled corticosteroids in children with asthma modify the natural history of the disease or prevent recurrence of asthma later in life?
3. Does treatment with ICS reduce symptoms in non-asthmatic wheezy children and improve their lung function at age 6 years?
4. Do inhaled corticosteroids improve the quality of life of families with wheezing children?
5. Is continuous treatment with ICS at this dose in young children associated with any local or systemic side effects?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Occurrence of asthma at age 5 and 6
2. Lung function at age 5
3. Non-specific bronchial hyper-reactivity at age 5
4. Number of courses and total dose of add-on fluticasone propionate required</primaryOutcome>
      <secondaryOutcome>1. Rescue and added asthma medication
2. Number of exacerbations
3. Safety parameters &#150; length/height, weight
4. Symptom scores
5. Adrenal function</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>ERP/97/023, 21st April 1997</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86717853</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A randomized double blind placebo controlled study investigating the effects of early intervention with low dose inhaled corticosteroids (fluticasone propionate) in young children with wheeze</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e62e832d-7637-46ca-bb73-100d7d766a0b">
	  <name>North West Lung Research Centre</name>
	  <address/>
	  <city>Manchester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>M23 9LT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 6 months to 4 years
2. Two episodes of doctor verified wheeze or one episode continuous for more than 4 weeks</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="4.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Pre-term less than 34 weeks gestation
2. Neonatal lung disease or other lung disease
3. Other chronic disease
4. Children already or previously used an inhaled corticosteroid
5. Children who cannot use the spacer device</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Asthma in children</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Low dose inhaled corticosteroids (fluticasone propionate) versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone propionate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16935686 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a4a20e32-9608-4c4f-859a-d172f2821efd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16935686"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14186-0</funderId>
      <contactId>Contact51895_14186</contactId>
      <sponsorId>Sponsor50321</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51895_14186">
    <title>Dr</title>
    <forename>Clare</forename>
    <surname>Murray</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>North West Lung Research Centre

Wythenshawe Hospital

Southmoor Road</address>
      <city>Manchester</city>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 291 4199</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cmurray@fs1.with.man.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50321">
    <organisation>Wythenshawe Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Andrew Maines

R&amp;D Directorate

ERC Building

Wythenshawe Hospital

Southmoor Road</address>
      <city>Manchester</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 291 5775</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">amaines@fs1.with.man.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.417286.e</gridId>
    <rorId>https://ror.org/05vpsdj37</rorId>
  </sponsor>
  <funder id="Funder14186-0">
    <name>GlaxoSmithKline (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/100004330</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">88861431</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study of safety and immunogenicity of Measles vaccine (Rouvax®) administered by transcutaneous route (France)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 23rd March 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88861431</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC 037</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-23T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5728d984-e44e-428a-9fc3-34ebd890c27f">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy adults between 18 and 22 years of age of haplotype HLA-A201 who have previously been immunised against measles and for whom the anti-measles antibodies are low
2. Female participants must be under contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Previous infection with measles
2. Contra-indications to the use of Rouvax® vaccine
3. Hypersensitivity to egg proteins
4. Human Immunodeficiency Virus (HIV) seropositive
5. Treatment with corticosteroids or immunosuppressors in 15 days prior to enrolment
6. Exposure of back-skin to sun in 15 days prior to enrolment
7. Dermatological pathology on back
8. Acute and evolutive disease
9. Blood donation in three months prior to enrolment
10. In a period of exclusion following previous clinical trials
11. Having received 3800 or more Euros in preceeding 12 months from participation in clinical trials</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-23T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunisation</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 1 dose of Rouvax® vaccine administered to the skin of the shoulder after stripping (abrading) the skin
Control: 1 dose of Rouvax® administered by injection</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Measles vaccine (Rouvax®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14243-0</funderId>
      <contactId>Contact51966_14243</contactId>
      <sponsorId>Sponsor50396</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51966_14243">
    <title>Dr</title>
    <forename>Martin</forename>
    <surname>Friede</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4398</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">friedem@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50396">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14243-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">86632774</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa)</title>
      <scientificTitle/>
      <acronym>Rota014</acronym>
      <studyHypothesis>This study was undertaken to identify whether the immunogenicity of live Oral Poliovirus (OPV) vaccine was affected by the concomitant administration of the candidate Human Rotavirus (HRV) vaccine and also to assess the safety of the candidate HRV vaccine given concomitantly with poliovirus vaccine (OPV or IPV). The study was conducted in two parts, the first part (subset enrolled before the start of the 2002 Rotavirus [RV] season) and the second part of the study (subset enrolled after the end of the 2002 rotavirus season).

Objective:
To demonstrate that co-administering HRV vaccine with OPV does not induce a significant decrease in poliovirus immune response one month after the third dose of polio vaccine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Seroprotection for each polio serotype:
1. Proportion of subjects with anti-poliovirus type 1 antibody titre greater than or equal to 1:8 one month after the third dose
2. Proportion of subjects with anti-poliovirus type 2 antibody titre greater than or equal to 1:8 one month after the third dose
3. Proportion of subjects with anti-poliovirus type 3 antibody titre greater than or equal to 1:8 one month after the third dose</primaryOutcome>
      <secondaryOutcome>1. Proportion of subjects with vaccine take one month after each dose of study vaccine at visits 2 and 3 for subset before RV season
2. Proportion of subjects with vaccine take one month after each dose of study vaccine at visits 3 and 4 for subset after RV season*
3. Viral shedding in a subset of subjects
4. Presence of rotavirus in diarrhoeal stools collected between visits 1 and 3 for subset before RV season, and between visits 1 and 4 for subset after RV season
5. Antibody titres for anti-poliovirus type 1, anti-poliovirus type 2, anti-poliovirus type 3 one month after the third dose
6. Serum anti-rotavirus IgA (immunoglobulin A) antibody titres in subjects in the subset before RV season at study visits 1 to 3
7. Serum anti-rotavirus IgA antibody titres in subjects in the subset after RV season at study visits 2 to 4
8. For each type of solicited symptom, occurrence of the symptom within the 15-day (day 0-14) solicited follow-up period after each study vaccine dose
9. Occurrence of unsolicited adverse events within 43 (day 0&#150;42) days after each study vaccine dose, according to World Health Organization (WHO) classification
10. Occurrence of serious adverse events (SAEs) throughout the entire study period (including long term follow-up for 6 months after Dose 2 of HRV vaccine/placebo)

*Not done since no stool samples were collected after RV season</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received in 2001</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86632774</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled study with three parallel groups with balanced allocation (1:1:1).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0732331b-b1be-4eff-b683-3e2a676c3b5d">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents/guardians of subjects who could comply with the protocol requirements (e.g. completion of diary cards, return for follow-up visits)
2. Male or female 6 - 10 weeks of age at the time of first vaccination
3. Written informed consent from parents/guardians
4. Born after a gestation period of 36 - 42 weeks</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Weeks" value="6.0"/>
      <upperAgeLimit unit="Weeks" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>271</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>271</totalTarget>
      <exclusion>1. Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period
2. Previous routine vaccination except Bacillus Calmette-Guerin (BCG) and hepatits B virus (HBV)
3. Clinically significant history of chronic Gastrointestinal Tract (GIT) disease including any incorrected congenital malformation of GIT
4. History of allergic disease or reaction likely to be exacerbated by any component of the vaccine
5. Acute illness at the time of enrolment
6. Diarrhoea with in 7 days preceding the study vaccination
7. Administration of immunoglobulins and/or blood products since birth or planned during study period
8. Use of any investigational or non-registered drug or vaccine other than study vaccines during the study period</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunisation</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two doses of GSK Biologicals&#146; oral live attenuated human rotavirus (HRV) vaccine (RIX4414) at 106.5 CCID50 viral concentration, one dose of placebo
Control: three doses of placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Live attenuated human rotavirus vaccine (RIX4414), oral poliovirus vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14240-0</funderId>
      <funderId>Funder14240-1</funderId>
      <contactId>Contact51963_14240</contactId>
      <sponsorId>Sponsor50393</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51963_14240">
    <title>Dr</title>
    <forename>Duncan</forename>
    <surname>Steele</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3752</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steeled@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50393">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14240-0">
    <name>RAPID trials (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14240-1">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-28T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">37373664</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa</title>
      <scientificTitle/>
      <acronym>Rota013</acronym>
      <studyHypothesis>The aim of this study was to determine if there was a difference in immune response between the two different schedules that were tested.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of subjects who seroconverted at visit 4 (2 months after dose 3) in the vaccine groups.</primaryOutcome>
      <secondaryOutcome>Immunogenicity:
1. Proportion of subjects with vaccine take at visit 2 (dose 2) and visit 4 in a subset of subjects
2. Serum rotavirus IgA (immunoglobulin A) antibody concentrations in all subjects at visits 1, 2 and 4
3. Proportion of subjects with anti-poliovirus type 1, 2 and 3 antibody titre greater than or equal to 1:8, at visit 4
4. Antibody titres for anti-poliovirus types 1, 2 and 3, at visit 4
5. Viral shedding in a subset of subjects

Safety:
1. For each type of solicited symptom, occurrence of the symptom within the 15-day (day 0-14) solicited follow-up period after each dose
2. Occurrence of unsolicited adverse events within 43 days (day 0 - 42) after each dose, according to MedDRA (medical dictionary for adverse events) classification
3. Presence of rotavirus in diarrhoeal stool collected until visit 4
4. Occurrence of serious adverse events throughout the entire study period

Efficacy:
1. Occurrence of rotavirus gastroenteritis/severe rotavirus gastroenteritis during the period starting from dose 1 up to visit 5
2. Occurrence of severe rotavirus gastroenteritis during the entire study period</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved prior to 2002</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37373664</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC103</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A double blind, randomised placebo controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5cb4fcb-8be7-4e53-b035-d013406a0be0">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents/guardians of subjects who could comply with the protocol requirements (e.g. completion of diary cards, return for follow-up visits)
2. Male or female 6 - 10 weeks of age at the time of first vaccination
3. Written informed consent from parents/guardians
4. Born after a gestation period of 36 - 42 weeks</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Weeks" value="6.0"/>
      <upperAgeLimit unit="Weeks" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>285</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>285</totalTarget>
      <exclusion>1. Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period
2. Previous routine vaccination except Bacillus Calmette-Guerin (BCG) and hepatits B virus (HBV)
3. Clinically significant history of chronic gastrointestinal tract (GIT) disease including any incorrected congenital malformation of GIT
4. History of allergic disease or reaction likely to be exacerbated by any component of the vaccine
5. Acute illness at the time of enrolement
6. Diarrhoea with in 7 days preceding the study vaccination
7. Administration of immunoglobulins and/or blood products since birth or planned during study period
8. Use of any investigational or non-registered drug or vaccine other than study vaccines during the study period</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunization</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two doses of GSK Biologicals&#146; oral live attenuated human rotavirus (HRV) vaccine (RIX4414) at 106.5 CCID50 viral concentration
Control: placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Human rotavirus vaccine (RIX4414)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14241-0</funderId>
      <funderId>Funder14241-1</funderId>
      <contactId>Contact51964_14241</contactId>
      <sponsorId>Sponsor50394</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51964_14241">
    <title>Dr</title>
    <forename>Duncan</forename>
    <surname>Steele</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3752</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steeled@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50394">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14241-0">
    <name>RAPID trials (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14241-1">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-11-17T00:00:00.000Z">28535118</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bowel preparation or not in elective colon surgery</title>
      <scientificTitle/>
      <acronym>Boniec</acronym>
      <studyHypothesis>Postoperative complication rate in the bowel preparation group is the same as in the non-bowel preparation group (null hypothesis).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mortality within 30 days postop
2. Local infectious complications
3. Cardiovascular complications</primaryOutcome>
      <secondaryOutcome>1. Postop bleeding
2. Reoperation
3. General infectious complications
4. Length of postop hospital stay
5. Rehospitalisation within 30 days postop</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28535118</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3734e404-b7bd-4657-9530-36df8cab668b">
	  <name>Kirurg Kliniken</name>
	  <address/>
	  <city>Umeå</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>90185</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient aged 18 - 85 years
2. Elective resection for cancer, adenoma or diverticular disease
3. Survival over 6 months foreseen
4. Written consent after written and spoken information</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1500</totalTarget>
      <exclusion>Bowel preparation given preoperatively from other reasons than surgery.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Elective colon surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colon surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study compares colon surgery with preoperatively given bowel preparation (standard today) with no given bowel preparation preoperatively.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17514668 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ebef58f9-ba8a-4d24-ad8b-6b6fccf315b6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17514668"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13290-0</funderId>
      <contactId>Contact50898_13290</contactId>
      <sponsorId>Sponsor49286</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50898_13290">
    <title>Prof</title>
    <forename>Erik</forename>
    <surname>Nilsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kirurg Kliniken
Norrlands Universitetssjukhus</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>90185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">erik.nilsson@surgery.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49286">
    <organisation>Umea University/The Health Research Council of South-East of Sweden (FORSS Sydöstra sjukvårdsregionen) (Sweden)</organisation>
    <website/>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Norrlands Universitetssjukhus</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>90185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.naredi@surgery.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.12650.30</gridId>
    <rorId>https://ror.org/05kb8h459</rorId>
  </sponsor>
  <funder id="Funder13290-0">
    <name>The Health Research Council of South-East of Sweden (FORSS Sydöstra sjukvårdsregionen) (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">72633488</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intraarticular Application of Opioids versus Glucocorticoids versus Placebo in Gonarthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Assessment of efficacy and safety of intraarticular applicated Morphine versus Dexamethasone versus Placebo in gonarthritis in inflammatory rheumatic disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement of VAS pain of at least 20 mm on a 0-100 scale.</primaryOutcome>
      <secondaryOutcome>Impovement of a numeric pain scale, sleep quality, global daily activity, knee mobility with Lysholm and Gilquist Score, Western Ontario McMaster Universities Osteoarthritis (WOMAC) index, relief of pain on a numeric scale from 0-3.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72633488</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f0f27f7d-dbb6-49ea-bce3-31ed8139a115">
	  <name>Charité Campus Benjamin Franklin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 19-70
2. Gonarthritis with sonographically evident effusion in inflammatory rheumatic disease
3. Visual analogue score (VAS) pain &gt;30 mm
4. Body weight 50-90 kg
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Pregnancy, lactation
2. Severe or opportunistic infection, infection of the knee
3. Malignant diseases
4. Any other severe diseases
5. Platelets &lt;100/nl, Quick &lt;50
6. Significant findings during clinical examination
7. Participation in a clinical trial within 30 days before inclusion
8. Abuse of hard drugs, benzodiacepines, analgesics, alcohol
9. Therapy with anticoagulants</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gonarthritis in inflammatory rheumatic disease</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Gonarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Single injection of Morphine 3 mg or Dexamethasone 4 mg or Placebo during needle arthroscopy. Rearthroscopy after 7 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Morphine, Dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13412-0</funderId>
      <contactId>Contact51048_13412</contactId>
      <sponsorId>Sponsor49442</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51048_13412">
    <title>Prof</title>
    <forename>Joachim</forename>
    <surname>Sieper</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité Campus Benjamin Franklin
Dept of Rheumatology
Hindenburgdamm 30</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)3084454414</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joachim.sieper@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49442">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Benjamin Franklin Campus 
Department of Rheumatology
Hindenburgdamm 30</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)3084454414</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joachim.sieper@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder13412-0">
    <name>German Research Foundation  (Deutsche Forschungsgemeinschaft) KFO 100</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">75125874</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised phase III clinical trial in patients radically operated for stage III melanoma (American Joint Committee on Cancer [AJCC]): comparison between Interferon (IFN) alpha-2b (sec Eastern Cooperative Oncology Group [ECOG] 1684) versus intensified Interferon alpha-2b</title>
      <scientificTitle/>
      <acronym>IMI - Mel.A.</acronym>
      <studyHypothesis>To verify if intensive intravenously IFN regimen is better than ECOG 1684 IFN regimen in patients with high risk melanoma (Stage III AJCC).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Overall survival</primaryOutcome>
      <secondaryOutcome>1. Toxicity
2. Disease free survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75125874</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3e559ea-618c-44f1-81da-28a5cd953ff1">
	  <name>Medical Oncology Unit</name>
	  <address/>
	  <city>Venezia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>30100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Primary melanoma of any tumour stage in presence of N1 regional lymph node metastases detected at elective or selective lymph node dissection with clinically not apparent regional lymph node metastases (designed CS1PS2, any TpN1M0)
2. Clinically apparent N1 regional lymph node involvement synchronous with primary melanoma of T1-4 (designed CS2PS2, any TcN1M0)
3. Regional lymph node recurrence at any interval after appropriate surgery for primary melanoma of any depth (designed CS2R, TxrN1M0)
4. ECOG performance status (PS) zero to one
5. Age 18 to 70
6. Absence of active medical or psychiatric troubles requiring medical or pharmacological interventions
7. Absence of thyroid or auto-immune pathology
8. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>328</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>328 patients</totalTarget>
      <exclusion>1. Patients with non-cutaneous primary melanoma
2. Clinical or pathological evidence of not completely resected melanoma or of lymph-node metastases
3. Clinical history of progressed neoplasia, except for the in situ carcinoma of the cervix and of radically treated basal carcinomas
4. Patients requiring a continuous treatment with steroids, non-steroid antiinflammatory drugs or other inhibitors of the prostaglandins synthesis, antihistaminic (cimetidine, ranitidine, famotidine and nazatidine) or other known immunomodulators
5. Patients with history of (ventricular or supraventricular) heart rhythm troubles needing treatment, or congestive heart failure (class New York Heart Association [NYHA] more than two)
6. Patients with organic brain syndrome or significant deterioration of the basal cognitive function or with any psychiatric trouble which may hinder the complete participation in the protocol or which may be exacerbated from the IFN therapy (e.g. depression)
7. Patients previously submitted to adjuvant therapy, chemotherapy, immunotherapy, including any perfusion therapy before surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melanoma of cutaneous origin with regional lymph-node metastasis radically resected</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Melanoma of cutaneous origin with regional lymph-node metastasis radically resected</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dose-Dense/Dose-Intense arm: IFN alpha-2b 20 MU/m^2/day intravenously five days a week for four weeks, repeated for four times on weeks nine to 12, 17 to 20, 25 to 28

Standard arm: IFN alpha-2b 20 MU/m^2/day intravenously five days a week for four weeks followed by 10 MU/m^2 subcutaneously three times per week for 48 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Interferon alpha-2b</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16504154 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c43c2fa1-3e8d-4ff7-806f-f4ef988d0687" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-02-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16504154"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14151-0</funderId>
      <contactId>Contact51846_14151</contactId>
      <sponsorId>Sponsor50270</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51846_14151">
    <title>Dr</title>
    <forename>Adriano</forename>
    <surname>Paccagnella</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Oncology Unit
SS Giovanni e Paolo Hospital</address>
      <city>Venezia</city>
      <country>Italy</country>
      <zip>30100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">adriano.paccagnella@ulss12.ve.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50270">
    <organisation>Italian Melanoma Intergroup - IMI (Italy)</organisation>
    <website>http://www.imi-online.it</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Istituto Oncologico Romagnolo
Corso Mazzini 65</address>
      <city>Forlì</city>
      <country>Italy</country>
      <zip>47100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)543 35929</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cor.epiclin@unipd.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14151-0">
    <name>Non-profit trial, partially supported by Italian Melanoma Intergroup (IMI)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-10-19T00:00:00.000Z">05087777</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and immunogenicity of one and two doses of the live, attenuated oral ETEC candidate vaccine BB01 in healthy adults - a phase I, randomized, double-blind study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vaccination with an oral live attenuated EnteroToxigenic Escherichia Coli (ETEC) candidate vaccine is safe and well tolerated and immunogenic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety as measured by the incidence of adverse events reported post-vaccination.</primaryOutcome>
      <secondaryOutcome>1. Seroconversion rates as determined by antibody titers pre- and post-vaccination against ETEC candidate vaccine antigens  
2. Responder rates as determined by the number of antibody secreting cells pre- and post-vaccination against ETEC candidate vaccine antigens 
3. Shedding of ETEC candidate vaccine strain post-vaccination as measured by duration and number of bacteria shedded</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05087777</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="928f2ed1-7968-4cb5-8384-edce375c5b39">
	  <name>Center for Immunization Research</name>
	  <address/>
	  <city>Baltimore</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>21205</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy adults between 18 and 45 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>Any confirmed or suspected immunosuppressive or immunodeficient condition or prior exposure to ETEC.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>ETEC disease.</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Enterotoxigenic E. coli infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Single dose of ETEC candidate vaccine 
2. Two doses of ETEC candidate vaccine</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13718-0</funderId>
      <contactId>Contact51395_13718</contactId>
      <sponsorId>Sponsor49799</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51395_13718">
    <title>Dr</title>
    <forename>Robin</forename>
    <surname>McKenzie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Immunization Research
Department of International Health
Johns Hopkins University
Bloomberg School of Public Health</address>
      <city>Baltimore</city>
      <country>United States of America</country>
      <zip>21205</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49799">
    <organisation>Berna Biotech Ltd (Switzerland)</organisation>
    <website>http://www.bernabiotech.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Rehhagstrasse 79A</address>
      <city>Bern</city>
      <country>Switzerland</country>
      <zip>3018</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.432742.4</gridId>
  </sponsor>
  <funder id="Funder13718-0">
    <name>Berna Biotech Ltd (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-17T00:00:00.000Z">31625370</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of POstoperative Nausea and Vomiting with metoclopramide and dexamethasone</title>
      <scientificTitle/>
      <acronym>MultiPONV</acronym>
      <studyHypothesis>A prophylactic treatment of postoperative nausea and vomiting consisting of an optimal dosage of metoclopramide combined with dexamethasone increases effectiveness and lowers side effects.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Occurrence of nausea and/or vomiting within 24 hours after the end of surgery.</primaryOutcome>
      <secondaryOutcome>1. Occurrence of post-operative nausea (PON) and vomiting (POV) separately
2. Frequency and severity of PON and POV
3. Time to first PONV event
4. Need of rescue medication
5. Frequency of hypotension and arrhythmia after intra-operative administration of the study drugs
6. Frequency and severity of adverse effects within 24 hours after the end of surgery: 
6.1. Headache
6.2. Dizziness
6.3. Drowsiness
6.4. Dry mouth
6.5. Itching
6.6. Flush
6.7. Urticaria
6.8. Restlessness
6.9. Extrapyramidal symptoms
6.10. Dyskinesia
6.11. Central-anticholinergic syndrome
6.12. Bradycardia/tachycardia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31625370</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8133f48d-1691-4391-8970-2dcb75ee7ae4">
	  <name>Liebigstr. 20</name>
	  <address/>
	  <city>Leipzig</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-04103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age greater than 18 years
2. Patient receives balanced anaesthesia (with intubation) or spinal, peridural, or combined spinal epidural anaesthesia for any of the following surgeries: 
2.1. Hysterectomy
2.2. Cholecystectomy
2.3. Hernia repair
2.4. Otorhinolaryngological surgery
2.5. Thyroid surgery
2.6. Total endoprothesis of the hip or knee
2.7. Arthroscopy
3. Patient is able to answer questions regarding symptoms (taking his/her physical, emotional and mental constitution, understanding and compliance into consideration)
4. Informed consent in writing</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>3000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>3000</totalTarget>
      <exclusion>1. Anaesthesiological risk level of American Society of Anaesthesiologists (ASA) IV
2. Presence of at least one of the following cardiac risk factors: 
2.1. Unstable angina pectoris
2.2. Heart failure with New York Heart Association (NYHA) greater than or equal to III and/or left ventricular ejection fraction (LVEF) less than 40%
2.3. Atrioventricular block grade II or III
3. Current treatment with any of the following: 
3.1. Study medication
3.2. Other anti-emetic drugs except ranitidine
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.4. Monoamine oxidase (MAO) inhibitors
3.5. Tricyclic antidepressants
3.6. Antiarrhythmics class I or III
4. Disposition of the patient to malignant hyperthermia, or known occurrence thereof
5. History of any of the following diseases: 
5.1. Parkinson's disease and other extrapyramidal-motoric impairment
5.2. Hepatic insufficiency (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] greater than 2 x upper normal value [UNV])
5.3. Renal insufficiency (Creatinine greater than 2 x UNV)
5.4. Phaeochromocytoma
5.5. Mechanical ileus
5.6. Epilepsy
6. Known anaphylaxis following any of the study drugs
7. Pregnancy or breast feeding
8. Participation in another therapeutic trial
9. Planned or foreseeable post-operative application of propofol
10. Planned or foreseeable post-operative artificial respiration
11. Planned or foreseeable leaving of a stomach tube post-operatively</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative nausea and/or vomiting following inhalational or regional anaesthesia.</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Postoperative nausea and vomiting</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomised to receive either of 0, 10, 25 or 50 mg metoclopramide in addition to 8 mg dexamethasone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Metoclopramide, dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16861255 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0723b4a0-ad4b-4e2c-9bbc-c94db2aa928f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16861255"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13519-0</funderId>
      <funderId>Funder13519-1</funderId>
      <contactId>Contact51177_13519</contactId>
      <sponsorId>Sponsor49576</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51177_13519">
    <title>Prof</title>
    <forename>Derk</forename>
    <surname>Olthoff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Liebigstr. 20</address>
      <city>Leipzig</city>
      <country>Germany</country>
      <zip>D-04103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)341 9717701</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olthoff@medizin.uni-leipzig.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49576">
    <organisation>University of Leipzig (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ritterstr. 26</address>
      <city>Leipzig</city>
      <country>Germany</country>
      <zip>D-04109</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)341 9730100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kanzler@uni-leipzig.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9647.c</gridId>
    <rorId>https://ror.org/03s7gtk40</rorId>
  </sponsor>
  <funder id="Funder13519-0">
    <name>Self-funded by the Department of Anaesthesiology and Intensive Care Medicine and by the Committee of Clinical Innovation of the University of Leipzig (Germany).</name>
    <fundRef/>
  </funder>
  <funder id="Funder13519-1">
    <name>Supply of the study drugs free of charge by the manufacturers.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-10-06T00:00:00.000Z">49873657</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A  double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the systemic and local safety and tolerance of 5% PSK 3841 solution versus vehicle (70% ethanol) when administered topically twice-a-day over 4 weeks on the scalp of Caucasian males with androgenic alopecia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety and tolerability based on pharmacodynamic endocrine profile (gonadotropins, steroids) on day 1, 15 and 28 of treatment.</primaryOutcome>
      <secondaryOutcome>1. To characterize the pharmacokinetics of PSK 3841 and its metabolites in alopecic males treated twice daily with topical applications on the scalp over a 4-week period
2. To assess whether an eventual exposure to PSK 3841 in untreated female partners occurred under real life conditions during the study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49873657</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PSK 3841/1011</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5bb7354d-b21a-4c74-aaa2-ae1443e08d30">
	  <name>7-9 Rue Jean Louis Bertrand</name>
	  <address/>
	  <city>Rennes</city>
	  <state/>
	  <country>France</country>
	  <zip>35000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>For male subjects:
1. Caucasian healthy male subjects aged between 18 and 50 years old with an androgenic alopecia graded as IIIa, IIIv, IV, IVa or V according to Norwood-Hamilton classification
2. Subjects cohabiting with their female partner during all the study treatment

For their female partners:
1. Healthy female subjects</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>A total of 30 couples (30 treated males, 30 untreated females).</totalTarget>
      <exclusion>For male subjects: 
1. Mobile working activities preventing sleeping at home on a regular basis
2. Baldness due to medical illness, alopecia aerata, trichotillomania or any other form of pathologic alopecia other than androgenetic alopecia
3. Any pathology or abnormality of the skin in the areas to be treated
4. History of skin allergy
5. Regular use of medication which might interfere with the results of the study

For their female partners:
1. Mobile working activities preventing sleeping at home on a regular basis
2. Pregnant or lactating female
3. Female of childbearing potential without adequate efficacious contraception</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Androgenetic alopecia.</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Androgenetic alopecia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>5% PSK 3841 solution or vehicle.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>PSK 3841</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13617-0</funderId>
      <contactId>Contact51289_13617</contactId>
      <sponsorId>Sponsor49690</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51289_13617">
    <title>Dr</title>
    <forename>Evelyne</forename>
    <surname>Guénolé</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>7-9 Rue Jean Louis Bertrand</address>
      <city>Rennes</city>
      <country>France</country>
      <zip>35000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49690">
    <organisation>ProStrakan Pharmaceuticals (France)</organisation>
    <website>http://www.prostrakan.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>102 Route de Noisy
Romainville</address>
      <city>Paris</city>
      <country>France</country>
      <zip>93230</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487449.2</gridId>
    <rorId>https://ror.org/03bvd4t69</rorId>
  </sponsor>
  <funder id="Funder13617-0">
    <name>Proskelia Pharmaceuticals - a part of ProStrakan Pharmaceuticals.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">93119886</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Effect of Subcutaneous Ghrelin On Appetite And Nutritional Status In Patients Receiving Maintenance Peritoneal Dialysis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The short term administration of ghrelin to patients with anorexia with end stage kidney disease will result in increased appetite and calorie intake</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN93119886</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0016148177</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double blind cross over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0e867452-9098-4023-851f-b91c4f2ec2c4">
	  <name>6th Floor, Commonwealth Bldg.</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W12 0HS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with end stage kidney disease</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12 volunteers</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urological and Genital Diseases: Kidney disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Kidney disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ghrelin vs placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Subcutaneous Ghrelin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15888560 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d9ac8ffd-c1ea-4dfa-b38e-9614f74fea06" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15888560"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13832-0</funderId>
      <contactId>Contact51788_13832</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51788_13832">
    <title>Prof</title>
    <forename>Stephen</forename>
    <surname>Bloom</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>6th Floor, Commonwealth Bldg.
Imperial College School of Medicine
Hammersmith Hospital
Du Cane Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W12 0HS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 8383 3242</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bloom@imperial.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13832-0">
    <name>Hammersmith Hospital NHS Trust (UK) - NHS R&amp;D Support</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">58354123</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of cryoanalgesia on pain perception during infiltration of local anaesthetic agents: a randomised double blind controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does cryoanalgesia used prior to injection of local anaesthetic agent, reduce pain perception during inflitration of the agents?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Level of pain perception during infiltration of local anaesthetic agents and the operative procedure</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58354123</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0515154546</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3987f7f0-117f-4013-84d4-eb02aa9749b8">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Harrow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HA1 3UJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients coming for hernia repairs under local anaesthetic in 'One-Stop Hernia Clinic' at ACAD will be requested to enter into trial on the day of arrival. Patient will be give complete information regarding the trial and will be explained that they are free no to enter if the so wish. Approximately 50 patients in each group.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Signs and Symptoms: Pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients from one-stop hernia clinic will be given the research protocol information sheet on arrival (i.e. one hour prior to surgery). Surgeons will explain the research and the operation and obtain an informed consent, for both the operation and entry into the trial. Surgeons will answer any and every patient query regarding the trial and the operation. Patients will have the right to withdraw from the trial at any point without explanation. Patients will be randomised alternately into:
1. The control group 
2. The trial group</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17567343 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e8bc8ef4-b09f-4005-b663-9b86969043ac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17567343"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14092-0</funderId>
      <contactId>Contact51716_14092</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51716_14092">
    <title>Mr</title>
    <forename>Raj</forename>
    <surname>Bhutiani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
North West London Hospitals NHS Trust
Northwick Park Hospital
Watford Road</address>
      <city>Harrow</city>
      <country>United Kingdom</country>
      <zip>HA1 3UJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14092-0">
    <name>North West London Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">19439616</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of local anaesthetic techniques in cataract surgery.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the pain patients experience during cataract surgery with three different types of local anaesthesia, using two types of pain questionnaires (McGill pain questionnaire and visual analoque scale).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Quality of pain control through cataract surgery with different types of anaesthetic.  Assessment of pain the patients have with anaesthetic administration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19439616</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0065149380</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33c8e441-5f61-410e-8a87-c427ad355fe3">
	  <name>Department of Ophthalmology</name>
	  <address/>
	  <city>Sunderland</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SR2 9HP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 patients in each arm - 300</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Cataract</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A randomised, controlled trial comparing three types of anaesthesia: peribulbar, sub-tenon and topical.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Abstract results in http://www.ncbi.nlm.nih.gov/pubmed/16113395 publication in Br J Ophthalmol.  Sep;89(9):1228 entitled "Patient satisfaction with anaesthesia comparing sub-Tenon's block and topical anaesthesia" but no abstract available</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7d39d0c8-73ea-43d1-905b-90937c846fa8" outputType="abstract" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16113395"/>
	<description>publication in Br J Ophthalmol.  Sep;89(9):1228 entitled "Patient satisfaction with anaesthesia comparing sub-Tenon's block and topical anaesthesia" but no abstract available</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13906-0</funderId>
      <funderId>Funder13906-1</funderId>
      <contactId>Contact51717_13906</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51717_13906">
    <title>Mr</title>
    <forename>RWD</forename>
    <surname>Bell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Ophthalmology
Sunderland Eye Infirmary
Queen Alexandra Road
Sunderland</address>
      <city>Sunderland</city>
      <country>United Kingdom</country>
      <zip>SR2 9HP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13906-0">
    <name>City Hospitals Sunderland NHS Trust R&amp;D Department</name>
    <fundRef/>
  </funder>
  <funder id="Funder13906-1">
    <name>NHS R&amp;D Support Funding</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>